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1.1  Epigenetics and chromatin 
1.1.1 Epigenetics 
While most cells of a multicellular organism share the same DNA sequence, they vastly 
differ in their functions and morphologies. This discrepancy between the genotype and 
the phenotype of different cells was termed by ‘epigenotype’ by Conrad Hal Waddington 
in 1942 (Waddington, 2012). The term was used to describe the processes that lead from 
the uniform genotype to variable phenotypes. The science investigating the process was 
named ‘epigenetics’. In 1958, David Nanney proposed that ‘cells with the same genotype 
may not only manifest different phenotypes, but these differences in expressed 
potentialities may persist indefinitely during cellular division in essentially the same 
environment’ (Nanney, 1958). This is the origin of our contemporary definition of 
epigenetics which defines all meiotically or mitotically heritable changes in the cellular 
phenotype that occur without changing the underlying DNA sequence as epigenetic (Allis 
et al., 2007). The investigation of these processes in the last few decades has revealed that 
the molecular basis of these inheritable changes is chromatin. 
1.1.2 The nucleosome  
Chromatin is a polymeric complex of genomic DNA, nuclear proteins and RNA that is 
necessary to maintain accessibility while the compaction of the eukaryotic genome in in 
the nuclear compartment (McGinty and Tan, 2015). The basic units of chromatin are the 
nucleosome core particles, which are connected by a segment of linker DNA. A 
nucleosome core particle with linker DNA is called a nucleosome, which repeats in the 
genome every 160 to 240 bp (McGhee and Felsenfeld, 1980).  
The nucleosome core particle is formed by the nucleosome core, an octameric complex of 
two copies each of four core histone proteins, wrapped by 147 bp of DNA in 1 ¾ 
superhelical turns (Figure 1-1) (Luger et al., 1997). All core histones share a so-called 
histone-fold motif in the center of the protein, which is formed by three α-helices linked 
by intervening loops. The histone-fold motif is flanked by N- and C-terminal extensions 
(McGinty and Tan, 2015). The core histones interact with each other according to their 
complementary histone-fold to form heterodimers, H3 pairs with H4 and H2A pairs with 




heterodimers and the subsequent binding of two H2A/H2B heterodimers to each half of 
(H3/H4)2, through the interaction between the H4 and H2B histone-fold motifs. The 
surface of the symmetrical core histone octamer bears a strong positive charge and binds 
to the central 121 bp of nucleosomal DNA. The 13 bp DNA flanking this central region is 
mainly organized by the two N-terminal histone-fold α-helices of H3 in the octamer 
(Figure 1-1C, D) (Davey et al., 2002; Luger et al., 1997).  
 
Figure 1-1 The nucleosome core particle structure and the histone-fold heterodimers 
(A) Nucleosome core particle structure (PDB ID 1KX5). Histones and DNA are depicted in cartoon and sticks 
representations, respectively, and colored as indicated. (B) H3/ H4 histone-fold heterodimer. (C) H2A/ H2B 
histone-fold heterodimer. Structures (top) and schemes (bottom) with secondary structure elements indicated. 
Based on high-resolution structure in (Davey et al., 2002)(PDB ID 1KX5). Structures were visualized and 
rendered using MacPyMOL (pymol.org). Graphic was adapted from (McGinty and Tan, 2015).  
 
Apart from the structured regions of the histones that form the histone octamer, the N-
terminus of all four core histones comprises a conserved unstructured region, the histone 
‘tail’ domain (Bohm and Crane-Robinson, 1984; Cutter and Hayes, 2015). In nucleosomes 
under physiological salt conditions, most of these unstructured domains are clinging to 
the nucleosome body. The ‘tail’ regions contribute to nucleosome stability and regulate 
DNA accessibility for binding factors (Ausio et al., 1989; Polach et al., 2000; Wang and 
Hayes, 2007). Nevertheless, the histone ‘tail’ domains are subject of extensive 
posttranslational modifications and a platform for protein interaction with the 




1.1.3 Higher order chromatin structures 
Nucleosomes are linked to one another by a 10-80 bp long segment of linker DNA 
forming a polynucleosome. The polynucleosome forms a 10 nm fiber, described as ‘beads-
on-a-string’. This structure is able to compact the DNA five- to ten-fold (Figure 1-2) (Bruce 
Alberts, 2007). Under physiological salt conditions and in presence of magnesium the 
‘beads-on-a-string’ array is arranged in a compact higher order structure of roughly 30 
nm diameter in vitro (Boule et al., 2015). The structure of this 30 nm chromatin fiber 
remains elusive, however, and its existence in vivo in the nucleus of the cell is contentious 
(Grigoryev and Woodcock, 2012; Joti et al., 2012; Luger et al., 2012; Staynov, 2008). The 
binding of linker histone H1 (or H5) to the nucleosome and the DNA linker segment 
stabilizes the 30 nm fiber (Allan et al., 1986; Hansen, 2002). The higher order structures of 
chromatin beyond the 30 nm fiber are little understood to date. The formation of these 
structures involves looping and long-range contacts of chromatin domains facilitated by 
non-histone scaffold proteins. One loop contains up to 100 kb of DNA (Figure 1-2). 
 
Figure 1-2 Chromatin condensation 
The organization of DNA within the chromatin structure is shown. The lowest level of organization is the 
nucleosome, in which two superhelical turns of DNA (a total of 165 base pairs) are wound around the outside 
of a histone octamer. Nucleosomes are connected to one another by short stretches of linker DNA. At the next 
level of organization the string of nucleosomes is folded into a fiber about 30 nm in diameter, and these fibers 
are then further folded into higher-order structures. At levels of structure beyond the nucleosome the details 





The degree of chromatin compaction varies throughout the cell cycle. In non-dividing 
cells, the chromatin structure is generally less condensed, as compared to mitosis when 
further compaction forms the mitotic chromosome (Cooper and Hausman, 2000; Hames 
and Hooper, 2000). The described chromatin packaging is important for all cellular 
processes, since regulatory signals target chromatin, not the DNA. The accessibility of a 
specific DNA sequence to proteins, such as RNA polymerase or transcription factors, is 
particularly dependent on the compaction state of the surrounding chromatin structure 
(Dillon and Festenstein, 2002).  
1.2 Epigenetic modifications 
The formation and maintenance of the chromatin structure is achieved by epigenetic 
modifications. The classical definition of epigenetic, as described above, includes the 
heritability of the modification. These modifications were shown to be responsible for the 
transmission of cellular phenotypes from generation to generation such as gene silencing, 
X chromosome inactivation and imprinting (Saksouk et al., 2015). Especially the 
components of the nucleosome, histones and DNA, are subject to a broad variety of 
heritable chemical modifications. These are associated with transcriptional activity of the 
underlying genomic regions (Bernstein et al., 2007; Kouzarides, 2007; Li et al., 2007). The 
modifications include different covalent histone posttranslational modifications and DNA 
methylation. 
1.2.1 Histone posttranslational modification  
Histone proteins are part of the basic unit of chromatin and are amongst the most 
conserved proteins in mammalian organisms. Yet, histones contribute largely to the 
extraordinary plasticity of chromatin structures. Hence, several amino acids either within 
the histone ‘tails’, which extend from the center of the nucleosome core, as well as the 
histone fold part are subject to covalent posttranslational modification.  
In the last decades, many of these modifications have been identified including 
acetylation (Sterner and Berger, 2000), methylation (Zhang and Reinberg, 2001), 
phosphorylation (Nowak and Corces, 2004), ubiquitylation (Shilatifard, 2006), 
sumoylation (Nathan et al., 2006), ADP ribosylation (Hassa et al., 2006), deimination 
(Cuthbert et al., 2004) and propyl isomerization (Nelson et al., 2006). It has been shown 
that these modifications are not homogenously distributed throughout the genome but 
are specifically enriched in defined domains. Histone lysine acetylation was identified as 




promoter and in the 5’ end of coding regions (Millar and Grunstein, 2006). The coding 
region itself is enriched in lysine trimethylation at histone H3 lysine 4, 36 and 79 
(H3K4me3, H3K36me3, H3K79me3) (Bernstein et al., 2007). In contrast, three different 
lysine methylation sites are involved in transcriptional silencing and chromatin 
compaction, H3K9, H3K27 and H4K20 (Kouzarides, 2007). H3K9me3 was shown to play a 
role in transposon silencing and repression of transcription. H3K27me3 was shown to be 
essential for X chromosome inactivation in female mammals. H4K20me3 is an important 
modification in DNA repair processes.  
It is generally assumed that each individual modification of a histone leads to a well-
defined consequence. Histone modifications function in different ways. First, 
modifications can recruit a subset of effector proteins equipped with specific modification 
binding domains. Second, they disrupt the contacts between neighboring nucleosomes by 
affecting the interactions between histones or histone and DNA (Kouzarides, 2007). 
1.2.2 DNA methylation 
In 1975, R. Holliday and A. D. Riggs suggested that genomic DNA methylation is 
transmitted in S-phase and might even play a role in gene expression regulation during 
development (Holliday and Pugh, 1975; Riggs, 1975). Now, we know that DNA 
methylation maintains lineage-specific expression patterns through continuous cell 
divisions. In mammals, this mark mostly occurs at carbon-5 of cytosine. 5-Methylcytosine 
is often referred to as the fifth base of the mammalian genome, reflecting its high 
abundance. However, the levels of DNA methylation differ between the genomes of 
different organisms (Lister et al., 2009; Zemach et al., 2010). Remarkably, some genomes, 
such as those of S. cerevisiae, S. pombe, C. elegans and D. melanogaster do not reveal 
canonical cytosine methylation (Raddatz et al., 2013).  
DNA-methylation is implemented by a group of DNA methyltransferases (Dnmt), 
including the de novo methylatransferases DNMT3A and DNMT3B as well as the 
maintenance methyltransferase DNMT1. DNA methylation by these enzymes is catalyzed 
in the context of CpG motifs. These CpG motifs are symmetrically methylated, so that the 
methylation mark is present on the sense and antisense strand of DNA, ensuring 
propagation during replication (Breiling and Lyko, 2015). However, clusters of CpGs, 
CpG islands, are generally unmethylated. While Dnmts are known to implement DNA 
methylation, the mechanisms to target these enzymes to specific regions in the genome 




The knock out of DNMT1 and DNMT3 in mouse embryonic stem cells suggested a role of 
DNA methylation in genomic imprinting, X chromosome inactivation and silencing of 
transposon sequences (Breiling and Lyko, 2015). DNA methylation was shown to prohibit 
binding of transcription factors to the DNA as well as to recruit specific 5-methylcytosine 
binding proteins. Additionally, it is essential for recruitment of chromatin domains to the 
nuclear lamina (Saksouk et al., 2014). The Dnmts were also found to interact with co-
transcriptional modifications (H3K36me) in actively transcribed gene bodies implying a 
role of DNA methylation in promoting gene transcription. Contrary, promotor regions 
show a loss of DNA-methylation after binding of transcription factors and upon 
transcriptional activation (Bestor et al., 2015). Nevertheless, DNA methylation patterns are 
dynamic and their specific function in the epigenetic regulation of gene expression is not 
fully understood.  
1.3 Heterochromatin 
1.3.1 Chromatin domains - Euchromatin and Heterochromatin 
Early cytological studies discerned two different compaction states of chromatin based on 
their different staining properties for DNA, euchromatin and heterochromatin (Heitz, 
1928). Euchromatin is generally less condensed and transcriptionally active. It is gene-rich 
particularly in housekeeping genes and replicates in early S-phase (Dileep et al., 2015). 
The predominant fraction of chromatin in interphase nuclei is euchromatin. Only about 
10% of chromatin in interphase nuclei is highly condensed and transcriptionally inactive 
heterochromatin (Cooper and Hausman, 2000). Heterochromatin was defined as the part 
of chromatin that remains condensed and is intensively stained by nuclear dyes 
throughout the cell cycle. It is comprised of few genes, mainly tissue specific genes, and is 
rich in repetitive sequences and transposable elements (Richards and Elgin, 2002). 
Heterochromatin is mainly associated with telomeric and pericentric regions in the 
periphery of the nucleus and replicates in late S-phase.  
1.3.2 Facets of heterochromatin 
In lower eukaryotes, only centromeres and telomeres are constantly heterochromatinized, 
while the residual genome is in a euchromatic active state (Grewal and Jia, 2007). 
Increasing genome size and complexity is thought to be responsible for the larger content 
and growing importance of heterochromatic regions in higher eukaryotes (Bird et al., 




nuclear staining techniques led to the postulation that heterochromatic regions are 
partitioned into facultative and constitutive heterochromatin (Brown, 1966).  
Facultative heterochromatin was originally described as a developmentally regulated 
heterochromatinization of tissue specific genes or only one allele of homolog 
chromosomes (Richards and Elgin, 2002). The most prominent example of facultative 
heterochromatin is the inactive X chromosome in female mammals. Facultative 
heterochromatin is transcriptionally silent and this silent state is heritable during 
continuous cell divisions. Therefore, it has been defined as an epigenetic chromatin state. 
Nevertheless it retains the potential for conversion to transcriptionally active 
euchromatin. Facultative heterochromatin is often associated with Polycomb proteins and 
H3K27me2/3 as well as histone hypoacetylation (Trojer and Reinberg, 2007). 
Additionally, H3K9me2 and DNA-methylation were found in inactive alleles (Feil and 
Berger, 2007). 
Similar to facultative heterochromatin, constitutive heterochromatin is transcriptionally 
silent and this silent state is heritable throughout mitosis and meiosis. Constitutive 
heterochromatin is mainly formed at regions with very low gene content, next to 
centromeres, at telomeres and throughout chromosomes. The bulk of constitutive 
heterochromatin is present at pericentromeric regions (Saksouk et al., 2015). It is usually 
associated with repetitive sequences as tandem repeats, satellites in size from five up to a 
few hundred bp, and transposable elements (retrotransposons) (Eymery et al., 2009). Since 
these repetitive sequences are not conserved between different species or different 
chromosomes of the same individual, it was suggested that constitutive heterochromatin 
is epigenetically demarcated. High levels of H3K9me3, H4K20me3, vast histone 
hypoacetylation and DNA methylation generally characterize constitutive 
heterochromatin (Dejardin, 2015). These modifications are essential for formation and 
maintenance of the silent chromatin.  
1.3.3 Maintenance of constitutive heterochromatin  
The silencing of repetitive elements in constitutive heterochromatin is critical for the 
repression of transposable elements as well as for genome stability and maintenance 
(Almouzni and Probst, 2011). Thus, the faithful transmission of the epigenetic marks 
defining constitutive heterochromatin is essential to prevent genome dysfunction. The 
best-studied example of constitutive heterochromatin is murine pericentromeric 
heterochromatin. In mice, DNA methylation and H3K9me3 modifications at the 




hypomethylation, conversely loss of DNA methylation significantly affects H3K9me3, 
which finally disrupts pericentromeric architecture (Saksouk et al., 2014).  
Heterochromatin protein 1 (HP1) is a highly conserved protein that is implicated in gene 
silencing and genome stability. In cells, H3K9me3 is bound by the three isoforms of HP1. 
H3K9me3 in the constitutive heterochromatin is dependent on the histone 
methyltransferases Suv39h1 and Suv39h2. Both proteins, HP1 and Suv39h1/2, are 
thought to be part of a self-sustaining loop mechanism to spread heterochromatin features 
(Maison and Almouzni, 2004). This mechanism involves the interaction of Suv39h1/2 
with HP1, which recruits the histone methyltransferase to regions harboring H3K9me3 
and leads to propagation of the modification in this region. Additionally, HP1 interacts 
with the de novo DNA methyltransferase DNMT3B and might be the foundation of DNA 
methylation at these regions (Lehnertz et al., 2003). In turn, MECP2, a factor binding to 
methylated DNA, was shown to bind Suv39h1 and might thus stimulate H3K9me3 at sites 
of DNA methylation (Dejardin, 2015).  
DNA methylation maintenance is highly dependent on the function of the maintenance 
DNA methyltransferase DNMT1 that was shown to specifically methylate 
hemimethylated CpG motifs generated during replication. DNMT1 is found in a protein 
complex with histone deacetylases (HDACs) and Ubiquitin-like with PHD and RING 
Finger domains 1 (UHRF1). UHRF1 is an ubiquitin ligase that is essential for the 
recruitment of DNMT1 to hemimethylated DNA. It facilitates the maintenance of 
constitutive heterochromatin by physically linking two essential modifications, 
hemimethylated DNA and H3K9me3. Loss of UHRF1 compromised not only DNA 
methylation maintenance but also integrity of pericentromeric regions (Bostick et al., 2007; 
Sharif et al., 2007). 
1.4 UHRF1 
1.4.1 Function of UHRF1 
Ubiquitin-like with PHD and RING Finger domains 1 (UHRF1) is a chromatin effector 
protein that is involved in different chromatin regulating processes like DNA methylation 
maintenance as well as de novo methylation, histone H3 methylation and histone H4 
deacetylation (Bostick et al., 2007; Kim et al., 2009; Meilinger et al., 2009; Papait et al., 2007; 
Sharif et al., 2007; Unoki et al., 2004). It is incorporated in macromolecular complexes with 
enzymes catalyzing these modifications, DNMT1, DNMT3a/b, HDAC1 and G9a, and is 




facilitate DNA replication, cell cycle progression, immune cell maturation and DNA 
damage response (Arima et al., 2004; Jeanblanc et al., 2005; Mistry et al., 2008; Mistry et al., 
2010; Obata et al., 2014; Rajakumara et al., 2011; Yao et al., 2016). Recent finding imply a 
function for UHRF1 as sensor of DNA interstrand crosslinks (Liang et al., 2015; Tian et al., 
2015). It is implicated in gene expression regulation, particularly in gene silencing 
possibly by affecting chromatin structure through histone and DNA methylation (Bronner 
et al., 2010; Rajakumara et al., 2011; Wang et al., 2012). In addition to that, UHRF1 is a 
putative oncogenic factor over-expressed in numerous cancers and might be involved in 
establishment of aberrant DNA methylation and H3K9me3 patterns (Alhosin et al., 2011). 
It was recently suggested as a novel target for chemotherapeutic drugs (Unoki et al., 
2009).  
1.4.2 Sequence conservation of UHRF1 proteins 
UHRF1 proteins are conserved throughout all vertebrate species analyzed to date, while 
no equivalents are found in D. melanogaster (flybase), C. elegans (wormbase) or S. cerevisiae 
(yeastgenome). Comparison of UHRF1 amino acid sequences showed a high degree of 
conservation during the entire vertebrate evolution. The mouse UHRF1 orthologue, 
known as NP95, has two different splicing variants and shares nearly 77% sequence 
identity with the human protein. In contrast to that, in Xenopus leavis, two different genes 
encode two splicing variants. Both share 68.3% and 66.8% sequence identity with the 
human UHRF1, respectively. Interestingly, the five known folded domains of UHRF1 
exhibit very high sequence identity and almost identical predicted secondary structures 
throughout different vertebrate species, arguing for their essential role in protein function 
(Bronner et al., 2007).  
1.4.3 UHRF1 - Domain structure and function 
The five conserved domains of UHRF1 comprehend an ubiquitin-like domain often 
referred to as UBL. Walker and colleagues 2005 showed for NP95 that this domain has the 
classic α/β ubiquitin fold and comprises the structurally conserved surface lysines K31 
and K50, which are putative targets of mono- or poly-ubiquitination and therefore might 
regulate protein function and/or proteasomal protein turnover (Figure 1-3; pdb entry 
2FAZ, not published). However, the role of the UBL domain in context of UHRF1 is not 
yet fully understood.  
UHRF1 is additionally endowed with a Really Interesting and New Gene (RING) domain 




constructed by a zinc-finger, coordinated by two zinc atoms, and a novel unique α-helix 
bundle structure, formed by three helices upstream and one helix downstream of the Zn-
finger (Figure 1-3; pdb entry 3FL2, not published). A recent report suggests that the RING 
domain is involved in histone H3 lysine 23 (H3K23) ubiquitination during S-phase as a 
prerequisite of successful recruitment of maintenance DNA methyltransferase DNMT1 
(Nishiyama et al., 2013).  
 
Figure 1-3 UHRF1 is a multi-domain factor with several conserved protein motifs and linker regions 
Schematic representation of UHRF1 domain organization is shown (UniProtKB: Q96T88). (Top) The structures 
of the individual domains of UHRF1 as determined by X-ray crystallography and NMR spectroscopy 
visualized and rendered using MacPyMOL v 1.7.0.3 (pymol.org). (Middle) Domain boundaries are given by 
respective starting and ending amino acid positions. TTD-PHD linker and PBR are indicated (red boxes). 
(Botom) Chromatin ligands of the different domains of UHRF1 are shown. Schematic representation of a 
single nucleosome in interphase (left) and immediately after replication in S-phase (right) are displayed. For 
simplicity only one H3-tail is shown. UBL, ubiquitin like; TTD, tandem tudor domain; PHD, plant 
homeodomain; SRA, SET and RING associated; PBR, polybasic region; RING, really interesting and new gene. 
pdb entries are: UBL, 2FAZ; TTDN:TTDC, 3DB3; PHD, 3SHB; SRA, 2PB7; RING, 3FL2, modified from (Tauber 
and Fischle, 2015). 
 
Furthermore, UHRF1 comprises three domains, which allow its accurate localization to 
specific chromatin regions by facilitating the binding to the modified H3-tail as well as 
methylated DNA. There is a tandem tudor domain (TTD) C-terminal of the UBL domain, 
which is composed of two individual tudor domains (TTDN:TTDC) both showing a typical 




di- or trimethylated lysine 9 of histone H3 (H3K9me2/3), between its N- and C-terminal 
tudor domains by an aromatic cage that is formed by residues F152, Y188 and Y191 of 
TTDN. Interestingly, the isolated TTD binding to H3K9me3 peptide is not sensitive to 
adjacent serine 10 phosphorylation (H3S10ph), while Lysine 4 trimethylation (H3K4me3) 
and threonine 6 phosphorylation (H3T6ph) impair its peptide affinity, by disrupting the 
interaction of K4 and T6 side chain and backbone residues with the peptide binding 
groove between TTDN and TTDC (Figure 1-3) (Nady et al., 2011). 
The proximate plant homeodomain (PHD) is a Zn-finger domain; accordingly three zinc 
atoms coordinate its rod-shape structure. The crystal structure of the PHD with bound H3 
peptide revealed that the first two residues of the H3-tail are anchored to the domain with 
alanine 1 (H3A1) building hydrogen bonds with P353 and E355, while arginine 2 (H3R2) 
interacts with M332, D334 and D337 (Figure 1-3) (Lallous et al., 2011). The PHD domain is 
known to recognize this very N-terminus of the H3-tail solely if the H3R2 is unmodified 
(Rajakumara et al., 2011). Remarkably, the first zinc atom coordinates a loop, which 
precedes the canonical PHD and is referred to as prePHD. This feature is not found in 
other described histone binding PHD domains and its detailed function still needs to be 
determined (Hu et al., 2011; Lallous et al., 2011). It was predicted that the prePHD is 
essential for the right orientation of the C316, which makes contact with H3K4 (Lallous et 
al., 2011). However, the PHD alone possesses a very low selectivity towards a specific 
methylation status of H3K4. 
The C-terminally following SET and RNG-associated domain (SRA) is a DNA binding 
domain, which is constructed of a β-barrel flanked by α-helical elements (Figure 1-3) 
(Avvakumov et al., 2008) forming a half moon-like structure with a basic inner surface. 
Two loops sticking out of this structure grasp into the major and the minor groove of the 
DNA helix and are therein stabilized by V446 and R491 side chains making van der Waals 
contacts. The R491 is part of the so-called NKR finger, which specifically forms hydrogen 
bonds with CpG in the DNA sequence. These contacts flip out a cytosine from the double 
helix and place it in a binding pocket, which is tailored for the recognition of 5-
methylcytosine (5mC) and therefore generates SRA specificity for methylated DNA. In 
this pocket the methylcytosine is sandwiched by stacking interactions with two aromatic 
residues (Y478, Y466) and additionally forms hydrogen bonds with D469, T479 and S481 
(Avvakumov et al., 2008; Hashimoto et al., 2009). Interestingly, the SRA domain exhibits a 
great specificity for hemi-methylated DNA. This is facilitated by N489, which is a part of 
the NKR finger and makes contacts to the non-methylated adverse cytosine on the second 
DNA strand. Methylation of this cytosine disturbs positioning of the NKR- finger and 




All these three separate domains might bind to a specific target in isolation or collaborate 
with either one of the chromatin interacting domains or both and thereby facilitate a joint 
readout and crosstalk of histone and DNA modifications. In cells, UHRF1 is preferentially 
localized to pericentromeric heterochromatin during mid and late S-phase of the cell cycle 
(Papait et al., 2007; Sharif and Koseki, 2011). It is known to specifically interact with 
H3K9me3 and DNA methylation in silent chromatin. This was shown to be essential for 
the maintenance of pericentromeric heterochromatin (Nishiyama et al., 2013). However, it 
can also be found in euchromatic regions (Karagianni et al., 2008; Liu et al., 2013; 
Rajakumara et al., 2011), where it is recruited to loci comprising DNA methylation and 
unmodified histone H3 arginine 2 (H3R2me0) (Rajakumara et al., 2011). How the specific 
localization of UHRF1 to chromatin loci is regulated during cell cycle and changing 
cellular environment remains elusive.  
1.4.4 TTD-PHD interplay in recognizing the H3-tail 
Different biophysical studies have quantified the interaction strength of the isolated TTD 
of UHRF1 with H3K9me3 peptides. Depending on the experimental conditions the 
dissociation constant (Kd) was determined within a range of 1.0 µM to 2.5 µM (Gelato et 
al., 2014; Rothbart et al., 2012) et (Cheng et al., 2013) (Arita et al., 2012). Similarly, binding 
of the isolated PHD domain to the unmodified N-terminus of H3 was mapped at a Kd of 
0.7 µM to 2.5 µM (Arita et al., 2012; Hu et al., 2011; Rajakumara et al., 2011; Xie et al., 
2012). In contrast, a UHRF1 TTD-PHD fragment showed around 5-fold enhanced binding 
(Kd between 0.15 µM and 0.5 µM) to a histone H3 peptide containing both, an unmodified 
N-terminus of H3 and the K9me3 mark, implying a multivalent binding mode (Arita et 
al., 2012; Cheng et al., 2013; Gelato et al., 2014; Rothbart et al., 2013).  
Since the H3-tail is embedded in the peptide-binding groove of the TTD in the isolated 
structure of this complex, how can the PHD get access to the ultimate N-terminus of H3 in 
the context of the TTD-PHD cassette? Fluorescence/Förster Resonance Energy Transfer 
(FRET) experiments revealed a conformational shift induced in the TTD-PHD cassette 
upon interaction with the H3-tail (Cheng et al., 2013). In agreement, structural studies 
using co-crystalization as well as NMR measurements indicate that the H3-binding mode 
of the TTD-PHD cassette is different from that of the isolated TTD. Obviously, the short 
region connecting TTD and PHD (TTD-PHD linker) replaces the H3-tail from the peptide-
binding groove of the TTD and itself occupies this interface. The resulting arrangement 
has the H3-tail connecting the PHD, which binds the ultimate N-terminus, with the TTD, 
which binds K9me3. Two arginine residues, a lysine and a serine residue (R295-R296-




Indeed, the mutation of R295 and R296 resulted in loss of multivalent binding (Arita et al., 
2012; Rothbart et al., 2013). In contrast, dynamic NMR studies indicate multiple modes of 
PHD linkage in relation to TTD-PHD linker and TTD (Rothbart et al., 2013). Also, the 
TTD-PHD fragment only crystalized in presence of the H3K9me3-tail peptide (Arita et al., 
2012). The findings imply that the two domains do not directly interface but that their 
relative localization is variable without ligand (Tauber and Fischle, 2015).  
1.4.5 Control of TTD/H3K9me3 interaction by a C-terminal polybasic 
region 
While reductionistic approaches studying isolated domains and combinations thereof 
have provided detailed insights into the chromatin interaction potential of UHRF1, other 
studies looked directly at the full-length protein. Here, striking differences in interaction 
specificity for the H3-tail were observed. While native UHRF1 analyzed in the context of 
mammalian cell extracts shows clear preferences for H3K9me3, the recombinant protein 
expressed in bacteria or insect cells binds similarly to unmodified H3 and H3K9me3 
peptides (Gelato et al., 2014; Karagianni et al., 2008; Liu et al., 2013; Rajakumara et al., 
2011; Rottach et al., 2010). We recently showed that this discrepancy is due to 
intramolecular interaction of the TTD with a polybasic region (PBR) located between the 
SRA and RING domains of UHRF1 (Figure 1-3) (Gelato et al., 2014). Our studies imply 
that in the absence of ligands (i.e. the recombinant purified protein) the PBR but not TTD-
PHD linker occupies the peptide-binding groove of the TTD. This prevents interaction 
with H3K9me3, whereas the PHD is unaffected and can bind the ultimate unmodified H3-
tail. NMR experiments have revealed that a K-R-K-S motif (K648-R649-K650-S651) is 
essential for placing the PBR in the peptide-binding groove of the TTD surface. 
Competition experiments with isolated domains indicate that this interaction is stronger 
than the similar TTD/TTD-PHD linker interplay. It also fully blocks the binding of the 
H3K9me3-tail. In the context of the recombinant, full-length protein mutagenesis of the K-
R-K-S motif is necessary to release the PBR from the TTD (Gelato et al., 2014). The 
resulting mutant UHRF1 protein appears to be in an intermediate state as the TTD and 
PHD both can bind their respective K9me3 and H3 unmodified N-terminus ligands 
(Tauber and Fischle, 2015).  
Dialysis of recombinant UHRF1 against nuclear extract isolated from HeLa cells induced 
yet another UHRF1 binding state. Interestingly, this form resembles the native cellular 
protein in preference for H3K9me3 over H3K9me0 (Gelato et al., 2014). The results infer 




1.5 Nuclear PIPs 
Since gene expression patterns change in response to transient changes in cellular 
physiology (e.g. external stress stimuli), it has been suggested that small signaling 
molecules can have a direct effect on chromatin (Lu and Thompson, 2012). In this context, 
Phosphatidylinositol phosphates (PIP) are particularly interesting, because a pool of these 
lipids was found in the nucleus that is independently regulated from the membrane-
bound cytoplasmic fraction in response to extracellular and/or intracellular stimuli. PIPs 
are amphiphilic glycerophospholipids that consist of a polar inositol head group linked 
by a phosphodiester bridge to a glycerol backbone branching two non-polar fatty acids. A 
great fraction of nuclear phospholipids is isolated together with chromosome associated 
nonhistone proteins (Manzoli et al., 1976) and further analysis revealed that lipids could 
thus be associated with hetero- and euchromatin (Rose and Frenster, 1965). 
1.5.1 PI(5)P 
PI(5)P is a low abundance PIP present primarily in mammalian cytoplasmic cell 
membranes with a smaller population in the cell nucleus (Figure 1-4A) (Pendaries et al., 
2005). While its nuclear functions are not fully clear, its presence in this compartment is 
highly conserved throughout eukaryotes (Balla et al., 2012; Barlow et al., 2010; Clarke et 
al., 2001). The levels of cytosolic and nuclear PI(5)P are modulated spatially and 
temporally in response to physiological and pathological stimuli, such as cell cycle 
progression signals, oxidative stress, UV radiation, cancer formation and dehydration in 
plants (Clarke et al., 2001; Divecha et al., 1991; Jones et al., 2006; Jones et al., 2013; Keune et 
al., 2012; Shisheva, 2013). 
1.5.2 Phosphoinositol dependent regulation of chromatin factors 
PI(5)P was shown to be a physiological ligand of several chromatin associated proteins. 
The best understood example is the tumor suppressor inhibitor of growth 2 (ING2). The 
structure of ING2 comprises a PHD domain, which specifically interacts with H3K4me3, 
the hallmark for actively transcribed genes. ING2 is part of a chromatin modifying 
complex comprising Sin3A and HDAC1 that targets gene promoter regions, where it 
leads to histone deacetylation and thus to transcriptional silencing (Shi et al., 2006). In 
vitro studies revealed that ING2 interacts with PI5P via basic residues in its PHD domain 
as well as via an adjacent polybasic patch. This interaction was shown to facilitate ING2 
chromatin association in vivo and thereby affect gene transcription (Figure 1-4B) (Gozani 




ING2 localization in BalbC-3T3 cells in response to the treatment with exogenous PI5P 
undergoes rapid changes. Zhao and colleagues (Zhao et al., 1998) made similar 
observations. 
 
Figure 1-4 Regulation of chromatin interaction of several known factors by PIs 
(A) Structure of PI(5)P with the C5 position phosphorylated and the phosphodieester linkage to the 
dialcylglycerole. (B) Chromatin interacting factors and their PIP interaction motif are shown. ING2 and ATX 
bind PIP via a PHD domain. UHRF1 and TopoIIα via a R/K rich PIP consensus sequence. ATX1 binding to 
chromatin is blocked by interaction with PIs, while UHRF1 and ING2 binding affinity/specificity is changed 
or enhanced. For simplicity, chromatin is represented by four nucleosomes. Histones (grey) and DNA 
(yellow) are indicated  
 
In A. thaliana another factor, ATX1, was shown to interact with PI5P through its PHD 
finger. In contrast to ING2 binding of PI5P inhibits chromatin association and leads to 
cytoplasmic localization of ATX1 (Figure 1-4B) (Alvarez-Venegas et al., 2006; Ndamukong 
et al., 2010). This indicates that a PHD domain with an accompanied polybasic patch is an 
important platform for PI binding and its subsequent manipulation of effector 
functionality. Unfortunately it is not known until now how PI5P affects chromatin 






1.5.3 Regulation of UHRF1 TTD/ PBR interaction by PI(5)P 
We previously showed that allosteric ligands provide a level of regulating UHRF1 
conformational states. Based on our observations that recombinant UHRF1 behaved 
differently from cellular protein but could be converted to a state with similar  
H3K9me3-binding properties after dialysis against nuclear extract, we biochemically 
defined the cofactor and regulator as PI(5)P (Figure 1-4A, B) (Gelato et al., 2014). We could 
show that PI(5)P binding to UHRF1 specifically requires the PBR region and that this 
interaction releases the latter from the peptide-binding groove of the TTD. In 
consequence, a conformation of UHRF1 is established that allows the TTD to bind 





1.6 Aims of the thesis 
Since UHRF1 is recruiting chromatin modifying enzymes to specific loci, the right 
localization of the protein is of great importance to facilitate downstream events affecting 
the chromatin structure and function. The aim of this thesis is to gain insight in the 
interaction of UHRF1 proteins with chromatin modifications. In this context, I focus on 
the regulation of UHRF1 by flexible inter-domain linker regions. 
In particular, I have the following objectives:  
• To investigate the role of the PBR region in UHRF1 nuclear localization 
• To investigate the influence of changing nuclear PI(5)P levels on the nuclear 
localization of UHRF1 
• To identify novel small molecule regulators of UHRF1 
• To investigate whether the inter-domain linker dependent regulation is conserved 
in murine NP95 
• To investigate the influence of different inter-domain linker regions on the nuclear 
localization of UHRF1 and NP95 
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2 Material and Methods 
2.1 Materials 
2.1.1 Laboratory equipment! 
Commonly used laboratory equipment is listed in table 2-1.  




Centrifuge Sorvall Evolution RC 
Centrifuges 5415R/ 5810R/5424 
EmulsiFlex-C5 High Pressure Homogenizer 
FACS Canto II 
Gel documentation system ChemiDoc MP 
Gene Pulser II 
Heraeus HERAcell 240 Incubator  
Heraeus HERAsafe Biol. safety cabinet 
Axiovert 40CFL (HBO50/AC)  
TCS SP5 




PCR Mastercycler epgradient S 
pH Meter  
PlateChameleon 
Infinite M1000 Pro 
Power supply Power Pack basic 
SpeedVac Savant SPD131DDA 
Stuart Gyrorocker SSL3 
Sub-Cell-GT Agarose gel electrophoresis 
Thermomixer comfort 
Waterbath TW12 
Mettler-Toledo, Giessen  
Kern & Sohn, Balingen 
Thermo Scientific, Braunschweig 
Eppendorf, Hamburg 
Avestin, Ottawa (CA) 
BD Biosciences, Heidelberg 
Bio-Rad, München 
Bio-Rad, München 
Thermo Scientific, Braunschweig 
Thermo Scientific, Braunschweig 








Hidex, Turku (FI) 
Tecan, Männedorf (CHE) 
Bio-Rad, München 
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2.1.2 Chemicals ! 
Commonly used chemicals are listed in table 2-2.  
Table 2-2 Commonly used chemicals 
Chemical Supplier 
2-Mercaptoethanol 
2X YT medium 
4,6-Diamidin-2-phenylindol (DAPI) 
Acetic acid 
Acrylamide/ Bisacrylamide solution (37.5:1) 
Agar 
Agarose 
Ammonium persulfate (APS) 
Ampicillin 
Bovine serum albumin  
Bromophenol Blue 
BS3 protein crosslinker 
Calcium chloride  
Chloramphenicol 
Chloroform 
Coomassie Brilliant Blue 







Ethidium bromide solution 









Sigma, Steinheim  
Roth, Karlsruhe  







Sigma, Steinheim  
Serva, Heidelberg 
Thermo Scientific, Braunschweig 
Roth, Karlsruhe 

















Amresco, Solon (USA) 
MOBIO, Hamburg 
Merck, Mannheim  







ethansulphonic acid (HEPES) 
Nocodazole 
Nonidet P-40 (NP-40) 







Rotiphorese Gel 40  
Rotiphorese Gel A  
Rotiphorese Gel B 
Sodium chloride 





Tris(hydroxymethyl)aminomethane (Tris base) 




Yeast extract  
Roth, Karlsruhe 
Merck, Mannheim  
Régilait, Saint-Martin-Belle-Roche (FR) 
VWR, Poole (UK) 
 
Sigma, Steinheim 
Sigma, Steinheim  











Roth, Karlsruhe  
Merck, Mannheim 
Sigma, Steinheim 









2.1.3 Phosphatidylinositol phosphates 
All phosphatidylinositol phosphates were purchased from Echelon Biosciences Inc., Salt 
Lake City (USA). 
Phosphatidylinositol-4-phosphate  Catalog No.:  P-4016 
Phosphatidylinositol-5-phosphate  Catalog No.:  P-5016 
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2.1.4 Commonly used buffers and solutions 
10X DNA loading dye 
 
30 % [v/v] 
10 mM  




































1 % [w/v] 
 










Tris base ! 
Boric acid  
EDTA-NaOH pH 8.0 
 
Coomassie staining solution 
 
0.1 % [w/v] 
10 % [v/v] 
50 % [v/v] 
 
Coomassie Brilliant Blue R250  





10 % [v/v]  
7.5 % [v/v] 
 
Acetic acid  
Methanol 
 
DNA hybridization buffer  10 mM  
50 mM 
1 mM  
Tris pH 7.5 
NaCl 
EDTA 




SDS-PAGE stacking gel 0.68 M 
0.1 % [w/v] 
4% 
0.1 % [v/v] 
0.1 % [w/v] 






SDS-PAGE resolving gel 0.4 M 










LB agar plates 
 
25 g/l 
1.5 % [w/v] 
 
LB broth  
Agar 
 
Ponceau stain 5 % [w/v] 
1 % [v/v] 
Ponceau S 
Acetic acid ! 
 
Propidium iodide stain 
in 1xPBS 
100 µg/ml 



















Lysis buffer  
 
50 mM  
300 mM  
10 mM  
1x 
Tris-HCl pH 8.0/7.5 
NaCl 
Imidazole pH 8.0 
Protease Inhibitor cocktail (EDTA-free) 
 





50 mM  
500 mM  
10 mM 
 
Tris-HCl pH 8.0/7.5 
NaCl 
Imidazole pH 8.0 
Elution buffer  
 
50 mM  
100 mM  
300 mM  
5 % [v/v] 
 
Tris-HCl pH 8.0/7.5 
NaCl 




50 mM  
150 mM 
10 % [v/v] 
1 mM  




2.1.5 Cell culture media and reagents 
Commonly used cell culture media and reagents are listed in table 2-3. 
Table 2-3 Commonly used cell culture media and reagents 
Media/Reagent Supplier 
0.05% Trypsin/EDTA, Gibco Thermo Scientific, Braunschweig 
DMEM/DMEM+GlutaMax-I, Gibco Thermo Scientific, Braunschweig 
DPBS, Gibco Thermo Scientific, Braunschweig 
D-Glucose solution (10%) Sigma, Steinheim 
HyClone Bovine growth serum Thermo Scientific, Braunschweig 
Lipofectamine LTX and Plus reagent Invitrogen, Karlsruhe ! 
MEM non-essential amino acids Sigma, Steinheim 
OptiMEM, Gibco Thermo Scientific, Braunschweig 
Sodium pyruvate, Gibco Thermo Scientific, Braunschweig 
TC-Protector cell freezing medium Bio-Rad, München 
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2.1.6 Chromatographic materials and consumables 
Chromatographic materials and consumables are listed in table 2-4. 
Table 2-4 Chromatographic materials and consumables 
Consumables Supplier 
1 Kb Plus DNA ladder 
6-well TC dish 
96 well polystyrene plate, black, flat bottom 
Amersham Hyperfilm ECL 
Amicon Ultra centrifugal filter devices 
(MWCO 3, 10, 30 kDa) 
Dynabeads M-280 sheep anti-mouse IgG !  
HisPur cobalt resin 
Kodak BioMax MR film  
Myc-tag magnetic bead conjugate 
Nitrocllulose membrane 
Protease Inhibitor (EDTA-free) 
SeeBlue Plus2 prestained protein standard 
Slide-A-Lyzer dialysis units (MWCO 3,500 
and 10,000; volume 0.5 ml) 
Spectra/Por Dialysis Membrane (MWCO 
3,500 and 6-8,000) 
Streptavidin MagneSphere Paramagnetic 
Particles 
TC Dishes (100/150 standard) 
TC serological pipettes cellstar (5ml, 10ml, 
25ml) 
Invitrogen, Karlsruhe ! 
Corning, Corning (USA) 
Corning, Corning (USA) ! 
GE Healthcare, Buckinghamshire (UK)  
Millipore, Billerica (USA) 
 
Dynal Biotech/Invitrogen, Karlsruhe  
Thermo Scientific, Braunschweig  
Carestream Health, New York (USA)  
Cell signaling technology, Cambridge (UK)  
GE Healthcare, Buckinghamshire (UK)  
Roche, Basel (CHE) 
Invitrogen, Karlsruhe ! 
Pierce/Thermo Scientific, Rockford (USA) 
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2.1.7 Commercial enzymes 
Commercial enzymes used for this work are listed in table 2-5. 
Table 2-5 Commercial enzymes 
Enzyme Supplier 
Antarctic phosphatase New England Biolabs, Frankfurt 
DpnI Fermentas, St. Leon-Rot 
Micrococcal nuclease Takara Clontech, Saint-Germain-en-Laye (FR) 
Pfu Polymerase Fermentas, St. Leon-Rot 
PfuUltra II Fusion HS polymerase Stratagene, La Jolla (USA) 
Q5 High-Fidelity DNA polymerase New England Biolabs, Frankfurt 
Restriction enzymes New England Biolabs, Frankfurt 
T4 DNA ligase New England Biolabs, Frankfurt 
2.1.8 Commercial kits 
Commercial kits used in this work are listed in table 2-6. 
Table 2-6 Commercial kits 
Kit Supplier 
ECL Plus Western Blotting Detection 
System 
ECL Western Blotting Detection Reagent 
NucleoBond Xtra Midi Plus 
NucleoSpin Plasmid 
NucleoSpin Gel and PCR clean up 
GE Healthcare, Buckinghamshire (UK)  
 
GE Healthcare, Buckinghamshire (UK) 
Machery&Nagel, Düren  
Machery&Nagel, Düren  
Machery&Nagel, Düren 
2.1.9 Monoclonal antibodies and antisera 
Monoclonal antibodies and antisera used in this work are listed in table 2-7. 
Table 2-7 Monoclonal antibodies and antisera 






1 µl (IP) 
 
Sigma Aldrich, F1804 
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α-H3 rabbit, polyclonal 1:10,000 (WB) Abcam, ab1791 
α-H3K9me3 rabbit, polyclonal 1:1,000 (IF) Active motif, #39161 
α-His6 mouse, monoclonal 1:1,000 (WB) Santa cruz, sc-57598 
α-myc tag mouse, monoclonal 1:1,000 (WB) 
1:500 (IF) 
1 µl (IP) 
Abcam, ab9103 
CST, #2276 
α-UHRF1 mouse, monoclonal 1:1,000 (WB) 
1 µl (IP) 









α-rabbit HRP swine, polyclonal 1:5,000 Dako, P0399 
α-rabbit Alexa 488 donkey, polyclonal 1:500/1,000 (IF) Invitrogen, A21206 
α-mouse Alexa 546 goat, polyclonal 1:500/1,000 (IF) Invitrogen, A11003 
2.1.10 Peptides 
Peptides that were used for this work are listed in table 2-8. 
Table 2-8 Peptides 
Peptide Sequence Supplier 
H3(1-15)unmod-
FAM 















FAM-ARTKQTARK(me3)STGGKA-CONH2 Prof. Dirk Schwarzer, 
University of 
Tübingen 
H3 unmod 1-20 
biotin 










Prof. Dirk Schwarzer, 
University of 
Tübingen 









Prof. Hiroaki Suga, 
University of Tokyo 
L2 (biotin) ySYRIKHHTTKWTKTP-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
L3 (biotin) ySWRIKGHHNRWKQTP-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
L4 (biotin) yRYRVRTHNSRWTVLS-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
L5 (biotin) yKSQVRHHPSTKQNNY-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
D1 (biotin) yRYWTHTHKSHKTTIP-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
D2 (biotin) yTWLDHHDWHRYTRLA-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
D3 (biotin) yTYKSLIVKNHKRHLS-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
D4 (biotin) yPYNRILIKRHRVKII-CG-(PEG)11-K-biotin Prof. Hiroaki Suga, 
University of Tokyo 
D5 (biotin) yPYVLIYVNNHKRPSR-CG-(PEG)11-K-
biotin 
Prof. Hiroaki Suga, 
University of Tokyo 
L1 (fluorescein) yAAIWVKHHYRELVKN-CGK-fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
L2 (fluorescein) ySYRIKHHTTKWTKTP-CGK- fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
L3 (fluorescein) ySWRIKGHHNRWKQTP-CGK- fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
L4 (fluorescein) yRYRVRTHNSRWTVLS-CGK-fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
L5 (fluorescein) yKSQVRHHPSTKQNNY-CGK- fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
D1 (fluorescein) yRYWTHTHKSHKTTIP-CGK- fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
D2 (fluorescein) yTWLDHHDWHRYTRLA-CGK- 
fluorescein 
Prof. Hiroaki Suga, 
University of Tokyo 
D3 (fluorescein) yTYKSLIVKNHKRHLS-CGK- fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
D4 (fluorescein) yPYNRILIKRHRVKII-CGK- fluorescein Prof. Hiroaki Suga, 
University of Tokyo 
D5 (fluorescein) yPYVLIYVNNHKRPSR-CGK-fluorescein Prof. Hiroaki Suga, 
University of Tokyo 









All oligonucleotides were obtained from Sigma Life Science (Steinheim). 
12mer DNA meth bottom 5’-GTCAG[5MedC]GCATGG-3’ 
12mer DNA meth top biotin 5’-[btn]-CCATG[5MedC]GCTGAC-3’  
12mer DNA bottom 5’-GTCAGCGCATGG-3’ 
12mer DNA top biotin 5’-[btn]-CCATGCGCTGAC-3’ 
12mer DNA meth top FAM 5’-[FAM]-CCATG[5MedC]GCTGAC-3’ 
12mer DNA top FAM 5’-[FAM]-CCATGCGCTGAC-3’ 
Primers for cloning and mutagenesis are listed in tables 7-1 and 7-2 of the Addendum. 
2.1.12 Plasmids 
Plasmids used for cloning and protein expression in mammalian and bacterial cells are 
listed in table 2-9. 
Table 2-9 Plasmids 














































EMBL; His6 was 
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2.1.13 Bacterial strains 
Bacterial strains used in this work are listed in table 2-10. 
Table 2-10 Bacterial strains 
Strain Genotype Supplier 
BL21-CodonPlus 
(DE3)-RIL 
E. coli B F– ompT hsdS(rB– mB–) dcm+ 
Tetr gal l (DE3) endA The [argU ileY 
leuW CamR] 
Stratagene, La Jolla (USA) 
 






E. coli F- f80lacZDM15 D(lacZYA-argF) 
U169 deoR recA1 endA1 hsdR17(rk-, 
mk+) phoAsupE44 l-thi-1 gyrA96 relA1 
Invitrogen, Karlsruhe 
 
NovaBlue endA1 hsdR17 (rK12- mK12+) supE44 thi-1 





2.1.14 Mammalian cell lines 
Mammalian cell lines used in this work are listed in Table 2-11. 
Table 2-11 Mammalian cell lines 
Name Organism Morphology/Tissue Disease/Source 
HeLa  Homo sapiens, human epithelial/ cervix adenocarcinoma; ATCC 
U-2 OS  Homo sapiens, human epithelial/ bone osteosarcoma, ATCC 
NIH/3T3  Mus musculus, mouse embryonic fibroblast spontaneous 
immortalization, ATCC 




IMR90  Homo sapiens, human myofibroblast/ lung finite lifespan, ATCC 
iMEF JCR  Mus musculus, mouse embryonic fibroblast  immortalized; gift from 
Prof. Judd Rice, 
University of Southern 
California, Los Angeles 
iMEF W9  Mus musculus, mouse embryonic fibroblast  immortalized; gift from 
Prof. Thomas Jenuwein, 
MPI, Freiburg  
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2.2 Molecular biology methods 
2.2.1 Analysis of nucleic acids 
 Spectrophotometric determination of the concentration of nucleic acids  2.2.1.1
The absorbance (A) of nucleic acid solutions at 260 nm was determined in relation to an 
adequate buffer control using the Spectrophotometer NanoDrop ND-1000. The 
concentration was calculated using the average extinction coefficient of double stranded 
DNA 0,02 µg/ml-1 cm-1, which results in the following equation.  
A260nm = 1 ≙ 50 µg/ml double stranded DNA 
 Agarose gel electrophoresis 2.2.1.2
Nucleic acid solutions were mixed with 10x DNA loading dye in a 1:10 ratio and loaded 
on the polymerized agarose gel. The size of different DNA fragments was analyzed using 
0.5% to 2% agarose gels in 1x TBE Buffer with 0.1 µg/ml ethidium bromide. Samples were 
run along with a size standard (1 kb Plus Ladder) on agarose gel for 1 h at 100-120 V using 
the Sub-Cell-GT electrophoresis system. The DNA was than imaged using a UV 
transilluminator and gel documentation system ChemiDoc MP. 
2.2.2 Cloning and mutagenesis procedures 
 Polymerase chain reaction (PCR) 2.2.2.1
Desired cDNA sequences were amplified by polymerase chain reaction following 
standard protocols (Mullis et al., 1986), polymerase supplier’s protocols. Specific primers 
(see Addendum Table 7-1) were designed using Lasergene 11. These contained restriction 
sites suitable for the subsequent cloning procedure. Standard reactions were set up as 
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Table 2-12 PCR standard reaction set up 
PfuUltra II Fusion HS DNA Polymerase Q5 High-Fidelity DNA Polymerase 
10x PfuUltra II reaction buffer 1x 5x Q5 reaction buffer 1x 
dNTP mix 0.25 mM dNTP mix 0.2 mM 
forward primer 0.2 µM forward primer 0.5 µM 
reverse primer 0.2 µM reverse primer 0.5 µM 
cDNA template 50-100 ng cDNA template 50-100 ng 
  5x Q5 High GC enhancer 1x 
polymerase 1 U polymerase 1 U 
 
The final reaction mix was incubated in a PCR thermocycler epgradient S using the 
following conditions.  
PfuUltra II Fusion HS DNA Polymerase 
temperature time  
95 °C 2 min  
95 °C 30 sec  
55-65 °C 30 sec 30 cycles 
72 °C 15 sec / kb DNA  
72 °C 5 min  
10 °C ∞  
Q5 High-Fidelity DNA Polymerase 
temperature time  
98 °C 30 sec  
98 °C 10 sec  
50-72 °C 10 sec 30 cycles 
72 °C 20-30 sec / kb DNA  
72 °C 2 min  
10 °C ∞  
The PCR amplified DNA fragments were purified using the NucleoSpin Gel and PCR 
clean up kit for subsequent restriction enzyme digestion according to the manufacturer’s 
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protocol. Yield and purity of the PCR products were checked by agarose gel 
electrophoresis. 
 Restriction enzyme digest and ligation reaction 2.2.2.2
Target vector DNA as well as the PCR-amplified insert DNA were digested with the 
matching restriction endonucleases (New England Biolabs) according to the 
manufacturer’s instructions. The reaction conditions were optimized using the New 
England Biolabs double digest finder online tool (https://www.neb.com/tools-and-
resources/interactive-tools/double-digest-finder). The digested DNA fragments were 
separated according to their size using agarose gel electrophoresis. The relevant DNA 
fragments were subsequently extracted from the gel using the NucleoSpin Gel and PCR 
clean up kit. The purified target vector was dephosphorylated using Antarctic 
phosphatase following the manufacturer’s protocol. For ligation reactions, 50 ng of 
digested target vector were mixed with 4 to 8-fold molar excess of the purified insert 
DNA. The mixture was incubated in a final volume of 20 µl 1x T4 DNA ligase buffer 
containing 1 µl T4 DNA ligase. For fast ligation, PEG6000 was added to a final 
concentration of 3 % [w/v]. Ligation reactions were incubated at 16 °C o/n and 
transformed the next day into NovaBlue chemically competent bacteria. 
 Site directed mutagenesis 2.2.2.3
Site-directed mutagenesis was performed using specific overlapping primers (see 
Addendum table 7-3). These carried the appropriate mutation flanked both upstream and 
downstream by 10 to 18 nucleotides of the native vector sequence (Kunkel, 1985). The 
following PCR reaction was performed with native Pfu DNA polymerase in a final 
volume of 50 µl. 
10x Pfu Buffer 1x 
MgSO4 3 mM 
dNTP mix 0.2 mM 
forward primer 0.2 µM 
reverse primer 0.2 µM 
DNA template 200 ng 
polymerase 2.5 U/µl 
 
The final reaction mix was incubated in a PCR thermocycler epgradient S using the 
following conditions.  
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temperature time  
95°C 3 min  
95°C 30 sec  
55-65°C 45 sec 20 cycles 
72°C 2 min / kb DNA  
72°C 20 min  
10°C ∞  
The PCR-amplified DNA fragments were digested with DpnI methylation sensitive 
nuclease for 1 h at 37 °C to remove the template plasmid DNA. The final reaction mix was 
subsequently transformed into NovaBlue chemically competent bacteria. 
 Preparation and transformation of chemically competent bacteria 2.2.2.4
Competent bacteria were prepared using the calcium chloride (CaCl2) method (Dagert 
and Ehrlich, 1979; Hanahan, 1983; Sambrook and Russell, 2001) and frozen at -80 °C for 
storage. Chemically competent bacteria were transformed by heat shock. For 
transformation, a 50-100 µl aliquot of competent bacteria was mixed with  
10-50 ng of plasmid DNA, 5-10 µl of ligation mix or 5 µl mutagenesis reaction. Reactions 
were incubated on ice for 20 min. The bacteria were subsequently heat shocked at 42 °C 
for 30-45 sec in a thermomixer and cooled for 2 min on ice. The heat shocked bacteria 
were recovered by addition of 450 µl SOC medium and were then incubated in a 
thermomixer at 37 °C at 850 rpm. After 1 h cells were plated on LB agar supplemented 
with antibiotic for selection (100 µg/ml ampicillin, 50 µg/ml kanamycin) and plates were 
incubated o/n at 37 °C. 
 Propagation and preparation of plasmid DNA 2.2.2.5
A single colony was picked from the transformation plate for propagation and grown in 5 
ml LB medium with antibiotic at 37 °C for 16 h. Bacteria were harvested by centrifugation 
at 3,200x g and the LB medium was decanted. The plasmid DNA was purified by alkaline 
lysis of the bacterial pellet (Birnboim and Doly, 1979) and subsequent DNA isolation with 
a silica membrane spin column. The isolation was performed with the Nucleospin 
Plasmid purification kit according to the manufacturer’s protocol. Purified plasmid DNA 
was analyzed by restriction enzyme digest and subsequent gel electrophoresis. Plasmid 
DNA was sent to SeqLab laboratories (Göttingen) for sequencing. Sequencing primers are 
listed in the Addendum table 7-3. The sequenced and validated plasmid DNA of the 
desired plasmid were stored at -20 °C in 5 mM Tris/ HCl pH 8.5. 
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For large-scale preparation of plasmid DNA a single colony was picked from the 
transformation plate for propagation and grown in 200 ml of LB medium containing 
antibiotics. DNA purification was carried out using the NucleoBond Xtra Midi Plus kit. 
 Oligonucleotide annealing 2.2.2.6
The lyophilized oligonucleotides listed under 2.1.11 were dissolved in DNA hybridization 
buffer and complementary strands were mixed for annealing of double stranded DNA. 
The mix was incubated at 95 °C for 15 min and than slowly cooled down to RT.  
2.3 Protein biochemistry 
2.3.1 Analysis of proteins 
 Spectrophotometric determination of protein concentration 2.3.1.1
The concentration of protein solutions was determined using the spectrophotometer 
NanoDrop ND-1000. For this, absorbance at 280 nm was measured. Concentrations were 
determined using the molecular weights in combination with the theoretical molar 
extinction coefficients calculated on the basis of the amino acid sequence with the aid of 
the ProtParam online tool (http://web.expasy.org/protparam/ (Gasteiger et al., 2003)). 
Final concentrations were calculated according to the following formula derived from the 
Lambert-Beer equation: 




with A (λ 280) being the absorbance of the solution at 280 nm, ε representing the 
theoretical molar extinction coefficient, d being the path length of the photometer, 
resulting in c the molar protein concentration of the solution. The molar concentration 
was multiplied with the molecular weight [g/mol] to calculate the [w/v] concentration. 
Table 2-13 Molecular weight and molar extinction coefficient of proteins used in this study 
Protein Molecular weight 
[g/mol] 
Molar extinction 
coefficient [M -1 cm -1] 
UHRF1 
FL WT His6 
























3xFlag TTD His6 
PBR-Ring His6 











NP95 I  
FL WT His6 
TTD-PHD His6 









NP95 II  








 Polyacrylamide gel electrophoresis (SDS-PAGE) 2.3.1.2
Protein solutions were mixed with the adequate amount of 6x SDS loading buffer and 
boiled at 95 °C for 10 min to denature and prepare the sample for discontinuous 
polyacrylamide gel electrophoresis in presence of sodium dodecyl sulfate (SDS) 
(Gallagher, 2007; Laemmli, 1970). Tris glycine gels were used for protein separation with 
4% stacking gel and 10-20% resolving gel (Chapter 2.1.4). SDS-PAGE gels were cast and 
run using the Mini-Protean gel casting system. Protein samples were separated at 30-50 
mA (300 V max) in 1x SDS running buffer along side with a reference SeeBlue Plus2 Pre-
stained protein marker. 
 Western blot analysis 2.3.1.3
After SDS-PAGE electrophoresis, the gel, a nitrocellulose membrane and Whatman 
chromatography paper were equilibrated in transfer buffer (20% [v/v] methanol, 1x SDS 
running buffer) and arranged in a pile. The protein transfer for immunoblotting (Burnette, 
1981; Towbin et al., 1979) was performed using the MiniTrans Blot system. The 
equilibrated stack was packed with a Mini Gel holder cassette and placed with the core 
unit in the buffer tank containing transfer buffer. The proteins were then transferred to 
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the nitrocellulose membrane at constant voltage setting 100 V for 60-90 min at 4 °C. To 
check the transfer of proteins, the nitrocellulose membrane was incubated with Ponceau 
stain for 2 min at RT and then destained with water. Subsequently, the membrane was 
blocked with PBST (1x PBS, 0.1% [v/v] Tween20) containing 5% [w/v] BSA or milk 
powder for 30-60 min at RT. The membrane was then incubated with primary antibody 
solution (Table 2-7) containing PBST, 0.02% sodium azide and 2.5% [w/v] BSA or milk 
powder for 1 h at RT or o/n at 4 °C. After primary antibody incubation, the blot was 
washed three times with PBST and the according HRP-coupled secondary antibody 
solution (Table 2-7) in PBST was added. After 1 h incubation at RT, the membrane was 
again washed with PBST three times. The immunostaining was than visualized by an 
HRP-dependent chemiluminescence reaction using ECL or ECL Plus Western Blotting 
Detection Reagent according to the manufacturer’s instructions. The luminescence was 
documented using the gel documentation system ChemiDoc MP. 
 Coomassie staining of polyacrylamide gels 2.3.1.4
After running, SDS-PAGE gels were stained using Coomassie Blue staining solution to 
visualize proteins (Vesterberg et al., 1977). Gels were incubated with the stain for 20-30 
min while rocking and subsequently destained with destaining solution for 1 h or water 
o/n at RT. 
2.3.2  Expression and purification of proteins 
 Bacterial expression 2.3.2.1
Chemically competent BL21 (DE3) codon plus RIL were transformed with a bacterial 
expression vector carrying the coding sequence of the required protein. A single colony of 
this transformation was then used to inoculate a pre-culture of 200 ml 2xYT medium with 
0.4% glucose and antibiotic. The pre-culture was incubated for 16 h at 37 °C, 125 rpm and 
was subsequently diluted 1:40 in 3 L of pre-warmed 2xYT medium containing 0.4% 
glucose and antibiotic. Bacterial cultures were grown at 37 °C, 125 rpm to OD600 of 0.5. 
Protein expression was induced by adding 0.5 mM IPTG at 25 °C for 3-4 h (Gelato et al., 
2014; Sambrook and Russell, 2001). 
Proteins that were used for cyclic peptide screening experiments (UHRF1 FL WT His10 
and UHRF1 FL RKS 649/650/651 AAA mt His10) were transformed into chemically 
competent E. coli Rosetta and treated as described above. The culture was then diluted 
1:50 in the described medium and grown until it reached an OD600 of 0.5. The protein 
expression was induced using 0.5 mM IPTG and incubated o/n at 18 °C and 125 rpm. 
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Subsequently, bacteria were pelleted by centrifugation at 6,200x g for 15 min at 4 °C and 
the bacterial pellets were stored at -20 °C until further use. 
 Purification by metal ion affinity chromatography 2.3.2.2
UHRF1 FL and domains were purified at pH 8.0, while NP95 FL proteins and domains 
were purified at pH 7.5. The bacterial pellets of 3 L cultures were resuspended in 40 ml 
lysis buffer. Protease inhibitor cocktail (EDTA-free) was added immediately before the 
purification to the pre-cooled lysis buffer. The resuspended bacteria were lysed by 3-4 
passages at 1,000-1,500 bar through the EmulsiFlex C5 cell disruptor. Bacterial cell debris 
and insoluble material was removed by centrifugation at 25,000x g for 25 min at 4 °C. The 
supernatant was applied to 5 ml HisPur Cobalt resin equilibrated with lysis buffer in a 
gravity flow column and was loaded onto the column twice. The resin was than washed 
with 150 to 250 ml of pre-cooled wash buffer and the protein was subsequently eluted in 
20-25 ml elution buffer. NP95 PBR-RING was washed with 250 ml of wash buffer 
containing 1 M NaCl. Eluted fractions were dialyzed o/n against dialysis buffer with 
freshly added DTT using SpectraPor MWCO 3,500 Da dialysis tubing. Purified proteins 
were checked by SDS-PAGE electrophoresis. Subsequently, the proteins were 
concentrated using Amicon Ultra centrifugal filter units and stored at 4 °C. 
2.3.3 Biophysical and biochemical binding assays 
 Fluorescence polarization (FP) 2.3.3.1
Fluorescence polarization experiments (Tota et al., 1994) were performed using the 
HIDEX PlateChameleon or TECAN Infinite M1000 Pro plate reader at 4 °C and RT. The 
association of fluorescently labeled peptides with purified recombinant protein was 
measured. The protein solution was adjusted to a starting concentration of 50 or 100 *M. 
The solution was then repeatedly diluted 1:1 resulting in a 12 step dilution series. 
Fluorescent peptide (final concentration 10 nM) was mixed with each protein dilution in a 
final reaction volume of 10 µl per measurement point and reactions were transferred to a 
black flat bottom 384-well plate. Binding reactions were incubated on ice for 10 min and 
transferred to the plate reader. The fluorophore was excited using linear polarized light at 
485 nm and the intensity of parallel and perpendicular orientated light emitted at 535 nm 
was measured. Fluorescence polarization was calculated from the measured intensities 
using the following equation: 
  𝑃𝑃 =   
𝐼𝐼∥ − 𝐺𝐺 ∗    𝐼𝐼!
𝐼𝐼∥ + 𝐺𝐺 ∗    𝐼𝐼!
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𝐼𝐼∥   is the intensity of the parallel oriented emitted light; 𝐼𝐼! is the intensity of the 
perpendicular oriented emitted light; 𝐺𝐺 is a device specific factor. The anisotropy values 
were calculated by: 




Datasets were analyzed using KaleidaGraph and the data points in each dilution series 
were fit with the equation:   




For:  𝑌𝑌 = 𝐹𝐹 𝑀𝑀0  
With m1 and m2 being the minimum and maximum boundary values, respectively, and 
KD the estimated dissociation constant. Each titration series was normalized to a curve 
where m1 (Min) = 0 and m2 (Max) = 1, and then averaged with the normalized curves of 
all replicates with a minimum of three independent measurements. 
 Peptide pull down assay with recombinant protein (PPD) 2.3.3.2
For peptide pull down assays, 40 µl streptavidin paramagnetic bead suspension 
(MagneSphere) were used per reaction. Beads were washed three times with PBS in low-
binding tubes before incubation in 200 µl PBS with 10 µg biotin labeled peptide (H3 
unmodified, H3K9me3) or equivalent amount water for 2 h at 4 °C with rotation. The 
peptide-loaded or unloaded control beads were washed three times with PBS and 
equilibrated with PD300 buffer (20 mM HEPES pH 7.9/7.5, 300 mM KCl, 0.2% [v/v] 
Triton X-100, 20% [v/v] glycerol). Subsequently, the beads were charged with 5-10 µg 
recombinant protein and the reaction was adjusted to 500 µl with PD300 buffer. Each 
peptide pull down reaction was then incubated rotating at 4 °C for 3-5 h. Beads were 
washed six times with 200 µl PD300 buffer and the supernatant carefully and thoroughly 
removed. The beads were resuspended in 20 µl 6x SDS loading buffer and eluted by 
boiling for 5 minutes. 
 Co-immunoprecipitation (Co-IP)  2.3.3.3
Co-IP with recombinant UHRF1 domains: For co-immunoprecipitation, 0.22 nmol 
recombinant UHRF1 PBR-RING were mixed with 1 µl α-UHRF1 antibody. BSA was 
added to 5% [w/v] final concentration. The mix was incubated for 1 h at 4 °C. In parallel, 
10 µL Dynabeads M280 sheep anti mouse (Invitrogen) were washed once with PBS, twice 
with IP150 buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5% [v/v] glycerol, 0.05% [v/v] 
Triton X-100), and resuspended in IP150 buffer supplemented with 5% [w/v] BSA. After 
Material and Methods 
 
40 
incubation, the 10 µl equilibrated beads were added to the UHRF1 PBR-RING/antibody 
mixture and the reaction was rotated at 4 °C. After 1 h incubation, 0.22 nmol UHRF1 TTD 
or TTD-PHD were added to UHRF1 PBR-RING/antibody/bead mix for 3 h. All Co-IP 
reactions were washed four times, 1 min each with 150 µl IP150 buffer and eluted using  
20 µl 6x SDS loading buffer (Gelato et al., 2014). 
Co-IP reactions with H3 peptide as competitor: biotin-labeled unmodified H3 or H3K9me3 
biotin peptides were pre-incubated with UHRF1 TTD for 30-60 min before addition to 
UHRF1 PBR-RING/antibody/bead mixture. The molar ratio of UHRF1 TTD to H3 
peptide was 1:5. All other steps were carried out as described above. 
Co-IP reactions with PIPs as competitor: UHRF1 PBR-RING and PIPs were mixed in a molar 
ratio of 1:10 and incubated at 4 °C o/n, before α-UHRF1 antibody was added. For Co-IP 
with PIP, the detergent was omitted in the IP150 buffer. The subsequent steps outlined 
above were carried out as described. 
Co-IP reactions with cyclic peptide as competitor: UHRF1 PBR-RING and the cyclic peptides 
were mixed at a molar ratio of 1:5 and incubated at 4 °C o/n before the α-UHRF1 
antibody was added to the mixture. The subsequent steps were carried out as described 
above. 
Co-IP with recombinant NP95 domains I: For co-immunoprecipitation, 10 µl Myc-Tag mouse 
mAB magnetic bead conjugate were washed once with PBS, twice with IP150 buffer, and 
resuspended in IP150 buffer supplemented with 5% [w/v] BSA. The beads were mixed 
with 0.44 nmol recombinant NP95 myc-PBR-RING and BSA was added to 5% [w/v] final 
concentration. After 3 h incubation at 4 °C with rotation, the NP95 myc-PBR-
RING/antibody/bead mix was supplemented with 1.1 nmol of NP95 I or NP95 II TTD-
PHD. After three more hours of incubation, all Co-IP reactions were washed four times 
1 min each with 150 µl IP150 buffer and eluted using 20 µl 6x SDS loading buffer.  
Co-IP with recombinant NP95 domains II: For co-immunoprecipitation, 0.22 nmol 
recombinant NP95 3xFLAG-TTD were mixed with 1 µl α-Flag M2 antibody and BSA was 
added to 5% [w/v] final concentration. The mix was incubated for 1 h at 4 °C with 
rotation. In parallel, 10 µL Dynabeads M280 sheep anti mouse were washed once with 
PBS and twice with IP150 buffer. The beads were then resuspended in IP150 buffer 
supplemented with 5% [w/v] BSA. After Incubation, the 10 µl equilibrated beads were 
added to the NP95 3xFLAG-TTD/antibody mixture and the reaction was rotated at 4 °C. 
After 1 h, 0.44 nmol NP95 PBR-RING were added to NP95 3xFlag/antibody/bead mix 
and incubated with rotation for 3 more hours. All Co-IP reactions were washed four times 
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with 150 µl IP150 buffer and eluted using 20 µl 6x SDS loading buffer. Samples were 
analyzed by SDS-PAGE followed by western blotting, using α-His primary antibody. 
 
Figure 2-1 Flow scheme of cyclic peptide screening procedure. 
 Cyclic peptide screening 2.3.3.4
Shiori Umemoto (Laboratory of Hiroaki Suga, University of Tokyo) generated the short 
random peptides from a DNA library by transcription, fusion to DNA-PEG-CCA-
Puromycin resistance and subsequent translation (Figure 2-1) (Hayashi et al., 2012). This 
resulted in a hybrid containing not only the translated peptide but also the associated 
mRNA. The translated peptide underwent a spontaneous macro-cyclization involving the 
terminal tyrosine and cysteine residues of the peptides. A reverse transcription step 
created an mRNA/DNA hybrid that was in the end used for peptide identification using 
PCR. The affinity selection of the cyclic peptides consisted of three steps. First, pre-
clearing was used to eliminate the unspecific peptides. Second, selection A used full 
length UHRF1 R649A/K650A/S651A mutant to purge all peptides binding to the protein 
body but not the PBR. Third, selection B with WT UHRF1 selected the peptides of the 
resulting pool that were bound by the PBR. Repeating the selection procedure led to 
conversion of the whole library and enrichment of the final peptide candidates. The 
remaining identified candidates and their sequences are listed in the materials section 
(Table 2-8). 
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2.4 Cell biology methods 
2.4.1 Cell culture, transfection and synchronization 
 Passaging of mammalian cell lines 2.4.1.1
Human and murine cell lines were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 1x GlutaMax I, 4.5 g/l D-glucose, 1x non-essential amino acids, 1 mM 
sodium pyruvate and 10% HyClone BGS. Cells were seeded in 10 ml culture medium in a 
100 mm petri dish and grown at 37 °C and 5% CO2 to confluency. For passaging, the 
culture medium was removed and the cells were washed with DPBS. The cells were 
detached and separated by incubation with 1 ml of 0.05% Trypsin/EDTA solution for 2-5 
min at 37 °C and 5% CO2. Cells were then suspended in 9 ml fresh medium and harvested 
by centrifugation for 5 min at 600-800 x g. The medium was decanted; the cells were 
resuspended and diluted 1:5 to 1:10 in 10 ml of fresh culture medium.  
For freezing, cells were harvested as described above and resuspended in TC-Protector 
cell freezing medium. Aliquots of cells were stored in cryotubes at -152 °C.  
 Transfection of mammalian cells 2.4.1.2
Transfection was carried out using the Lipofectamine LTX and Plus Reagent. Before each 
transfection, mammalian cells were grown in 6-well cell culture dish or on glass cover 
slips to 50% confluency. Per well, 150 µl Opti-MEM were supplemented with 3 µl of 
Lipofectamine LTX. In parallel, vector DNA (see below) and 3 µl of Plus Reagent were 
added to an additional 150 µl Opti-MEM. Both solutions were mixed thoroughly and 
pooled. After 5 min incubation at RT, 250 µl of the resulting mixture were added to the 
cells growth medium. Each transfection were incubated at 37°C with 5% CO2 for 14-16 h. 
For localization studies, cells were transfected with mammalian expression vectors 
pmCherry / pEGFP-C1 carrying the coding sequence of UHRF1, NP95 I, NP95 II FL WT 
or mt.  
For competition experiments, 1.25 µg pmCherry UHRF1 FL WT or SRA mt vectors were 
co-transfected with 2.5 µg pEGFP-C1 PBR WT or mt expression vector per 6-well. PI5P 4-
kinase α-EE and PI5P 4-kinase β –myc in a pcDNA3.1 backbone were a gift from Nullin 
Divecha (Centre of biological sciences, University of Southampton) (Ndamukong et al., 
2010).  
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For PI5P 4-kinase α/β experiments, 1.25 µg of each WT or the mt (PI5P 4-kinase α 
G131L/Y138F and PI5P 4-kinase β D278A) vectors was co-transfected with 2.5 µg 
pmCherry WT UHRF1 plasmid.  
Large-scale transfection in 150 mm petri dishes was carried out using the CalPhos Kit 
following the manufacturer’s protocol. The vector DNA (45 µg) was mixed with 198.5 µl 
of 2 M calcium solution and diluted with sterile water up to final volume of 1.6 ml. The 
mix was vortexed while 1.6 ml of 2x HEPES-buffered saline was added gradually. After 
10 min incubation, the solution was gently mixed and added to the culture dish. The cells 
were incubated with the mix o/n at 37 °C and 5% CO2. 
 Synchronisation of mammalian cells 2.4.1.3
Cells were synchronized in M phase of the cell cycle using a thymidine/ nocodazole block 
(Whitfield et al., 2000). Cells were grown to 30-40% confluency in described growth 
medium and then treated with 2 mM thymidine for 20-24 h to arrest the cell cycle in S 
phase. The arrest was released by washing the cells with DPBS and culture medium. 
Subsequently, the cells were covered with fresh growth medium and allowed to progress 
to G2 phase. After 3 h release, 100 ng/ml nocodazole was added to the culture medium 
for 12 h to arrest the progression of the cell cycle in M phase. Thereafter, the cells were 
released from the block as described and the cell cycle progression was analyzed by flow 
cytometry. 
2.4.2 Extract preparation 
 Cytosolic and nuclear extract preparation (rapid method) 2.4.2.1
Rapid nuclear extract preparation (Osborn et al., 1989) was used for peptide pull down 
with nuclear extract and expression analysis by SDS-PAGE gel and western blot. The 
standard protocol for a confluent 150 mm petri dish was scaled depending on the 
experimental conditions. Cells were pelleted by centrifugation at 300x g for 5 min and the 
medium was decanted. The pellet was washed with 10 ml PBS once and with 500 µl buffer 
A (10 mM HEPES-NaOH pH 7.9 at 4 °C, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT and 1x 
protease inhibitor cocktail) twice. After centrifugation at 600 x g at 4 °C, the washed cell 
pellet was resuspended in 500 µl buffer A with 0.2% [v/v] NP40 and incubated on ice for 
10 min to lyse the cell membranes. The nuclei were pelleted at 600x g and the supernatant 
was saved (cytosolic fraction). The nuclear pellet was resuspended in buffer C (20 mM 
HEPES-NaOH pH 7.9 at 4 °C, 25% [v/v] glycerol, 420 mM NaCl, 0.2 mM EDTA, 1.5 mM 
MgCl2, 1 mM DTT and 1x protease inhibitor cocktail) and the nuclei were lysed using a 
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pestle B size homogenizer 20 times every 5 min for a total of 15 min on ice. Lysed nuclei 
were spun at 20,000x g for 10 min at 4 °C to pellet insoluble material. The supernatant was 
removed and diluted with 600 µl buffer D (20 mM HEPES-NaOH pH 7.9 at 4 °C, 20% 
[v/v] glycerol, 50 mM KCl, 0.2 mM EDTA). Cytosolic and nuclear extracts were flash 
frozen in liquid nitrogen and stored at -80 °C.  
 Nuclear extract preparation with MNase 2.4.2.2
A standard protocol (O'Loghlen et al., 2012) is described for a confluent 150 mm petri 
dish. This was scaled depending on the experimental conditions. Cells were pelleted by 
centrifugation at 300x g for 5 min and the medium was decanted. The pellet was washed 
with 10 ml PBS twice. Nuclei were isolated by 20 min incubation with 1 ml pre-cooled 
sucrose buffer (0.32 M sucrose, 10 mM Tris-HCl pH 8.0, !3 mM CaCl2, 2 mM MgOAc, ! 0.1 
mM EDTA, !1 mM DTT, ! 0.5-1% Triton X-100 and 1x protease inhibitor cocktail EDTA-free) 
on ice. Nuclei were recovered by centrifugation at 2,000x g for 5 min at 4 °C and washed 
once with sucrose buffer without detergent. The nuclear pellet was than resuspended in 
250 µl lysis buffer (20 mM HEPES-KOH pH 7.9, 25% [v/v] glycerol, 420 mM KCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1 mM DTT !and 1x protease inhibitor cocktail EDTA-free) and 
subjected to repeated freeze-thaw cycles using liquid nitrogen and a 37 °C water bath. 
Insoluble material was pelleted by centrifugation at 2,000x g at 4 °C. The first supernatant 
was saved and kept on ice and the pellet was resuspended in MNase buffer (20 mM 
HEPES-KOH pH 7.9, 100 mM KCl, 1 mM CaCl2, 1.5 mM MgCl2, 1 mM DTT !and 1x 
protease inhibitor cocktail EDTA-free). The chromatin fraction was solubilized by 
digestion with 100-200 U of MNase at 37 °C for 15-30 min depending on the cell line. The 
reaction was subsequently quenched by addition of 4 mM EDTA. After 5 min incubation 
on ice, the first supernatant and the MNase digest were spun at 16,000x g for 15 min. The 
two supernatants were pooled and the KCl concentration was adjusted to 150 mM final 
with a salt-free lysis buffer. 
2.4.3 Staining procedures of mammalian cells  
 Immunofluorescence 2.4.3.1
Cells were grown on glass cover slips until 80% confluency was reached. After gently 
washing the cells twice with PBS, these were fixed with 3.7% [v/v] formaldehyde/PBS 
solution for 10 min. Formaldehyde was removed by thoroughly washing cells with PBS. 
Fixed cells were permeabilized by incubation with 0.5% Triton-X-100/PBS for 5 min and 
then blocked for 30 min in blocking buffer (2.5% BSA/PBS/ 0.05% Tween-20). Cells were 
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stained with primary antibody (Table 2-7) at 4 °C for 3-5 h. Subsequently, cells were 
washed three times for 5 min each with wash buffer (1x PBS/0.05% Tween-20) and 
treated with fluorescently labeled secondary antibody (Table 2-7). The cells were carefully 
washed with wash buffer and PBS. Finally, nuclear DNA was stained 3-5 min with DAPI 
stain (100 ng/ml DAPI) in wash buffer. Cells were rinsed once with PBS and mounted 
with vectashield. For experiments with fluorescently labeled proteins, slides were directly 
stained with DAPI after fixation and mounted in a drop of vectashield. 
 Nuclear counterstaining with propidium iodide (PI) staining 2.4.3.2
Mammalian cells were synchronized as described. For propidium iodide (PI) staining, 
cells were sedimented by centrifugation at 800x g for 5 min at RT and gently washed with 
a generous amount of PBS. After PBS wash, cells were detached with a cell scraper and 
suspended in 100 µl PBS. The carefully suspended cells were fixed with 5 ml of ice-cold 
70% ethanol. Fixed cells were stored at 4 °C for up to four weeks. For PI staining, cells 
were pelleted by centrifugation at 500x g for 5 min at 4°C and the ethanol was removed. 
Cells were washed twice with PBS/ 0.1% [v/v] NP40 and were resuspended in staining 
solution (100 µg/ml PI, 0.6% NP40, 1 mg/ml RNase A in PBS) and incubated for 45 min 
on ice in the dark. After incubation, staining solution was diluted with 400 µl PBS and the 
cells were analyzed using a BD FACSCanto II flow cytometer. 
 Nuclear counterstaining with Hoechst 33342 staining 2.4.3.3
NIH3T3 cells were grown to 70-80% confluency. 5 µg/ml of Hoechst 33342 (1 mg/ml 
stock in DMSO) were added to the culture medium and the cells were stained for 45-60 
min at 37 °C with 5% CO2 (Parrilla et al., 2004). Subsequently, cells were washed twice 
with DPBS and detached from the culture dish using 0.05% of Trypsin/EDTA for 2 min. 
Cells were resuspended in growth medium and pelleted by centrifugation at 800x g for 5 
min. The pellet was washed with DPBS twice and cells were resuspended in DPBS for 






Material and Methods 
 
46 
2.4.4 Analysis of mammalian cells 
 Fluorescence microscopy 2.4.4.1
Immunofluorescence samples were imaged using the Leica TCS SP5 confocal laser-
scanning microscope equipped with a Leica HCX PL APO lambda blue 63×/1.40-0.60 OIL 
UV objective lens. DAPI fluorescence was excited by a 405 nm laser (UV diode), EGFP as 
well as Alexa 488 were excited with the 488 nm argon laser and mCherry as well as 
Alexa546 were excited using the 561 nm CW-DPSS laser. Image section and channel 
brightness were adjusted using the Leica Application Suite Advanced Fluorescence (LAS 
AF). Samples were scanned supported by photo multiplier tubes (PMT) and imaged with 
a monochrome CCD camera. The pictures were saved at 1024x1024 pixel resolution. 
Subsequently, the pictures were analyzed and processed using Adobe Photoshop 
software.  
A Zeiss Axiovert 40CFL microscope was used for cell counting and transfection control. 
The HBO50/AC mercury short-arc lamp (OSRAM) and a beam splitter were used to 
excite the fluorescent dyes and labels. 
 Flow cytometric analysis 2.4.4.2
Flow cytometric analysis was carried out using the BD FACSCanto II, which includes 
three fixed-wavelength lasers for excitation. The collection optics is able to direct 
fluorescence as well as the light scatter to the according detectors. For flow cytometric 
analysis, the BD FACSDiva soft ware was used to gate cells depending on forward and 
side scatter to exclude dead and apoptotic cells from the analysis. Propidium iodide and 
EGFP fluorescence was excited with a 488 nm blue laser and Hoechst 33342 fluorescence 
was excited with the 405 nm violet laser. In the next analysis step, cells were gated for 
EGFP fluorescence and then for the nuclear counterstain Hoechst 33342. Alternatively, 
cells were only gated for PI fluorescence. Cells without staining or fluorescence were 
excluded from analysis by plotting the forward scatter against the fluorescence intensities. 
Depending on the intensity and area of the plotted nuclear staining signal, gates were set 
to only include single cells in the analysis. Only these cells were analyzed for their cell 
cycle stage using the nuclear stain area histogram. Location and shape of histogram peaks 
was adjusted manually to fit the optimal histogram shape with the G2/M peak having 
twice the value of the G1 peak. Subsequently the BD FACSDiva software calculated the 






3.1 UHRF1 localization in cells is dependent on linker regions 
3.1.1 Heterogeneous nuclear localization of UHRF1 
UHRF1 is crucial for the recruitment of chromatin modifying enzymes to differentially 
modified loci. Thus, the accurate localization of the protein in the nucleus during the cell 
cycle and differentiation is of great importance (Chapter 1.4). Previous reports showed 
that inter-domain linker regions regulate UHRF1 interaction with H3K9me3 in vitro. I was 
particularly interested in the co-localization of UHRF1 with the H3K9me3 modification in 
cells. 
In collaboration with Kyoko Hamada (Laboratory of Wolfgang Fischle, MPI, Göttingen), I 
investigated the general cellular distribution of human UHRF1 WT protein. We examined 
the distribution of endogenous and overexpressed UHRF1 WT protein in different 
mammalian cell lines (NIH3T3, IMR90, MCF7 and U2OS) by immunofluorescence and 
determined the co-localization of the protein with the H3K9me3 histone modification. In 
human cell lines we detected the endogenous protein and the modification by indirect 
immunofluorescence. The analysis with fluorescence microscopy showed that in the 
analyzed human cell lines, U2OS, MCF7, and IMR90, the distribution pattern of UHRF1 
was generally dispersed and only few cells showed strong co-localization of UHRF1 and 
H3K9me3 (Figure 3-1A).  
In murine NIH3T3 cells we transiently expressed mCherry-tagged UHRF1 to evaluate its 
co-localization with the H3K9me3 modification in the cell nucleus. In agreement with 
previous studies, the majority of NIH3T3 cells showed clear co-localization of transiently 
expressed mCherry-UHRF1 with H3K9me3. The protein and the histone modification 
were mostly localized to pericentromeric heterochromatin (Figure 3-1B) (Karagianni et al., 












Figure 3-1 UHRF1 nuclear 
localization in different cell 
lines  
(A) Co-localization of UHRF1 and 
H3K9me3 modification were 
analyzed in U2OS, MCF7 and 
IMR90 cells using specific 
antibodies. Microscopy images of 
separate and merged fluorescence 
channels (UHRF1-red, H3K9me3-
green) are shown. (B) mCherry-
tagged UHRF1 was transiently 
expressed in NIH3T3 cells. 
H3K9me3 was detected using 
specific antibodies. Microscopy 
images of separate and merged 
fluorescence channels (UHRF1-
red, H3K9me3-green) are shown. 
Scale bar represents 25 µm. 
Experiments were done in 
collaboration with Kyoko 
Hamada (Laboratory of Wolfgang 
Fischle, MPI, Göttingen).  
 
3.1.2 The TTD domain is responsible for the localization of UHRF1 to 
pericentromers 
UHRF1 comprises several domains that can specifically target the protein to 
heterochromatic regions (Bostick et al., 2007) (Rajakumara et al., 2011) (Liu et al., 2013) 
(Rothbart et al., 2013). While the exact regulation of UHRF1 sub-nuclear localization and 
chromatin association is unclear, the protein might rely on different domains for target 
binding. It was reported that the TTD as well as the SRA domain of UHRF1 contribute to 
the accurate localization of the protein to pericentromers (Rottach et al., 2010) (Liu et al., 
2013). Thus, I determined changes in UHRF1 localization to pericentromeric regions upon 
loss of TTD or SRA function in NIH3T3 cells.  
To this end, I generated mutants of full-length UHRF1 in the aromatic cage of the TTD 
domain (Y188A, Y191A) and the NKR-finger of the SRA domain (Figure 3-2A) (Rottach et 
al., 2010) (Liu et al., 2013). As shown before (Figure 3-1), in a majority of NIH3T3 cells 




DNA-methylation. I reasoned that UHRF1 co-localization with H3K9me3 and DNA-
methylation would be lost due to the mutations. 
It was shown before that pericentromeric heterochromatin can be visualized with  
4’,6’-diamidino-2-phenylindole (DAPI) staining (Matsuda and Chapman, 1991). I 
transiently expressed EGFP-labeled UHRF1 wild type or mutant protein in NIH3T3 cells 
and detected the pericentromeric heterochromatin with DAPI stain (Figure 3-2B). 
Monitoring these cells, I defined three phenotypes (Figure 3-2B). A dotted phenotype that 
is characterized by intense EGFP stained dots overlapping with the pericentromeric 
heterochromatin; an intermediate phenotype still showing these dots with an additional 
uniform EGFP background signal, and a diffuse phenotype, which only exhibited a 
uniformly distributed EGFP stain lacking any focal enrichment at pericentromeric regions. 
These categories enabled me to quantify changes in localization of UHRF1 in the nucleus 
of NIH3T3 cells upon loss of TTD or SRA domain function. 
I found that 69% of cells transiently over-expressing EGFP-UHRF1 wild type protein 
showed a focal enrichment matching the DAPI staining pattern (Figure 3-2C). This ratio 
changed when cells were transiently expressing the mutant constructs. Only 36% of TTD 
Y188A, Y191A mutant and 38% of SRA R491A mutant protein showed the characteristic 
dotted pattern. At the same time, only 7% of cells transiently expressing wild type UHRF1 
showed a diffuse nuclear EGFP signal phenotype. This diffuse fraction of cells exhibited a 
significant increase to 52% for TTD mutant and 31% for SRA mutant expressing cells. 
Almost all nuclei of cells expressing a protein carrying both mutations (Y188A, Y191A, 
R491A) displayed the diffuse phenotype (Figure 3-2D). Only 1% of cells still had a dotted 
phenotype of UHRF1 distribution and localization to the pericentromeric 
heterochromatin.  
These results demonstrate that the binding contribution of both TTD and SRA are of great 
importance for the nuclear localization of UHRF1. I showed that both domains are 
contributing equally to target the protein to pericentromeric loci in NIH3T3 cells. We had 
previously shown that, in a PBR-bound state of UHRF1, the TTD aromatic cage is not 
interacting with H3K9me3 (Chapter 1.4.5) (Gelato et al., 2014). Thus, I was particularly 
interested in the contribution of this domain to the faithful localization of UHRF1. 
Comparing the dotted phenotype fractions, I determined that 30% of the NIH3T3 cells 
showed de-localization caused by the mutation of the TTD. Therefore, I expected that an 
effect on the UHRF1 localization in cells due to TTD interaction with the PBR would only 






Figure 3-2 Nuclear localization of UHRF1 wild type and mutant in NIH3T3 cells 
(A) Schematic representation of UHRF1 domain architecture the TTD (Y188A, Y191A) and SRA (R491A) 
mutations are indicated. (B) NIH3T3 cells were transfected with EGFP-UHRF1 wild type or mutant. DAPI was 
used to stain DNA. Images were obtained by fluorescence microscopy. Localization phenotype was 
determined by signal overlap of EGFP-UHRF1 wild type or mutant (green) with DAPI-dense regions (blue). 
Representative pictures of the three identified phenotypes (dotted, intermediate and diffuse) of EGFP-UHRF1 
nuclear localization in NIH3T3 are shown. (C) UHRF1 wild type, TTD (Y188A, Y191A) and SRA (R491A) 
mutants were transiently expressed in NIH3T3 cells (n > 500). Relative quantification of cells exhibiting the 
EGFP-UHRF1 phenotypes shown in B. Error bars represent standard deviation of three independent 
experiments. (D) Representative fluorescence microscopy pictures of EGFP-UHRF1 TTD/SRA double mutant 
(Y188A, Y191A, R491A) with relative quantification of NIH3T3 cells (n > 500) exhibiting the EGFP-UHRF1 




At the same time, only 69% of NIH3T3 cells showed a focal enrichment of EGFP-UHRF1 
wild type protein to pericentromeric regions, while the other cells exhibited an 
intermediate or diffuse phenotype. Thus, release of the PBR from the TTD likely caused 
stronger focal enrichment to pericentromers in these 30% of cells, due to the increased 
binding of the domain to H3K9me3. 
3.1.3 The PBR directs the TTD-dependent nuclear localization of UHRF1 
Our previous experiments showed that the PBR residues K644, K646, K648, R649, K650, 
S651 are essential to make contacts with the TTD peptide binding groove. In vitro binding 
studies of a PBR mutant (K644A, K646A, K648A, R649A, K650A, S651A) had shown 
increased interaction with the FAM-H3(1-15)K9me3 peptide (Gelato et al., 2014). 
Therefore, we reasoned that the PBR is released from the TTD in this context. I deduced 
that mutation of this region could lead to stronger co-localization of UHRF1 with 
H3K9me3 in vivo. Therefore, I determined the influence of the mutation of the PBR on the 
localization of UHRF1 to pericentromeric heterochromatin.  
To this end, I generated an EGFP-tagged UHRF1 PBR mutant (K644A, K646A, K648A, 
R649A, K650A, S651A) to permanently release the PBR from the TTD (Figure 3-3A) 
(Gelato et al., 2014). I transiently expressed the PBR mutant EGFP-UHRF1 in NIH3T3 cells 
and determined the fractions of cells exhibiting the previously defined phenotypes 
(Chapter 3.1.2; Figure 3-2). I found that 67% of cells showed a focal enrichment of EGFP 
signal overlapping with the DAPI staining (Figure 3-3B). The remaining cells showed an 
intermediate or diffuse phenotype in 26% and 7% of the cells, respectively. Comparison of 
the co-localization of this PBR mutant and wild type UHRF1 with pericentromeric 
heterochromatin in NIH3T3 cells did not result in any significant difference in phenotype 
distribution (Figure 3-3B). Based on these findings, I deduced that the PBR mutation was 
not sufficient to change the subnuclear distribution of UHRF1. 
Since the constant release of the PBR region from the TTD surface in context of full-length 
UHRF1 did not lead to any change in the nuclear localization, I decided to investigate the 
effects of increased TTD/PBR interaction. Our laboratory had previously shown that the 
interaction of the TTD with H3K9me3 peptides is blocked upon addition of PBR-RING 
region in vitro (Gelato et al., 2014). I reasoned that additional expression of PBR-RING 
together with UHRF1 should enforce the blocking of the TTD and thereby result in 






Figure 3-3 Nuclear localization of the UHRF1 PBR mutant in NIH3T3 cells 
(A) Schematic representation of UHRF1 domain organization. The PBR mutant (K644A, K646A, K648A, 
R649A, K650A, S651A) is indicated. (B) EGFP-UHRF1 wild type or PBR mutant (K644A, K646A, K648A, 
R649A, K650A, S651A) were transiently expressed in NIH3T3 cells (n > 500). Relative quantification of cells 
that exhibited the defined EGFP-UHRF1 signal phenotypes for UHRF1 wild type and PBR mutant were 
plotted. Error bars represent standard deviation of three independent experiments. 
 
I generated a wild type EGFP-tagged PBR-RING fragment as well as controls, EGFP alone 
and the previously described EGFP-PBR-RING mutant (K644A, K646A, K648A, R649A, 
K650A, S651A) (Figure 3-4A). I transiently expressed EGFP-tagged PBR-RING or controls 
together with mCherry-UHRF1 in NIH3T3 cells (Figures 3-4B). I used the previously 
defined phenotypes (Chapter 3.1.2; Figure 3-2), dotted, intermediate and diffuse, to define 
the changes in localization of mCherry-UHRF1 to pericentromeric heterochromatin 
(Figure 3-4C). I reasoned that for strong blocking of the TTD in trans the PBR-RING has to 
be overrepresented compared to UHRF1 to compete with its binding to H3K9me3 in 
NIH3T3 cells. Thus, I exclusively analyzed cells exhibiting a strong EGFP-PBR-RING 
signal to determine the influence of the overrepresented PBR region on the mCherry-
UHRF1 localization.  
My results showed that an average of 58% of the cells exhibited a dotted localization 
phenotype of mCherry-UHRF1 when co-expressed with EGFP alone, while 29% were less 
enriched at pericentromers (intermediate) and 13% had a diffuse appearance (Figure 3-
4E). The quantification of the different phenotypes upon co-expression of wild type 
EGFP-PBR-RING indicated that around 12% of NIH3T3 cells shifted their mCherry-
UHRF1 distribution from the dotted to the intermediate or the diffuse phenotype (Figure 
3-4D). In contrast, co-expressing the mutant EGFP-PBR-RING did not result in a 
significant change in localization (Figure 3-4D, E). Comparable results were obtained 
when co-expressing the NKR-finger SRA (R491A) mutant with EGFP-PBR-RING WT 
(Figure 3-4F). The fraction of NIH3T3 cells showing a dotted phenotype was reduced by 
14% compared to the EGFP control. When mCherry-UHRF1 R491A was co-expressed 









Figure 3-4 PBR-RING changes the nuclear localization of wild type UHRF1  
(A) Schematic representation of UHRF1 domain organization highlighting the cassettes and mutants used in 
the experiments. (B) mCherry-UHRF1 together with EGFP-PBR-RING wild type (WT) or EGFP-PBR-RING 
K644A, K646A, K648A, R649A, K650A, S651A (mt) were transiently expressed in NIH3T3 cells. Total cell 
lysates were analyzed by western blotting. (C) mCherry-UHRF1 together with EGFP-PBR-RING wild type 
(WT) or EGFP-PBR-RING mutant (mt) were transiently expressed in NIH3T3 cells. Fluorescence signals were 
analyzed by confocal microscopy. Representative images of cells with different phenotypes observed at the 
indicated frequency (n > 500) are shown. DAPI was used to stain DNA. Scale bar represents 10 *m. (D) 
Relative change in phenotype distribution of wild type mCherry-UHRF1 upon co-expression of EGFP-PBR-
RING wild type (WT) and mutant (mt) compared to only EGFP control. (E) Total frequencies of different 
nuclear localization phenotype of mCherry-UHRF1 expressed together with EGFP control, EGFP-PBR-RING 
wild type (WT) or EGFP-PBR-RING mutant (mt) in NIH3T3 cells (n > 500). (F) Relative change in phenotype 
distribution of mCherry-UHRF1 R491A mutant upon co-expression of EGFP-PBR-RING wild type (WT) and 
mutant (mt) compared to only EGFP control. Error bars represent standard deviation of three independent 
experiments. 
 
My earlier experiments determined that in a fraction of 30% of NIH3T3 cells the 
localization of UHRF1 to H3K9me3-rich pericentromers is dependent on the function of 
the TTD domain (Figure 3-2). Thus, almost half of the expected fraction of cells shifted 
their phenotype upon expression of the PBR-RING but not the controls. Obviously, the 
PBR region is important for the correct localization of UHRF1 to pericentromeric 
heterochromatin in NIH3T3 cells. In addition to that, similar shifts of mCherry-UHRF1 
distribution were observed using the NKR-finger SRA (R491A) mutant. Thus, I reasoned 
that the PBR of UHRF1 is influencing the nuclear localization of the protein by its 





Figure 3-5 Influence of PI(5)P on the nuclear localization of UHRF1  
(A) Schematic representation of UHRF1 domain organization. The potential PI(5)P interaction site is indicated. 
Also, the reaction that is catalyzed by PIP4Kα/β is shown. PI(5)P is bound by the enzyme and phosphorylated 
to PI(4,5)P2. (B) mCherry-UHRF1 together with myc-PIP4Kβ/EE-PIP4Kα wild type (WT) or myc-PIP4Kβ 
(D278A)/EE-PIP4Kα (G131L/Y138F) mutant (mt) were expressed in NIH3T3 cells. Total cell lysates were 
analyzed by western blotting. (C) NIH3T3 cells were transiently expressing mCherry-UHRF1 and myc-
PIP4Kβ/EE-PIP4Kα WT or myc-PIP4Kβ/EE-PIP4Kα mt proteins. Fluorescence signals were analyzed by 
confocal microscopy. Representative images of cells with different phenotypes observed at the indicated 
frequency (n > 500) are shown. DAPI was used to stain DNA. Scale bar represents 10 *m. (D) Relative change 
in phenotype distribution of wild type mCherry-UHRF1 upon expression of myc-PIP4Kβ/EE-PIP4Kα WT or 
myc-PIP4Kβ/EE-PIP4Kα mt compared to an empty vector control. (E) Total frequencies of different nuclear 
localization phenotypes of mCherry-UHRF1 expressed together with vector control, myc-PIP4Kβ/EE-PIP4Kα 
WT or myc-PIP4Kβ/EE-PIP4Kα mt in NIH3T3 cells (n > 500). Error bars represent standard deviation of three 





3.1.4 Nuclear PI(5)P directs TTD-dependent localization of UHRF1 
We demonstrated before that the PBR of UHRF1 interacts with the small molecule 
regulator, PI(5)P. This blocked the interaction of the PBR with the TTD and improved 
binding of UHRF1 to H3K9me3 peptides (Gelato et al., 2014). My previous experiments 
showed that UHRF1 nuclear localization is dependent on the TTD domain and is affected 
by the PBR region. Thus, I wanted to analyze the putative role of PI(5)P as a small 
molecule regulator of UHRF1 sub-nuclear localization.  
It was reported previously that the pool of nuclear PI(5)P is regulated by PI(5)P 4-kinase 
β. The transient over-expression of PI(5)P 4-kinase β in MEL cells led to reduced nuclear 
PI(5)P levels (Jones et al., 2006). PI(5)P 4-kinase β is also essential for the subnuclear 
localization of PI(5)P 4-kinase α. Both enzymes metabolize PI(5)P to PI(4,5)P2 but PI(5)P 4-
kinase α was shown to be 2,000-fold more active compared to PI(5)P 4-kinase β (Bultsma 
et al., 2010). Therefore, I decided to transiently express both isoforms of PI(5)P 4-kinases 
(PIP4Ks) to effectively reduce the nuclear level of the co-factor in NIH3T3 cells (Figure 3-
5A).  
I expressed wild type and mutant EE-PIP4Kα and Myc-PIP4Kβ together with mCherry-
UHRF1 in NIH3T3 cells (Figure 3-5B) and analyzed the resulting phenotype of mCherry-
UHRF1 signal distribution (Figure 3-5C). I evaluated the experiment comparing the effects 
of the wild type as well as mutant PIP4Kα (G131L, Y138F) and Myc-PIP4Kβ (D278A) to a 
control expressing empty vector. I observed a shift from a dotted to an intermediate or 
even diffuse distribution in an average of 9% of cells upon PIP4Kα/β expression (Figure 
3-5D, E). This significant shift in UHRF1 localization was not observed when co-
expressing the PIP4Kα (G131L, Y138F)/β (D278A) mutant proteins.  
My results show that UHRF1 subnuclear localization changed upon PIP4Kα/β over-
expression in the NIH3T3 cells. This suggested that the lack of PI(5)P in this context might 
responsible for enhanced blocking of the TTD by the PBR and reduced interaction of the 
TTD with H3K9me3. Therefore, I reasoned that PI(5)P, a regulator of the TTD/PBR 
interaction in vitro, influences the nuclear localization of UHRF1 to H3K9me3-rich 







3.1.5 Novel cyclic peptides regulate the TTD/ PBR interaction  
It was reported that UHRF1 is highly expressed in different human cancerous tissues. 
This observation was linked to hypermethylation of tumor suppressor genes (Alhosin et 
al., 2011; Bronner et al., 2007; Unoki et al., 2009; Unoki et al., 2010). Therefore, it was 
proposed that UHRF1 might constitute an interesting target for new approaches in cancer 
therapy (Unoki et al., 2009). A recent study identified small molecule regulators of the 
UHRF1 SRA domain, which can alter DNA-methylation in cells (Myrianthopoulos et al., 
2016). I found that the localization of UHRF1 in vivo is not only dependent on the SRA 
domain but also on the TTD domain. I showed that the interaction of the TTD with 
H3K9me3-rich pericentromeric heterochromatin is affected by a small molecule regulator 
(PI(5)P) targeting the intramolecular interaction of the TTD with the PBR. Thus, I wanted 
to identify small molecules that have the potential to modulate the UHRF1 TTD/PBR 
interaction.  
In collaboration with the laboratory of Shiori Umemoto (Laboratory of Hiroaki Suga, 
University of Tokyo, Japan) a library of small random peptides was screened with the 
RaPID method (Random non-standard Peptide Integrated Discovery) for potential cyclic 
regulatory peptides (Hayashi et al., 2012). The candidate selection process of this method 
involves two steps, a negative and a positive selection. A PBR (R649A, K650A, S651A) 
mutant was used to perform negative selection to eliminate peptides that are not 
interacting on the basis of the PBR sequence or the PBR/TTD interaction. In the positive 
selection step, the remaining peptide candidates were screened for interaction with wild 
type UHRF1 to specifically select peptides interacting with the PBR or the PBR-bound 
conformation of the protein (Chapter 2.3.3.4). This screening procedure identified ten 
candidate peptides, L1-L5 and D1-D5 (Figure 3-6A) 
I characterized these candidate peptides to define small molecules specifically affecting 
the interaction between the PBR and the TTD. I first analyzed the affinity of the candidate 
peptides to UHRF1 wild type full-length protein using a peptide pull down assay, in 
which I used the immobilized peptides as baits for wild type UHRF1 protein (Figure 3-
6B). The results showed that UHRF1 was retained with five of the ten candidate peptides, 
namely L1, L4, D3, D4 and D5. For additional validation, I set up quantitative analysis 
using fluorescence polarization measurements (Table 3-1). Only the peptides L1, L3, L4, 
D1, D4 and D5 exhibited binding to UHRF1 full-length protein in this assay (Figure 3-6C). 
Both techniques identified L1, L4, D4 and D5 as potential candidates for the regulation of 





Figure 3-6 Regulation of the TTD/ PBR interaction by cyclic peptides  
(A) Amino acid sequences of cyclic peptide candidates resulting from the RaPID screening procedure 
performed in collaboration with Shiori Umemoto (Laboratory of Hiroaki Suga, University of Tokyo) (B) 
Peptide pull down assay with full-length wild type UHRF1. The biotin conjugated cyclic peptide candidates 
were immobilized on beads and incubated with UHRF1. Material retained after washing was analyzed by 
western blot. αUHRF1 signal (upper panel) and peptide loading control Streptavidin HRP (lower panel). 
Interaction of wild type UHRF1 (C) and UHRF1 PBR-RING fragment (D) with the indicated fluorescein 
labeled cyclic peptides was analyzed in fluorescence polarization binding experiments. (E) UHRF1 PBR-RING 
region was pre-incubated with L4, D4, D5 peptides or solvent control (Input) and coupled to beads using a 
specific antibody. Beads conjugated with the indicated peptide/PBR-RING mix and control beads were then 
incubated with UHRF1 TTD-PHD (Input) and used in a co-immunoprecipitation assay (IP). The material 





Next, I wanted to select cyclic peptides interacting with the C-terminal PBR-RING region 
of UHRF1 to find potential regulators of the PBR interaction with the TTD domain. 
Fluorescence polarization binding experiments with PBR-RING validated three of the 
above peptides L4, D4 and D5 (Figure 3-6D), as interaction partners of the PBR region. 
The peptide D5 showed the strongest interaction with PBR-RING (Kd = 6.4 µM), while L4 
and D4 were bound with a lower affinity (Kd = 15 µM). 
To determine the influence of the selected candidate peptides on the TTD/PBR 
interaction, I set up a domain co-immunoprecipitation experiment (Figure 3-6E). It had 
already been shown that the TTD but not the PHD domain co-precipitates with the PBR-
RING region (Gelato et al., 2014). In my experiment I used the PBR-RING and TTD-PHD 
regions of UHRF1. I pre-incubated the PBR-RING domain with a five-fold molar excess of 
L4, D4, D5 peptide candidates or the equivalent amount of peptide solvent and coupled it 
to beads using α-UHRF1 antibody. Subsequently, I added the TTD-PHD for co-
precipitation. The results showed that TTD-PHD was co-precipitated by PBR-RING that 
was incubated with peptide solvent but not by the antibody control, suggesting a direct 
interaction of the two UHRF1 regions. This interaction of PBR-RING with the TTD-PHD 
did not change upon addition of 5-fold molar excess of L4 peptide. In contrast, the 
addition of D4 and D5 peptides enforced the co-precipitation of TTD-PHD, arguing for 
strengthened interaction with PBR-RING. Thus, these candidate peptides might enforce 
the intramolecular interactions of UHRF1 and inhibit binding of the TTD to H3K9me3.  
Table 3-1 binding affinity of UHRF1 and PBR-RING to cyclic peptide candidates  
 
(apparent Kd values as determined by fluorescence polarization measurements in µM) 
 UHRF1 PBR-RING 
L1 21.5±4.6 38.9±23.2 
L2 - - 
L3 12.4±2.7 28.2±11.6 
L4 27.7±13.9 15.3±6.4 
L5 ND ND 
D1 36.1±21.6 88.1±56.7 
D2 74.1±33.2 ND 
D3 ND 45.6±18.8 
D4 54.4±45.0 15.1±7.6 




3.2 NP95 binding behavior is dependent on its linker regions 
UHRF1 is a factor responsible for the recruitment of DNMT1, G9a and HDAC1 to 
pericentromeric heterochromatin during S-phase of the cell cycle. Therefore, the proper 
nuclear localization of the protein, which is facilitated by the TTD and the SRA domain, is 
essential for the maintenance of epigenetic marks through continuous cell divisions. 
Others and we pointed out the importance of inter-domain linker regions in the 
regulation of UHRF1 interaction with the H3 tail (reviewed in (Tauber and Fischle, 2015)). 
At least two linker regions of the protein have been described that can influence the 
binding to H3K9me3 by differential interactions with the TTD (Figure 3-7A). The TTD-
PHD linker was shown to establish a multivalent binding mode of UHRF1 TTD and PHD 
domains binding to H3K9me3 and the unmodified N-terminus of H3, respectively (Arita 
et al., 2012; Cheng et al., 2013; Rothbart et al., 2013; Xie et al., 2012). We uncovered that the 
second linker region, the PBR, blocks the interaction of the TTD with H3K9me3. 
Consequently, UHRF1 did not specifically bind to H3K9me3 peptides in vitro (Gelato et 
al., 2014). My previous results showed that this PBR dependent blocking of the 
TTD/H3K9me3 interaction is relevant for the correct sub-nuclear localization of UHRF1.  
The structure and function of chromatin interacting domains of UHRF1 proteins of 
different vertebrate species are highly conserved (Bronner et al., 2007). Given the 
importance of the PBR region for the accurate localization of UHRF1, I reasoned that the 
inter-domain linker regions connecting these domains are also essential for the specific 
binding of UHRF1 proteins to chromatin modifications. To determine amino acid 
conservation in these regions, I performed sequence comparison of the two linkers 
between different representative species.  
3.2.1 The primary structures of TTD-PHD linker and PBR domains are 
highly conserved 
The sequences of UHRF1 orthologues from various species are highly conserved in 
vertebrates (Chapter 1.4.2) (Bronner et al., 2007). Thus, I analyzed the evolutionary 
conservation of the regulatory linker regions by comparison of amino acid sequences of a 







Figure 3-7 Sequence conservation of TTD-PHD linker and PBR  
(A) Schematic representation of the common domain structure of UHRF1 proteins of different species. (B) 
Multiple sequence alignments of sequence stretches within the TTD-PHD linker region are shown. Sequences 
of insertions found in splicing variants of mouse and chicken proteins are given. (C) Multiple sequence 
alignments of sequence stretches within the PBR region of UHRF1 are shown. A putative PIP binding 
consensus motif within the PBR is specified. All alignments were prepared using the PRALINE alignment tool 
(http://zeus.few.vu.nl/programs/pralinewww/). Numbers correspond to amino acid positions at the 
beginning and end of the respective protein sequences of the different species. UHRF1 amino acid sequences 
according to NCBI: Homo sapiens, NP_001276981.1; Mus musculus v1, NP_001104550.1, Mus musculus v2, 
NP_001104548.1, Gallus gallus v1, XP_418269.4, Gallus gallus v2, XP_004949013.1; Xenopus laevis, F6UA42.2; 
Danio rerio, NP_998242.1. 
 
I found that the TTD-PHD linker and the PBR show particular sequence conservation. The 
TTD-PHD linker has a conserved basic patch (R-R-K, K-R, R-K) that is accompanied by an 
adjacent Serine residue (Figure 3-7B). In UHRF1, a R-K-S motif in the linker was shown to 
make contacts with the TTD surface and thus establish multivalent binding of TTD and 
PHD to a single H3 tail (Arita et al., 2012; Rothbart et al., 2013). This essential R-K-S motif 
is only fully conserved in mouse (M. musculus). In chicken (G. gallus) and zebrafish (D. 
rerio), I found comparable sequences K-R-Q-S and K-R-S, respectively. Only in tropical 
clawed frog (X. tropicalis), the UHRF1 sequence does not comprise a similar sequence 
motif and only a basic patch is conserved (K-R-Q-N). Our analysis identified a second 
isoform of the protein in mouse and chicken that carries an insertion in the TTD-PHD 
linker. The large 54 amino acid insertion in chicken UHRF1 is surprisingly rich in cysteine 
and histidine residues and thus might include an alternative extension of the PHD zinc-
finger (Figure 3-7B, insertion 1). In mouse UHRF1 the insertion of 9 amino acids (P-P-P-A-
L-R-N-T-G) in NP95 isoform I (NP95 I) disrupts the conserved RKS motif in the TTD-PHD 




I have been used interchangeable in several studies (Bostick et al., 2007; Karagianni et al., 
2008; Nady et al., 2011; Nishiyama et al., 2013).  
The PBR exhibits a large basic patch with strong conservation of a sequence of basic 
residues, K-G-K-X-K-X-K-S (Figure 3-7C). Nevertheless, only the human (H. sapiens) basic 
patch sequence fit the described putative PIP recognition motif K/R-(X)3-7 -K-X-K/R-K/R 
(Figure 3-7C) (Lewis et al., 2011). Similar to the TTD-PHD linker, an adjacent serine 
residue accompanies the basic patches in all sequences analyzed. Strikingly, the amino 
acid conservation in all sequences mainly involved residues that were shown to be 
essential for the interaction of the TTD-PHD linker or the PBR with the TTD (Arita et al., 
2012; Gelato et al., 2014; Rothbart et al., 2013). 
3.2.2 The PBR region does not regulate NP95 binding to H3K9me3 
 Comparison of UHRF1 and NP95 binding to the H3 tail using FP 3.2.2.1
In mouse, I found two splicing variants of UHRF1, NP95 I and II. NP95 I TTD-PHD linker 
comprised a 9 amino acid insertion disrupting the described characteristic R-K-S motif. 
Due to this linker insertion, I hypothesized that the binding behavior of NP95 I differs 
from UHRF1 as well as NP95 II. At the same time, I expected that UHRF1 and NP95 II 
exhibit similarities in their H3K9me3 binding.  
I used these peptides in a fluorescence polarization read out, to compare the binding of 
UHRF1, NP95 I and NP95 II to the H3 tail and to determine how the different linker 
regions affect the binding of the TTD to H3K9me3, the PHD interaction with the H3 
unmodified N-terminus and the multivalent binding mode of both domains. Our 
previous study revealed H3 tail peptides that target specific domains of UHRF1 (TTD, 
PHD) or combinations of these (TTD+PHD) (Table 3-2) (Gelato et al., 2014). All peptides 
used for fluorescence polarization experiments comprised the amino acids 1 to 15 of the 
histone H3 tail. The FAM-H3(1-15)K9me3 peptide was additionally tri-methylated at the 
K9 residue and labeled with FAM at the very N-terminus. This peptide was exclusively 
bound by the TTD and not by the PHD domain. The H3(1-15)unmod-FAM peptide 
carried no modifications and was labeled with FAM at its C-terminus. It was bound by 
the PHD but not by the TTD. The third peptide H3(1-15)K9me3-FAM was tri-methylated 
at the K9 and labeled with FAM at the C-terminal end and hence was able to bind to both 





Table 3-2 Peptides used for fluorescence polarization and binding domains of UHRF1/ NP95 
Peptide Binding domain 
FAM-H3(1-15)K9me3 TTD 
H3(1-15)unmod-FAM PHD 
H3(1-15)K9me3-FAM TTD, PHD 
 
 
Table 3-3 binding affinity of all fragments and mutants of UHRF1 and NP95 to indicated peptides  
(apparent Kd values as determined by fluorescence polarization measurements in µM) 
Protein Cassette Mutation FAM-H3K9me3 1-15 H3 unmod 1-15 -FAM H3K9me3 1-15 -FAM 
UHRF1 full-length  ND 16.1±2.3 10.7±1.9 
  insertion mt ND 13.9±1.9 16.9±2.8 
 TTD  3.1±0.9 ND 1.9±0.7 
 TTD-PHD  15.9±4.6 1.9±0.9 1.3±0.5 
  insertion mt 64.9±103.5 1.3±0.6 2.2±0.8 
 PBR-RING  ND ND ND 
      
NP95 TTD  3.4±0.5 ND 2.6±0.7 
 PBR-RING  ND ND ND 
      
NP95 I full-length  ND 17.4±2.1 9.9±0.6 
  PPP-AAA ND 18.6±3.0 10.3±1.2 
  R-A ND 14.8±2.8 19.9±2.5 
  KS-AA ND 8.7±1.7 5.8±1.1 
  3KA ND 26.5±6.8 23.7±4.2 
  4KA ND 18.6±3.7 14.8±2.2 
 TTD-PHD  ND 2.9±0.4 1.9±0.2 
  YY-AA ND 10.3±1.2 12.1±1.1 
  DE-AA ND 39.5±8.9 46.9±12.1 
  PPP-AAA 11.1±2.2 3.8±0.7 4.5±0.95 
  R-A 5.0±0.7 2.2±0.3 2.4±0.3 
  KS-AA ND 2.5±0.5 2.5±0.5 
      
NP95 II full-length  39.8±11.2 37.0±14.9 24.8±2.7 
  RKS-AAA 29.3±6.3 12.1±2.1 14.3±2.3 
  3KA ND 28.5±9.7 43.9±12.2 
  4KA ND 33.1±11.3 29.2±8.6 
 TTD-PHD  21.7±6.1 11.1±1.5 6.3±0.65 
  YY-AA ND 10.4±2.5 13.6±3.2 
  DE-AA 16.3±3.5 ND 27.7±3.1 






 Full-length wild type UHRF1 and NP95 I show similar H3 tail binding 3.2.2.2
Our previous work had identified discrepancies between the H3K9me3 binding 
specificity of the TTD-PHD region and the full-length UHRF1 protein (Gelato et al., 2014). 
We found that the binding to H3K9me3 in context of the full-length protein is impaired by 
the interaction of the TTD with the PBR region. The PBR region is an inter-domain linker 
region in the C-terminus of the protein. It was shown to interact with the TTD surface of 
UHRF1 and blocked the interaction with H3K9me3 (Gelato et al., 2014). As described 
before, sequence comparison of the PBR region in mouse and human UHRF1 revealed 
high similarity (Chapter 3.2.1). This suggested a similar role of the PBR in human UHRF1 
and the two murine variants. To detect the potential influence of the PBR on the H3K9me3 
binding, I compared the H3 tail binding behavior of the full-length proteins of NP95 I and 
II with UHRF1 (Figure 3-8A). 
First, I investigated the H3 tail binding behavior using a peptide pull down assay with  
C-terminally biotin-labeled H3(1-20) unmodified or H3(1-20)K9me3 peptides. We had 
already described that in a similar assay with the wild type full-length UHRF1, the 
protein is similarly recovered by both peptides (Gelato et al., 2014). Similar to UHRF1, my 
experiments showed that murine variant NP95 I was recovered equally well by 
unmodified and K9 tri-methylated H3 tail peptides (amino acids 1-20) (Figure 3-8B). In 
contrast, NP95 II showed clear preference for the K9 tri-methylated peptide.  
To analyze the binding contribution of the single domains in context of the full-length 
proteins, I performed fluorescence polarization binding experiments with the described 
peptides targeting TTD, PHD or TTD and PHD. As previously reported, UHRF1 bound to 
the C-terminally FAM tagged peptides regardless of their K9 methylation, while it failed 
to interact with the FAM-H3(1-15)K9me3 peptide. This clearly showed that the TTD is not 
contributing to peptide binding in this context (Figure 3-8C) (Gelato et al., 2014). 
Fluorescence polarization experiments with NP95 I and the defined H3 tail peptides 
revealed a binding behavior comparable to UHRF1, as already suggested by the peptide 
pull down assay (Figure 3-8B, D). NP95 I bound to the C-terminally FAM-labeled 
unmodified  
(Kd = 17.4 µM) and K9 trimethylated (Kd = 9.9 µM) H3 tail peptides. In contrast, NP95 II 
moderately bound to all peptides regardless of their label or modification. Based on these 
findings, I reasoned that not only PHD but also the TTD is contributing to the peptide 





Contrary to my initial hypothesis, UHRF1 binding to the H3 tail differed from NP95 II, 
despite their strong sequence similarity. Instead, NP95 I and UHRF1 exhibited a similar 
H3K9me3 binding behavior. Both proteins did not interact with FAM-H3K9me3 peptide, 
suggesting that the TTD domain is blocked in context of the full-length wild type proteins 
and does not contribute to the H3 tail interaction. Given the sequence similarities of 
UHRF1 and NP95 in the PBR region, I reasoned that the block of the TTD might be 
conserved in NP95 I but not in NP95 II. 
 
Figure 3-8 Binding behavior of the two NP95 isoforms  
(A) Schematic representation of the domain organization of UHRF1, NP95 I and NP95 II. The TTD-PHD linker 
and the PBR region (red) and the sequence of the TTD-PHD linker insertion of NP95 I are highlighted. (B) Full 
length NP95 I and NP95 II wild type (NP95 FL) were used in a peptide pull down assay with no peptide 
(mock) or biotin conjugated H3 unmodified (H3 unmod) and H3K9me3 1-20 (H3K9me3) peptides. Western 
blot analysis of material recovered after washing is shown. (C) UHRF1, (D) NP95 I and (E) NP95 II full-length 
wild type protein was used in fluorescence polarization experiments with the indicated peptides. Fraction 
bound of labeled peptides was plotted depending on protein concentration. Error bars represent standard 





 Mutation of the PBR in NP95 affects binding to the H3 tail 3.2.2.3
Based on my previous results, I deduced a role of the PBR region in the regulation of 
H3K9me3 binding of NP95 I but not NP95 II. Thus, I wanted to analyze the role of the 
PBR in the NP95 proteins. In UHRF1, we had shown that mutation of basic residues in the 
PBR (K644A, K6464, K648A, R649A, K650A, S651A) released the block of the TTD domain, 
which resulted in improved binding to H3K9me3. Therefore, I wanted to investigate the 
influence of similar mutations on the H3 tail binding of NP95 I and II. 
The sequence comparison of the PBR region in the human and murine proteins had 
shown high sequence similarity and a common K-G-K-X-K-X-K-S motif. Based on this 
consensus motif, I generated a first PBR mutant in NP95 (4K-A). Studying the sequence of 
the SRA-RING linker in NP95, I found a second basic patch with the sequence K-E-K-S-R-
K-R. Since this sequence had considerable similarities with the consensus motif, I decided 
to generate a second PBR mutant in NP95 (3K-A). I performed mutagenesis of lysine 
residues in both these regions to impair charge-based interactions of these polybasic 
patches. In the first mutant, I replaced the K622, K624, K627 in NP95 Ι or K614, K616, K619 
in NP95 II with alanine (3K-A). In the second mutant, I mutated K641, K644, K646, K648 
in NP95 Ι or K633, K636, K638, K640 in NP95 II to alanine (4K-A; Figure 3-9A).  
Fluorescence polarization measurements of these mutants showed that the 3K-A mutation 
caused a moderate loss of binding to all C-terminally H3(1-15)K9me3-FAM peptide in 
context of NP95 I (Kd = 23.7 µM) as well as NP95 II (Kd = 43.9 µM) (Figure 3-9B, C). In 
NP95 II the mutation additionally caused a severe loss of FAM-H3(1-15)K9me3 peptide 
interaction (Figure 3-9C). Comparing NP95 Ι and NP95 II 3K-A mutants I recognized that 
the mutation had similar effects on the binding behavior of both proteins.  
As described, the 4K-A mutations comprised residues of the conserved PBR consensus 
sequence (Figure 3-7C). The NP95 I 4K-A mutant exhibited comparable binding behavior 
as the wild type protein (Figure 3-9D, 3-8D). In contrast, in NP95 II the 4K-A mutation led 
to a moderate loss of binding to H3(1-15)K9me3-FAM and H3(1-15)unmod-FAM peptides 






Figure 3-9 PBR mutations of NP95 Ι and II affect the binding to the H3 tail 
(A) Schematic representation of the domain architecture of NP95. Mutants used for the experiments are 
indicated. (B) NP95 I K622A, K624A, K627A mutant (3KA mt) and (C) NP95 II K614A, K616A, K619A mutant 
(3KA mt) were used in fluorescence polarization binding experiments with indicated FAM-labeled peptides. 
(D) NP95 I K641A, K644A, K646A, K648A mutant (4KA mt) and (E) NP95 II K633A, K636A, K638A, K640A 
mutant (4KA mt) were used in fluorescence polarization binding experiments with indicated FAM-labeled 
peptides. Fraction bound of labeled peptides was plotted depending on protein concentration. Error bars 
represent standard deviation of at least three independent experiments 
 
NP95 II binding to the H3 tail was negatively affected by the 3K-A and 4K-A mutations. 
As NP95 II, NP95 I binding affinity for H3 tail peptides was decreased by the 3K-A 




K-G-K-X-K-X-K-S motif (4K-A). In contrast to UHRF1, mutations of polybasic patches in 
the SRA-RING linker had a different effect on the H3 tail binding behavior of NP95. In 
conclusion, the PBR regions of NP95 Ι and II have functions different from the UHRF1 
PBR.  
 The PBR region does not affect TTD binding to H3K9me3 in NP95 3.2.2.4
We had shown that the PBR in UHRF1 interacts with the TTD domain. This interaction is 
the basis of the PBR dependent regulatory mechanism. Based on my former results, I 
deduced a different role of the PBR region in UHRF1 and NP95. To analyze these 
differences between UHRF1 and NP95 in greater detail, I wanted to investigate 
differences in the PBR and TTD interaction of the proteins as well as the influence of the 
PBR on the binding of the TTD. 
Initially, I investigated the interaction between the two TTD-PHD cassettes and the PBR-
RING of UHRF1 and NP95 using co-immunoprecipitation. I used a specific antibody to 
immobilize UHRF1 PBR-RING on beads. After incubation with TTD-PHD in a 1:1 molar 
ratio and washing, I detected strong recovery of TTD-PHD on PBR-RING coupled beads 
but not on antibody control beads. This result showed a strong interaction of these two 
regions in UHRF1 (Figure 3-10A). I performed a similar experiment with immobilized 
PBR-RING and the two TTD-PHD regions of NP95 using a 5-fold molar excess of the 
TTD-PHD (Figure 3-10B). This experiment showed a weak interaction of the PBR-RING 
with TTD-PHD of NP95 I but not NP95 II This weak interaction raised questions if the 
PBR region of NP95 could influence the binding of the TTD to H3K9me3.  
Next, I wanted to determine if the PBR-RING causes the blocking of the TTD domain and 
a loss of binding to H3K9me3 in NP95 I as it was shown for UHRF1 (Gelato et al., 2014). I 
used fluorescence polarization to characterize changes in binding of the TTD of NP95 to 
H3K9me3 upon addition of PBR-RING. I performed similar experiments with UHRF1 as a 
control. The UHRF1 TTD domain alone was specifically binding to H3K9me3 peptides, 
while it did not interact with the unmodified peptide (Figure 3-10C). As already 
described, the binding to H3K9me3 peptide was lost upon addition of 2-fold molar excess 
of PBR-RING to the binding reaction (Figure 3-10D) (Gelato et al., 2014). The TTD domain 
of NP95 showed specific binding to the FAM-H3(1-15)K9me3 and H3(1-15)K9me3-FAM 
peptides, comparable with the UHRF1 TTD (Figure 3-10C, E). In contrast to UHRF1, the 
NP95 TTD did not exhibit any significant change in its binding to FAM-H3(1-15)K9me3 
peptide in presence of 2-fold molar excess of PBR-RING (Figure 3-16C, D). Contrary, there 
was substantial gain of binding of both TTD-PHD to the H3(1-15)unmod-FAM when PBR-





Figure 3-10 Weak interaction of the TTD-PHD and PBR-RING region of NP95  
(A) UHRF1 PBR-RING region was coupled to beads using a specific antibody. Beads conjugated with the 
PBR-RING or control beads were then incubated with UHRF1 TTD-PHD (Input) and used in a 
 co-immunoprecipitation assay (IP). The material retained after washing was analyzed by western blot using 
α-His antibody. (B) NP95 PBR-RING region was coupled to beads using a specific antibody. Beads conjugated 
with the PBR-RING or control beads were then incubated with NP95 I or II TTD-PHD (Input) and used in a 




α-His antibody. (C) Fluorescence polarization binding experiments of UHRF1 TTD interaction with indicated 
FAM-labeled peptides. (D) Fluorescence polarization binding experiments of UHRF1 TTD interaction with 
FAM-H3(1-15)K9me3 peptide with and without 2-fold excess of PBR-RING added. (E) Fluorescence 
polarization binding experiments of NP95 TTD interaction with indicated FAM-labeled peptides. (F) 
Fluorescence polarization binding experiments of UHRF1 TTD interaction with FAM-H3(1-15)K9me3 peptide 
with and without 2-fold excess of PBR-RING added. Fraction bound of labeled peptides was plotted 
depending on protein concentration. Error bars represent standard deviation of at least three independent 
experiments. 
 
Contrary to the effects seen in context of UHRF1, my results showed that the NP95 PBR 
did not interact with the TTD-PHD region of NP95 II but was weakly binding to TTD-
PHD of NP95 I. My previous results showed that the TTD domain of NP95 I was blocked 
in context of the full-length protein. However, I could not detect an effect of the PBR on 
the target binding of the NP95 TTD, as detected for UHRF1 TTD (Gelato et al., 2014). This 
revealed major differences in the regulation of NP95 I and UHRF1 TTD interaction with 
H3K9me3. Further, these findings suggested that the TTD in context of NP95 I is blocked 
by a different region but the PBR.  
3.2.3 NP95 binding to H3 tail is regulated by different TTD-PHD linker 
regions 
 The TTD-PHD region of UHRF1 and NP95 II shows similar H3 tail 3.2.3.1
binding 
Based on the different H3 tail binding behavior of NP95 I and II in context of the full 
length protein, I hypothesized that the TTD blocking observed in NP95 I might be a result 
of the TTD-PHD linker insertion. To investigate the role of the TTD-PHD linker in the 
NP95 isoforms in comparison to UHRF1, I generated TTD-PHD fragments of UHRF1 and 
the NP95 variants (Figure 3-11A). I performed a peptide pull down assay, using peptides 
comprising amino acids 1 to 20 of the H3 tail unmodified as well as tri-methylated at K9. 
H3(1-20) unmodified or H3(1-20)K9me3 peptide were C-terminally biotin-labeled. Our 
laboratory had previously shown that UHRF1 TTD-PHD specifically enriches at H3(1-
20)K9me3 peptide in this context (Gelato et al., 2014). I analyzed the TTD-PHD of the two 
NP95 isoforms in the same way. The results showed that NP95 II TTD-PHD preferentially 
bound to the H3K9me3 peptide, comparable to UHRF1 (Figure 3-11B). In contrast, I found 






Figure 3-11 Binding behavior of the TTD-PHD fragments of the two NP95 isoforms  
(A) Schematic representation of the TTD-PHD fragment of UHRF1, NP95 I and NP95 II the TTD-PHD linker 
(red) and the sequence of the TTD-PHD linker insertion of NP95 I are highlighted. (B) TTD-PHD fragment of 
NP95 I and NP95 II wild type (TTD-PHD) were used in a peptide pull down assay with no peptide (mock) or 
biotin conjugated H3(1-20) unmodified (H3 unmod) and H3(1-20)K9me3 (H3K9me3) peptides. Material 
recovered after washing was analyzed by western blot. (C) UHRF1, (D) NP95 I and (E) NP95 II wild type 
TTD-PHD fragments were used in fluorescence polarization experiments with the indicated peptides. Fraction 
bound of labeled peptides was plotted depending on protein concentration. Error bars represent standard 
deviation of at least three independent experiments. 
 
Furter, I analyzed the TTD-PHD domains in fluorescence polarization binding 
experiments using the described fluorescently labeled peptides. The binding studies of 
UHRF1 TTD-PHD verified the described differences compared to the full-length protein 
(Gelato et al., 2014). The protein bound to all peptides analyzed with a strong preference 
for C-terminally FAM labeled peptides (Figure 3-11C). In contrast, the NP95 I TTD-PHD 
did not bind to the FAM H3K9me3 1-15 peptide. However, it showed robust interaction 




peptides (Figure 3-11D). NP95 II TTD-PHD interacted with FAM-H3(1-15)K9me3 (Kd = 22 
µM) and H3(1-15)unmod-FAM (Kd = 11 µM). The interaction with the bivalent peptide, 
H3(1-15)K9me3-FAM (Kd = 6 µM), was stronger compared to the peptides that were only 
bound by TTD or PHD domain alone (Figure 3-11E).  
In agreement with the results of the peptide pull down assay (Figure 3-11B), the TTD-
PHD of NP95 II bound to H3 peptides comparable to UHRF1 (Figure 3-11C, E). It 
interacted with all peptides independent of their modification status, suggesting a 
contribution of TTD as well as PHD to H3 tail interaction. In contrast, NP95 I TTD-PHD 
did not interact with the FAM-H3(1-15)K9me3 peptide that exclusively binds to the TTD 
domain. I reasoned that the TTD domain is not able to bind to K9me3 in context of the 
NP95 I TTD-PHD. Given the differences in binding of NP95 I and NP95 II TTD-PHD to 
H3K9me3, the results suggested a potential role of the NP95 I TTD-PHD linker insertion 
in blocking the TTD/H3K9me3 interaction. 
 The TTD domain is blocked in NP95 I but not NP95 II  3.2.3.2
The results to this end indicated that the TTD domain of NP95 I is not binding to 
H3K9me3 in context of the isolated TTD-PHD region and the full-length protein, while 
the TTD of NP95 II is functional under comparable conditions. To validate these 
differences in the H3 tail binding of NP95 Ι and II, I investigated the respective TTD and 
PHD mutants of both proteins (Figure 3-12A). I prepared mutants that perturbed the 
aromatic cage of the NP95 TTD (Y184A, Y187A) or the interaction of PHD with the A1 and 
R2 of the H3 tail (D339A, E340A or D331A, E332A) based on sequence conservation and 
domain similarity with UHRF1 (Gelato et al., 2014; Rothbart et al., 2013). I analyzed the 
resulting mutant TTD-PHD fragments of NP95 Ι and NP95 II using fluorescence 
polarization binding experiments. 
I found that the mutation of the TTD (Y184A, Y187A) of NP95 I TTD-PHD did not change 
the binding behavior compared to the wild type TTD-PHD (Figure 3-12B). The protein 
was still binding the C-terminally FAM-labeled H3(1-15)unmod (Kd = 10.3 µM) and 
H3(1-15)K9me3 (Kd = 12.1 µM) peptides but not the N-terminally FAM-labeled  
H3(1-15)K9me3 peptide. At the same time, the mutation of the NP95 I PHD domain 
(D339A, E340A) led to a severe loss of binding to all of three tested peptides (Figure 3-
12C). In contrast, the TTD mutant of NP95 II (Y184A, Y187A) still bound to the two  
C-terminally labeled peptides (Kd = 10.4 µM; Kd = 13.6 µM) but not to the N-terminally 
FAM-labeled H3(1-15)K9me3 (Figure 3-12D). The NP95 II PHD mutant (D331A, E332A) 




(Kd = 16 µM; Kd = 28 µM), while the H3(1-15)unmod-FAM peptide was not engaged 
(Figure 3-12E).  
 
Figure 3-12 Differential H3 tail binding by PHD mutants of the two NP95 TTD-PHD fragments  
(A) Schematic representation of the TTD-PHD fragment of NP95 I and NP95 II the TTD-PHD linker (red) and 
the TTD-PHD fragment mutants that were used for the experiments are highlighted. NP95 I TTD-PHD 
fragment TTD mutant (Y184A, Y187A) (B) and PHD mutant (D339A E340A) (C) were used in fluorescence 
polarization experiments with the indicated peptides. NP95 II TTD-PHD fragment TTD mutant (Y184A, 
Y187A) (D) and PHD mutant (D339A, E340A) (E) were used in fluorescence polarization experiments with the 
indicated peptides. Fraction bound of labeled peptides was plotted depending on protein concentration. Error 





Since mutation of the PHD domain had different consequences in NP95 Ι and II TTD-PHD 
fragments, I concluded that NP95 I TTD-PHD establishes interaction with the H3 tail only 
by the PHD domain. The mutation of the PHD domain of NP95 I caused a total loss of 
interaction with the H3 tail, whereas mutation of the PHD domain of NP95 II only led to 
loss of binding to the H3(1-15)unmod-FAM peptide. This suggested that the NP95 I TTD 
domain interaction with H3K9me3 is blocked. Since both NP95 wild type TTD-PHD 
fragments only differed by a nine amino acid insertion in the TTD-PHD linker, I reasoned 
that this linker region is directly or indirectly causing the block of the TTD. 
 The NP95 I TTD is blocked by the TTD-PHD linker insertion 3.2.3.3
Based on my previous results, I hypothesized that the TTD-PHD linker insertion of NP95 I 
is responsible for the blocking of the TTD/H3K9me3 interaction. Therefore, I investigated 
the effect of different mutations in the TTD-PHD linker insertion of NP95 I on the TTD 
binding to H3K9me3 (Figure 3-13A). In addition to that, I analyzed the PHD mediated 
interaction with the unmodified N-terminus of H3. Considering the sequence of the  
TTD-PHD linker insertion (P-P-P-A-L-R-N-T-G), I decided to mutate the proline patch 
(P293A, P294A, P295A). I rationalized that the conformational rigidity of proline affects 
the relative spacing of TTD and PHD as well as the positioning of the linker on the TTD 
surface. Given the importance of basic residues in general and the R-K-S sequence motif 
in particular for the interaction of TTD with different linker regions, I also mutated an 
arginine in the center of the linker (R298A) as well as a lysine and a serine (K302A, S303A) 
adjacent to the TTD-PHD linker insertion (Arita et al., 2012; Rothbart et al., 2013). I used 
fluorescence polarization measurements to investigate the H3 tail binding of these 
mutants.  
The NP95 I TTD-PHD PPP-AAA (P293A, P294A, P295A) (Kd = 11.1 µM) and R-A (R298A) 
(Kd = 5.0 µM) mutants showed a significant gain of binding to H3K9me3 peptide 
compared to the wild type TTD-PHD region (Figure 3-13B). At the same time, the KS-AA 
(K302A, S303A) mutant did not interact with the FAM-H3K9me3 peptide. Additional 
measurements with the described TTD-PHD mutants revealed no change of binding 
affinity to H3(1-15)unmod-FAM compared to the wild type TTD-PHD region  
(Figure 3-13C). Subsequent analysis of the full-length NP95 I PPP-AAA and R-A mutants 
did not resemble the effects that were detected in contexts of the TTD-PHD fragment. The 
binding of the two mutant proteins to FAM-H3K9me3 peptide did not differ from the 
wild type and KS-AA mutant (Figure 3-13D). The interaction of the full-length NP95 I 
proteins with the H3(1-15)unmod-FAM was not affected by any of the TTD-PHD linker 






Figure 3-13 Binding behavior of TTD-PHD linker mutants of NP95 I TTD-PHD fragment  
(A) Schematic representation of the full-length protein and TTD-PHD fragment of NP95 I the TTD-PHD linker 
and the PBR region (red) and TTD-PHD linker mutants that were used for the experiments are highlighted. (B, 
C) TTD-PHD fragment of wild type and different TTD-PHD linker mutants of NP95 I (P293A, P294A, P295A; 
R298A; K302A, S303A) were used in fluorescence polarization experiments with the indicated peptides. (D, E) 
Wild type and different TTD-PHD linker mutants of full-length NP95 I (P293A, P294A, P295A; R298A; K302A, 
S303A) were used in fluorescence polarization experiments with the indicated peptides. Fraction bound of 
labeled peptides was plotted depending on protein concentration. Error bars represent standard deviation of 





Altogether, these results indicated an important contribution of P293, P294, P295 and 
R298A residues but not K302A, S303A to TTD blocking in NP95 I TTD-PHD. Since the 
PHD domain binding to the unmodified N-terminus of the H3 tail did not change upon 
mutation of the linker sequence, I concluded that the linker is exclusively affecting the 
TTD. At the same time, the mutations had minor influence on the H3 tail binding 
behavior of the full-length NP95 I. I reasoned that in context of the full-length protein 
TTD binding regulation might be more complex and secondary interaction might stabilize 
the blocking by the TTD-PHD linker insertion. 
 The NP95 I TTD-PHD linker insertion changes UHRF1 binding 3.2.3.4
behavior 
It was reported before that transfer of the whole TTD-PHD linker of NP95 I to the 
structurally related NP97/NIRF (mUHRF2) causes blocking of H3K9me3 binding in this 
protein (Pichler et al., 2011). I wanted to investigate if the 9 amino acid NP95 I linker 
insertion alone is sufficient to cause blocking of the UHRF1 TTD domain. In addition to 
that, I wanted to analyze if the presence of the NP95 I TTD-PHD linker in the context of 
full-length UHRF1 is affecting the TTD/ PBR interaction. To this end, I inserted the 9 
amino acids into the TTD-PHD linker of UHRF1 TTD-PHD and full-length protein in a 
way that disrupted the R-K-S motif for TTD interaction (RRKS à R-PPPALRNTG-KS) 
(Figure 3-14A). I determined the binding affinities of the UHRF1 TTD-PHD fragment and 
full-length protein carrying this mutation in fluorescence polarization binding 
experiments.  
I observed that the full-length UHRF1 mutant bound to H3(1-15)unmod-FAM  
(Kd = 13.9 µM) and H3(1-15)K9me3-FAM (Kd = 16.9 µM), while the N-terminally FAM-
labeled H3(1-15)K9me3 remained unbound (Figure 3-12B). Therefore, the binding 
behavior of the mutant did not change compared to the wild type UHRF1 (Figure 3-8C). 
The UHRF1 TTD-PHD NP95 I insertion mutant showed strong binding to the C-
terminally labeled peptides and only weak interaction with the FAM-H3K9me3 1-15  
(Kd = 64.9 µM) (Figure 3-14C). Compared to the wild type UHRF1 TTD-PHD, the mutant 
did exhibit a substantial change in binding behavior, in which the interaction with FAM-
H3K9me3 was 4-fold reduced (Figure 3-11C). These results suggested that blocking of 
TTD binding to H3K9me3 by the NP95 I TTD-PHD linker insertion was also established in 
this context. The addition of UHRF1 PBR-RING to the fluorescence polarization 
measurement of the UHRF1 TTD-PHD insertion mutant led to an additional loss of 





Figure 3-14 NP95 I TTD-PHD linker insertion reduced binding of UHRF1 TTD-PHD to H3K9me3 
(A) Schematic representation of the full-length protein and TTD-PHD fragment of UHRF1. The TTD-PHD 
linker and the PBR region (red) and the TTD-PHD linker mutant with the NP95 I insertion used for the 
experiments are highlighted. Full-length UHRF1 (B) and TTD-PHD fragment (C) of NP95 I TTD-PHD linker 
insertion mutant protein were analyzed in fluorescence polarization experiments with the indicated peptides. 
(D) Fluorescence polarization binding experiments of the interaction TTD-PHD fragment of NP95 I TTD-PHD 
linker insertion mutant of UHRF1 with FAM-H3(1-15)K9me3 peptide with and without 2-fold molar excess of 
UHRF1 PBR-RING fragment added. Fraction bound of labeled peptides was plotted depending on protein 





The results showed that the NP95 I linker insertion causes reduced TTD interaction with 
H3K9me3 in context of UHRF1 TTD-PHD. Since addition of UHRF1 PBR-RING led to 
further reduction of TTD interaction with H3K9me3, I reasoned that both linker regions 
make contacts with the TTD. In addition to that, my results showed stronger interaction 
between TTD and PBR region compared to TTD and the TTD-PHD linker insertion. Since 
I detected strong blocking of the TTD by the TTD-PHD linker in context of NP95 I, I 
concluded that the different blocking mechanisms might use specific surfaces on the TTD 
of both proteins. These surfaces differ between UHRF1 and NP95 and, thus, cause the 
observed differences. Therefore, the results suggest that TTD surface is adapted to the 
interaction with the PBR in UHRF1 and the TTD-PHD linker in NP95.  
3.2.4 An R-K-S motif in the TTD-PHD linker influences binding of NP95 
II to the H3 tail 
It has been suggested that the UHRF1 TTD-PHD linker establishes a multivalent binding 
state of TTD and PHD (Arita et al., 2012; Rothbart et al., 2013). An R-K-S sequence motif in 
the linker plays an essential role in this process. Three TTD surface residues, G236, F237 
and W238 were found to be essential for the interaction with the TTD-PHD linker RKS 
motif (Arita et al., 2012; Cheng et al., 2013; Rothbart et al., 2013; Xie et al., 2012).  
I used the PRALINE sequence alignment tool to examine sequence conservation of these 
residues in NP95 (http://zeus.few.vu.nl/programs/pralinewww/). I found that the 
essential residues G236, F237 and W238 were conserved in the murine proteins (Figure 3-
15A). I reasoned that the reported function of the R-K-S motif might be conserved as well. 
To this end, I mutated the TTD-PHD linker R-K-S sequence motif (R293A, K294A, S295A) 
in context of the NP95 II TTD-PHD to impair the putative TTD/TTD-PHD linker 
interaction (Figure 3-15B). 
I analyzed the influence of this motif on the individual binding behavior of the TTD and 
PHD by fluorescence polarization measurements using the FAM-H3(1-15)K9me3 and the 
H3(1-15)unmod-FAM peptides. In addition to that, I investigated the multivalent binding 
of TTD and PHD domains to the same H3 tail using the C-terminally FAM-tagged  
H3(1-15)K9me3 peptide.  
The mutation of the R-K-S motif in NP95 II TTD-PHD caused a minor loss of binding to 
the FAM-H3(1-15)K9me3 peptide (Kd = 40.0 µM), which only interacts with the TTD 
domain (Figure 3-13C). At the same time, the RKS-AAA mutation caused a slight gain of 
binding to the H3(1-15)unmod-FAM peptide (Kd = 4.4 µM) compared to the wild type 




peptide (Kd = 1.6 µM), which can be bound by both, TTD and PHD, was increased 4-fold 
by the same mutation (Figure 3-13E).  
Since the mutation exclusively affected the binding to the bivalent target peptide  
H3(1-15)K9me3-FAM, I reasoned that the mutation had influence on the combined read 
out of TTD and PHD domain. In UHRF1 TTD-PHD, a similar mutation of the R-R-K-S 
motif led to impaired multivalent binding to a similar peptide (Arita et al., 2012). I 
concluded that the R-K-S motif in NP95 II might establish a multivalent binding mode 
comparable to UHRF1. 
 
Figure 3-15 Binding behavior of TTD-PHD linker mutant of NP95 II TTD-PHD fragment  
(A) Sequence alignment was prepared using the PRALINE tool (http://zeus.few.vu.nl/programs/ 
pralinewww/). Numbers correspond to amino acid positions at the beginning and end of the respective 
protein sequences of the different species. UHRF1 amino acid sequences according to NCBI: Homo sapiens, 
NP_001276981.1; Mus musculus V1, NP_001104550.1, Mus musculus V2, NP_001104548.1. (B) Schematic 
representation of the TTD-PHD fragment of NP95 II. The TTD-PHD linker (red) and TTD-PHD linker mutant 
used for the experiments (R293A, K294A, S295A) are highlighted. (B, C, D) TTD-PHD fragment of wild type 
and TTD-PHD linker mutant of NP95 II (R293A, K294A, S295A) were used in fluorescence polarization 
experiments with the indicated peptides. Fraction bound of labeled peptides was plotted depending on 




3.2.5 Structural differences between NP95 I  and II TTD-PHD  
 Similar structural features of TTD-PHD region of UHRF1 and NP95 II 3.2.5.1
but not NP95 I  
My previous experiments established clear differences in the function of the TTD-PHD 
linker in the two murine isoforms of UHRF1, NP95 I and NP95 II. The TTD-PHD linker 
insertion of NP95 I was shown to block the TTD domain interaction with H3K9me3. NP95 
II and UHRF1 TTD-PHD linker exhibit high sequence similarity and might share the same 
mode of action. In collaboration with Cheryl Arrowsmith (University of Toronto, Canada) 
we wanted to further investigate these differences between TTD-PHD NP95 I and NP95 II. 
We used SAXS and NMR spectroscopy to gain further insights into structural features of 
TTD-PHD and the TTD-PHD linker in this context. 
Small angle X-ray scattering (SAXS) and subsequent abinitio envelope prediction by 
DAMMIF software revealed great similarity of the overall surface shape of TTD-PHD 
cassettes of UHRF1 and the two murine isoforms (Figure 3-16A). We performed 
theoretical structure modeling on the assumption that TTD and PHD shapes were rigid 
while the TTD-PHD linker was flexible. This resulted in approximately 50,000 structures 
for TTD-PHD of NP95 I and NP95 II, respectively. These theoretical structures were 
plotted depending on their Rg value, the mass weighted average radius (Figure 3-16B, 
dashed line). In conjunction with the SAXS data that was experimentally generated these 
theoretical structures were merged to an optimal ensemble and plotted for comparison 
(Figure 3-16B, solid line). We used UHRF1 TTD-PHD as reference because its structure 
has been studied in great detail. In UHRF1 TTD-PHD, the first peak (Rg= 27) corresponds 
to the TTD-PHD structure with the linker in the peptide binding groove. The second peak 
(Rg= 39) represented the structure where the linker is not locked on the TTD surface but is 
randomly moving (Arita et al., 2012). NP95 II and UHRF1 TTD-PHD optimal ensemble 
distribution exhibited striking similarities (Figure 3-16B, solid line). The analogous 
distribution of the optimal ensemble in our SAXS data and their sequence similarities 
suggested that NP95 II TTD-PHD exhibits structural similarities with UHRF1 TTD-PHD. 
Thus, I reasoned that the TTD-PHD linker of NP95 II is able to interact with the TTD 






Figure 3-16 Structural differences between TTD-PHD fragments of NP95 I and NP95 II  
(A) Abinitio envelope prediction from SAXS curves of wild type TTD-PHD fragments of NP95 I and NP95 II 
were calculated with DAMMIF. Front view and view 90° rotated of both fragments are shown. (B) Rg 
distributions of TTD-PHD fragments of UHRF1, NP95 I and NP95 II, theoretical distribution (dashed line) and 




NP95. (D) TROSY overlay of HSQC spectra showing residue signals of 15N-TTD-PHD fragment of NP95 I and 
NP95 II highlighted are the assigned PHD resonances. (E) TROSY overlay of HSQC spectra showing residue 
signals of 15N-TTD-linker fragment of NP95 I and NP95 II. Aleksander Lemak performed SAXS experiments 
and data analysis. Scott Houliston performed NMR experiments and data analysis (Laboratory of Cheryl 
Arrowsmith, University of Toronto). 
 
The SAXS data revealed that the rigidity of the TTD-PHD structure of NP95 I was 
substantially different from NP95 II and UHRF1. The theoretical modeling of the optimal 
ensemble of the TTD-PHD of UHRF1 and NP95 II showed two distinct peaks, suggesting 
certain flexibility of the TTD-PHD linker in this context. I reasoned that UHRF1 and NP95 
II TTD-PHD share similar structural features. NP95 II TTD-PHD might adapt a 
multivalent binding mode to H3K9me3 with unmodified N-terminus as described for 
UHRF1 TTD-PHD. In contrast, NP95 I TTD-PHD optimal ensemble distribution only 
exhibited one sharp peak (Rg= 27). This finding argued for high rigidity of the TTD-PHD 
structure and only minimal flexibility of the TTD-PHD linker in this protein.  
  TTD-PHD linker causes structural differences in the TTD of NP95 I 3.2.5.2
and NP95 II 
Next, we wanted to study the structural features of the interaction between the TTD 
surface and the variable adjacent linker regions of NP95. To determine the nature of this 
interaction and the essential contributing residues in the TTD domain, we used NMR 
spectroscopy. We were able to assign all peaks of the HSQC spectra of the NP95 PHD 
domain (Figure 3-16C). Overlay of the plotted resonance peaks revealed the PHD 
resonances of both isoforms were superimposable (Figure 3-16D). Given these results, we 
analyzed a region of the NP95 variants only comprising the TTD and the TTD-PHD 
linker. The result showed great differences between the HSQC spectra of the NP95 Ι and 
NP95 II TTD-linker region (Figure 3-16D). However, the additional nine amino acids of 
the NP95 I linker insertion were not sufficient to explain these great differences of the 
TTD resonances of the two isoforms. Therefore, we reasoned that the observed differences 
in the HSQC spectra are due to the TTD-PHD linkers of NP95 Ι and NP95 II and especially 
their differential interaction with the TTD domain. 
Taken together the result of our structural studies, we found that the TTD-PHD linker of 
NP95 I exhibited exceptional features in all our assays. The findings imply a high rigidity 
of the structure of the TTD-PHD region and a direct interaction of the TTD-PHD linker 
with the TTD domain surface. This interaction is likely to cause the observed blocking of 





3.2.6 Different intramolecular interactions in UHRF1 and the NP95 
isoforms  
My results demonstrated that the PBR region had only minor influence on the H3 tail 
binding of the two NP95 isoforms. However, I showed functional similarities of the NP95 
I TTD-PHD linker and the UHRF1 PBR. In addition to that, the TTD-PHD of NP95 II and 
UHRF1 showed high similarity. Based on these differences between UHRF1, NP95 I and 
NP95 II, I reasoned that the intramolecular interactions of the different domains within 
the three proteins must significantly differ from each other. In collaboration with the 
laboratory of Henning Urlaub (MPI Goettingen, Germany) we performed BS3 protein 
crosslinking experiments with subsequent liquid chromatography-tandem mass 
spectrometry analysis to assess the intramolecular interactions in NP95 I, NP95 II and 
UHRF1. BS3 is crosslinking primary amines; therefore the analysis identified crosslinks 
connecting lysine residues in different regions of the protein. 
 Common intramolecular crosslinks of NP95 and UHRF1 3.2.6.1
Comparison of multiple data sets for all three proteins revealed similarities in the 
intramolecular connections of UHRF1 and the two NP95 isoforms. We found that in all 
three proteins the SRA domain is establishing many matching contacts inter alia with the 
UBL domain, the UBL-TTD linker, the PHD-SRA linker, and the PBR (Figure 3-17A, B, C, 
dark blue lines). In addition to that, we reproducibly found crosslink connections between 
the TTD domain and the SRA domain of all three proteins (Figure 3-17A, B, C, bold dark 
blue lines).  
In our previous experiments we had found a role for the PBR region in regulation of the 
TTD/H3K9me3 interaction in UHRF1. The crosslinking experiments validated these 
results. We found crosslinks connecting the TTD domain with the PBR in UHRF1 (Figure 
3-17A, bold dark blue lines). Importantly, we detected similar crosslink contacts between 
the PBR and the TTD in NP95 Ι and NP95 II (Figure 3-17 B, C, bold dark blue lines). 
However, we found no overlap of exact crosslink positions in the TTD and the PBR 
comparing UHRF1 and NP95.  
 Different crosslink positions in the NP95 isoforms 3.2.6.2
The results showed great differences in the H3K9me3 binding of NP95 Ι and NP95 II 
(Figure 3-8; 3-11). Structural analysis of the TTD-PHD regions of the two proteins 
additionally revealed different interactions of the TTD-PHD linker region with the surface 




intramolecular interactions in the proteins. Thus, we compared the intramolecular 
crosslinks of NP95 Ι and NP95 II. 
 
 
Figure 3-17 Intramolecular crosslinking of UHRF1, NP95 I and NP95 II 
Schematic representation of the domain organization of UHRF1 (A), NP95 I (B) and NP95 II (C); recombinant 
proteins were crosslinked with BS3, digested and analyzed by LC MS/MS. Arcs represent crosslink positions 
identified in the monomeric proteins. Common positions of UHRF1, NP95 I and II (dark blue line) are 
highlighted especially when TTD residues are involved (bold dark blue line). Unique crosslink positions are 
represented (red line). All shown crosslinks were identified with a score greater than 4.0. Experiment and data 
analysis was performed by Aleksander Chernev (Laboratory of Henning Urlaub, MPI-bpc Goettingen) 
 
We found substantial differences in the positioning of the crosslink connections in NP95 Ι 
and II (Figure 3-17B, C). We found that in NP95 I unique contacts were established 




agreement with my findings the TTD-PHD linker of NP95 I impaired the H3K9me3 
binding of the TTD domain, we detected one crosslink indicating a connection between 
the TTD and the TTD-PHD linker of NP95 I. In addition to that the crosslinking pattern 
showed close interactions of the TTD with the N-terminus of the protein as well as 
connections of the UBL-TTD linker with the SRA and the PBR. We reasoned that the 
unique contacts found in the protein are a result of the insertion in the TTD-PHD linker. 
Analyzing the NP95 II intramolecular contacts, we reproducibly found a unique crosslink 
connection between the TTD-PHD linker RKS motif and the SRA domain (Figure 3-17C, 
red line).  
 DNA induced changes in intramolecular crosslinking of UHRF1/ NP95 3.2.6.3
It was reported before that the NP95 I binding of hemimethylated DNA to the SRA 
domain slightly enhanced the binding to H3K9me3 (Pichler et al., 2011). I reasoned that 
DNA binding to the protein might be able to affect the block of the TTD domain by the 
TTD-PHD linker. In addition to that, our intramolecular crosslinking results showed 
connections between the SRA domain and the TTD domain indicating close interactions 
of both domains in UHRF1 as well as NP95 (Figure 3-17). I reasoned that such interactions 
could point to an interrelation of the binding processes of both domains in all three 
proteins.  
Thus, we wanted to know if the intramolecular interactions of the three proteins are also 
affected in a different manner to analyze the changes of intramolecular interactions upon 
DNA binding. We performed intramolecular crosslinking experiments adding hemi-
methylated DNA (same as used in the above experiments) and compared the results with 
our former experiments.  
Compared to the previous experiments, we found a substantial loss in total number of 
specific crosslink positions for UHRF1 (24%), NP95 I (48%) and NP95 II (60%) upon 
addition of hemimethylated DNA. Comparing the resulting crosslink contacts of UHRF1 
with DNA to the sample without, we determined a loss of 15 crosslink positions (see data 
tables in supplement). Ten out of these 15 involved SRA residues, while nine contacts 
were established by the PBR. The results showed that all previously described 
connections between TTD and PBR were lost upon addition of hemi-methylated DNA. At 
the same time, additional crosslinks were established between K650 (PBR) and K294 
(TTD-PHD linker) as well as K303 (pre-PHD) upon DNA titration. Thus, lost connections 





In NP95 I, comparison of our findings with and without DNA revealed a number of 33 
crosslinks lost upon addition of hemimethylated DNA. As for UHRF1, most of the lost 
connections involved SRA residues. Additionally, we recognized a loss of crosslink 
positions that were established by TTD and SRA-RING linker. In contrast to UHRF1, we 
found no complete loss of crosslink connections between TTD and PBR of NP95 I.  
In NP95 II, presence of hemimethylated DNA caused a loss of crosslink connections that 
involved SRA domain lysine residues. Out of 35 crosslink contacts that were lost upon 
DNA addition, 30 involved SRA residues. Therefore, NP95 II lost 94% of its 
intramolecular crosslinks with the SRA domain. The crosslink connections that were 
found between the TTD-PHD linker and the SRA in our former experiments  
(Figure 3-17C) were not found after addition of DNA, while the contacts between TTD 
and SRA-RING linker seemed rather unaffected.  
In general we found that the addition of DNA mainly affected the connections involving 
SRA residues. In UHRF1, we also found great changes of PBR crosslink connections with 
the TTD of the protein. These crosslinks were not found upon addition of hemimethylated 
DNA. Thus, DNA binding affected the TTD/PBR interaction. In contrast, we found no 
such effect in NP95 Ι or NP95 II. Upon DNA addition the murine proteins mainly lost 
crosslink connections involving residues of the SRA domain. This argues that all three 
proteins were differently affected by the addition of hemimethylated DNA. 
 Impact of DNA on the H3 tail binding of UHRF1/NP95 3.2.6.1
My former results showed that UHRF1, NP95 Ι and NP95 II intramolecular crosslinking 
connections were influenced differently by the addition of hemimethylated DNA. The 
intramolecular crosslinking results showed connections between the SRA domain and the 
TTD domain were lost in UHRF1 upon addition of DNA (Chapter 3.2.6.3). I reasoned that 
such loss interactions could point to an interrelation of the binding processes of both 
domains. Therefore, I wanted to determine the effects of the addition of hemimethylated 
DNA on H3 tail binding in UHRF1 and the two NP95 isoforms (Figure 3-18A).  
I used fluorescence polarization binding experiments to determine H3 tail peptide 
binding affinity of UHRF1 and NP95 after pre-incubation with hemi-methylated 12-mer 
DNA. I compared the peptide binding behavior of protein incubated with DNA with 
protein that was incubated with the DNA hybridization buffer. I analyzed the impact on 






Figure 3-18 Impact of DNA on the H3 tail binding of UHRF1/ NP95  
(A) Schematic representation of UHRF1/NP95 domain architecture. The hemimethylated 12mer 
oligonucleotide used for the experiments is shown. 5-Methylcytosine site is marked by a red dot. (B, E) 
UHRF1, (C, F) NP95 I and (D, G) NP95 II were used in fluorescence polarization binding experiments with the 
indicated FAM-labeled peptides with and without 2-fold molar excess of hemimethylated 12mer DNA. 
Fraction bound of labeled peptides was plotted depending on protein concentration. Error bars represent 




The presence of DNA to UHRF1 had striking effects on the binding to  
FAM-H3(1-15)K9me3 (Kd = 12.9 µM) (Figure 3-18B, Table 3-3). The interaction of TTD 
with the peptide improved more than 10-fold upon addition of 2-fold molar excess of 
hemi-methylated DNA. In contrast, the hemimethylated DNA had no effect on the NP95 I 
TTD binding to K9 trimethylation (Figure 3-18C) and only moderate effects on the NP95 II 
TTD (Kd = 14.0 µM) (Figure 3-18D). At the same time, there was a slight gain of binding of 
the PHD to the H3(1-15)unmod-FAM in all three proteins (Figure 3-18E, F, G).  
Taken together the results demonstrated that the addition of DNA had different effects on 
the binding of the TTD of UHRF1 or the NP95 variants to K9 trimethylation but similar 
effects on the PHD interaction with the unmodified H3 N-terminus. 
Table 3-4 binding affinity of UHRF1 and NP95 to indicated peptides with and without DNA 
(apparent Kd values in µM) 
  FAM-H3(1-15)K9me3 H3(1-15)unmod-FAM H3(1-15)K9me3-FAM 
UHRF1 − DNA ND 16.1±2.3 10.7±1.9 
 + DNA 12.9±3.2 3.2±0.8 1.9±0.4 
     
NP95 I − DNA ND 17.4±2.1 9.9±0.6 
 + DNA ND 6.7±1.1 8.4±1.4 
     
NP95 II − DNA 39.8±11.2 37.0±14.9 24.8±2.7 
 + DNA 14.0±3.9 7.9±1.9 5.1±0.9 
 
3.3 Expression and cellular localization of NP95 
3.3.1 Comparison of the nuclear localization of UHRF1 and NP95 
I showed substantial differences in the behavior of UHRF1, NP95 Ι and NP95 II in regard 
to histone binding alone and the interplay of histone and DNA binding. Thus, I wanted to 
investigate if these differences were reflected by their cellular localization. UHRF1 
localization was shown to be dependent on the ability of the TTD to interact with 
trimethylated H3 tails and the SRA to interact with DNA (Figure 3-2C). In addition to 
that, we found the PBR to impair the recruitment of the protein to H3K9me3 rich loci 
(Figure 3-4D, E). When analyzing the UHRF1 nuclear localization in human cells, we 
found that only a small fraction of cells showed co-localization of the protein with 





Figure 3-19 Co-localization of UHRF1, NP95 I and NP95 II with H3K9me3 in MCF7 cells 
Co-localization of UHRF1, NP95 I and II and H3K9me3 modification were analyzed in MCF7 cells. MCF7 cells 
cells transiently expressed mCherry-tagged UHRF1, NP95 II, NP95 I or Lac I. H3K9me3 was detected using 
specific antibodies. Microscopy images of separate and merged fluorescence channels (UHRF1-red, H3K9me3-
green) are shown. Scale bar represents 75µm. Experiments were done in collaboration with Sarah Kreuz 
(Laboratory of Wolfgang Fischle, MPI, Goettingen). 
 
In my studies, I compared the localization of mCherry-tagged UHRF1 and NP95 isoforms 
in cells. I found considerable differences in their subnuclear localization in human cells. In 
collaboration with Sarah Kreuz from the Laboratory of Wolfgang Fischle (MPI, 






Figure 3-20 Comparison of the nuclear localization of UHRF1 and NP95  
(A) Hela, (B) U2OS, (C) MCF7 and NIH3T3 (D) cells were transfected with mCherry-tagged UHRF1, NP95 I or 
II after transfection nuclear cell extracts were analyzed western blot (right panel). Cells were than analyzed by 
fluorescence microscopy and H3K9me3 was visualized using indirect immunofluorescence. Overlap of 
mCherry-tagged UHRF1 or NP95 was determined and plotted (left site histogram). All error bars show 
standard deviation of three independent experiments. Asterisks show significance and ns, not significant. 




exhibited co-localization of mCherry-UHRF1, mCherry-NP95 Ι or mCherry-NP95 II with 
the H3K9me3 modification using fluorescence microscopy and subsequent cell counting 
(Figure 3-19). Regardless of the differences in the overall expression levels of the three 
proteins, we found a reproducible pattern (Figure 3-20A, B, C). In HeLa cells only a small 
fraction of cells showed co-localization of mCherry-UHRF1 with H3K9me3  
(Figure 3-20A). We observed similar results for cells that were transiently transfected with 
mCherry-NP95 II. In contrast, a greater fraction of cells exhibited an overlap of mCherry-
NP95 I with the modification signal. We found the same pattern in U2OS (Figure 3-20B) 
and MCF7 cells (Figure 3-20C). Similar experiments in the murine cell line NIH3T3 led to 
the same result (Figure 3-20D).  
In cells, NP95 Ι is co-localized with H3K9me3, while binding to the modification was 
blocked in vitro. NP95 II TTD binding to H3K9me3 was not blocked in our in vitro 
experiments. Nevertheless, we found less co-localization of NP95 II with the modification 
in cells. At the same time, UHRF1 showed a stronger co-localization with H3K9me3 than 
NP95 II and less co-localization with the modification than NP95 I. Based on these results, 
I concluded that the different inter-domain linker regions influence the subnuclear 
localization of the proteins. 
3.3.2 mRNA expression analysis of NP95 I and NP95 II 
Since NP95 I and NP95 II exhibited different co-localization with H3K9me3, I reasoned 
that both proteins might have distinct nuclear target sites and thus might fulfill different 
functions. Therefore, we investigated the expression of the two murine protein variants in 
different tissues. In collaboration with Klaus Jung (UMG, Goettingen, Germany) we 
performed a retrospective analysis of RNA-Seq data. The data used in this analysis were 
publicly available datasets obtained from encode (http://genome.crg.es/encode_RNA 
_dashboard/mm9). The “Uhrf1-001” and “Uhrf1-004” were mRNA sequences encoding 
for full-length NP95 I and the “Uhrf1-002” and “Uhrf1-003” were mRNAs encoding full-
length NP95 II. “Uhrf1-005”, “Uhrf1-006” and “Uhrf1-007” were RNA sequences encoding 
for shorter isoforms of NP95, which were barely expressed in all samples. 
The first dataset consisted of 99 samples of Poly-mRNA, paired-end reads with quality 
measure. The dataset included replicates of 17 different types of tissues. The data showed 
that NP95 I (“Uhrf1-001” and “Uhrf1-004”) exhibited the highest expression in adult 
thymus (ThymusAdult8wks) as well as in testis (TestisAdult8wks), ovary 
(OvaryAdult8wks), and the large intestine (LgintAdult8wks) (Figure 3-21). Additionally 





Figure 3-21 Retrospective mRNA expression analysis of 17 different types of murine tissues  
Expression heat map of the first dataset for 99 samples against the 7 transcript isoforms, dataset was obtained 
from encode (http://genome.crg.es/encode_RNA_dashboard/mm9), number of NP95 transcripts relative to 
1 million total mRNA transcripts was analyzed and plotted, “Uhrf1-001” and “Uhrf1-004” were mRNA 
sequences encoding for full-length NP95 I, the “Uhrf1-002” and “Uhrf1-003” were mRNAs encoding full-
length NP95 II, “Uhrf1-005”, “Uhrf1-006” and “Uhrf1-007” were mRNAs encoding for not full-length 
isoforms, sample identification by tissue and age is indicated (left site), transcript isoforms are shown 
(bottom),samples were analysed from long intestine (Lgint), subcutaneous fat (Sfat), liver, colon, spleen, 
mammary gland, thymus, lung, kidney, heart, testis, ovary, small intestine (Smint), stomach (Stom), 
duodenum (Duod) and adrenal gland (Adrenal), all samples came from a 8 week old adult animal 





Figure 3-22 Retrospective mRNA expression analysis of different embryonic developmental stages 
Expression heat map of the second dataset for 16 samples against the 7 transcript isoforms, dataset was 
obtained from encode (http://genome.crg.es/encode_RNA_dashboard/mm9), number of NP95 transcripts 
relative to total mRNA was analyzed and plotted, “Uhrf1-001” and “Uhrf1-004” were mRNA sequences 
encoding for full-length NP95 I, the “Uhrf1-002” and “Uhrf1-003” were mRNAs encoding full-length NP95 II, 
“Uhrf1-005”, “Uhrf1-006” and “Uhrf1-007” were mRNAs encoding for not full-length isoforms, transcript 
isoforms are shown (bottom), sample identification by tissue and age is indicated (left site), samples came 
from whole brain (Wbrain), liver, limb and central nervous system, from 11.5, 14, 14.5 and 18 days old 





(DuodAdult8wks), subcutaneous fat tissue (SfatAdult8wks), small intestine 
(SmintAdult8wks) and spleen tissue (SpleenAdult8wks). In contrast to that we detected 
no expression of any transcript isoforms in adult adrenal gland tissue 
(AdrenalAdult8wks), heart (HeartAdult8wks), kidney (KidneyAdults8wks), liver 
(LiverAdults8wks), and lung (LungAdult8wks). The second dataset was a deep-sequence 
dataset of eight different embryonic stages and tissues with two replicates for a total of 16 
samples. Analysis of the second dataset revealed that NP95 I (“Uhrf-001” and “Uhrf1-
004”) were the primarily expressed transcripts in samples of embryonic day 11 central 
nervous system (CnsE11half), embryonic day 14 limb (LimbE14) and liver (LiverE14) as 
well as embryonic day 14.5 liver (LiverE14half) (Figure 3-22). The NP95 II transcripts were 
either low or not expressed in the different embryonic stages and tissue-types. 
UHRF1 mRNA is reported to be most abundant in human thymus and fetal liver but also 
highly expressed in bone marrow, lung, kidney, small intestine and testis (Hopfner et al., 
2000). Our results demonstrated comparable expression for NP95 I. It was most abundant 
in murine thymus and embryonic liver and was also highly expressed in ovary, testis, 
small intestine as well as large intestine. This might argue for similar cellular functions of 
UHRF1 in human and NP95 I in mouse. In contrast, NP95 II showed only low expression 
in all tissues analyzed. Given my finding that NP95 I and II show different co-localization 
with H3K9me3 in cells, I concluded that NP95 I and NP95 II might have distinct functions 








The combinatorial interaction of different domains with a complex target containing 
multiple ligands is referred to as multivalent binding. The first concept of multivalent 
readout of epigenetic marks (‘modification cassettes’) was introduced in 2003 and 
revealed a putative connection between different modifications that are in close proximity 
to each other (Fischle et al., 2003). Recent studies showed that multidomain proteins 
comprising several chromatin interacting domains are capable of combinatorial readout of 
epigenetic modifications of histones and DNA. Thus, this facilitates crosstalk of these 
marks (Du and Patel, 2014). This crosstalk is a fundamental element of the ‘histone code’ 
theory that postulates that patterns of chromatin marks constitute a complex signalling 
system (Strahl and Allis, 2000).  
UHRF1 is a multidomain protein that has three different domains to interact with 
different epigenetic modifications and it has been shown to localize to differently 
modified loci in cells. Recent findings imply that the intramolecular interactions between 
different inter-domain linker regions and the TTD domain of UHRF1 play a critical role in 
regulating the binding specificity of the protein for specific marks in vitro (Arita et al., 
2012; Cheng et al., 2013; Gelato et al., 2014; Rothbart et al., 2013; Xie et al., 2012). This 
uncovered that multivalent read out by multidomain proteins is not sufficiently described 
by a ‘beads-on a-string’ model based on simple co-localization of chromatin binding 
domains. Instead, our results exemplified that inter-domain linker regions provide a level 
of regulation for the combinatorial readout of epigenetic marks. Based on these findings, 
we proposed a new model for dynamic regulation of multidomain protein interaction 
with combinatorial chromatin modifications.  
4.1 Model for linker-dependent allosteric transition in UHRF1 
Our previous study demonstrated that the interactions of two inter-domain linker regions 
of UHRF1, PBR and TTD-PHD linker, are mutually exclusive events and establish two 
distinct conformational states of the protein (Figure 4-1A, B) (Gelato et al., 2014; Tauber 
and Fischle, 2015). These different conformational states can be characterized by their 
different binding specificity for H3K9me3.  
In one binding mode, The UHRF1 TTD peptide binding groove accommodates the  
TTD-PHD linker as shown in context of the isolated TTD-PHD fragment. NMR results 
have shown that the linker R-K-S motif interacts with the TTD residues, stabilizing the 




generate a scaffold and establish a multivalent binding of TTD and PHD (Figure 4-1B)  
(Arita et al., 2012; Cheng et al., 2013; Rothbart et al., 2013; Xie et al., 2012). This binding 
mode is characterized by the simultaneous binding of PHD and TTD to the same H3 tail. 
The TTD-PHD linker peptide displayed a moderate binding affinity (Kd = 30 µM) to the 
TTD in vitro (Gelato et al., 2014).  
In the other binding mode of UHRF1, the PBR interacts with the TTD peptide binding 
groove. In this state, only the PHD interacts with the unmodified N-terminus of the H3 
tail, while the TTD binding to H3K9me3 is blocked (Figure 4-1A) (Gelato et al., 2014). The 
isolated TTD domain exhibits comparable binding affinity to PBR and H3K9me3 peptide. 
Fluorescence polarization binding experiments displayed a strong interaction between the 
TTD domain and the PBR peptide (Kd = 3.5 µM) (Gelato et al., 2014).  
We think that depending on, which linker is associated with the TTD the protein adopts 
different conformational states (Tauber and Fischle, 2015). Due to the weaker affinity to 
the TTD, the TTD-PHD linker might not be able to compete with the PBR in the ground 
state of the protein (Gelato et al., 2014). In our previous study we demonstrated that 
mutation of the PBR and upon binding of PI(5)P the PBR dependent block of the TTD can 
be released. Therefore, we reasoned that UHRF1 is able to switch between these two 
conformations in response to specific external stimuli. This process leads to a delicate 
equilibrium of the described states. Regulatory processes targeting the mutually 
unstructured linker regions alter this equilibrium (Gelato et al., 2014). 
4.2 Inter-domain linker dependent regulation of NP95 binding 
to H3K9me3 
4.2.1 The PBR dependent blocking of the TTD in UHRF1 is not 
conserved in the two NP95 isoforms 
In this study, I show that, in contrast to UHRF1, the PBR region does not regulate the 
H3K9me3 binding of NP95. Mutagenesis of the PBR consensus sequence in NP95 has only 
minor effects on the H3 tail binding of the protein. In addition to that, PBR-RING did not 
cause a decreased binding affinity of NP95 TTD for H3K9me3 in fluorescence polarization 
measurements, as shown for UHRF1. Nevertheless, we reproducibly found connections 
between lysine residues of the PBR region and the TTD domain in intramolecular 
crosslinking analysis. This suggests a different role of the PBR in NP95 that remains 
elusive. Therefore, the PBR dependent regulation of binding specificity that we described 




others and I showed recently that the PBR region plays an important role in accurate 
recruitment of UHRF1 to chromatin (Chu et al., 2012; Gelato et al., 2014). Given the high 
level of functional conservation of UHRF1 and NP95, this argues that similar regulatory 
mechanisms might exist in murine NP95. Indeed, two different splicing variants of NP95 
are expressed in mice that exhibit differential interactions with the H3 tail.  
4.2.2 The binding states of UHRF1 are resembled by the two splicing 
variants of NP95 in vitro 
In this study, I demonstrate that the two H3 tail binding modes identified for UHRF1 are 
substituted by the two isoforms of NP95 in mouse (Figure 4-1). In the first binding state 
the TTD is not interacting with the H3K9me3 (UHRF1 A and NP95 I) and in the second 
binding state the TTD and the PHD together establish multivalent binding mode  
(UHRF1 B and NP95 II). 
The linker insertion in NP95 I prevented the TTD from interacting with H3K9me3 in 
context of the TTD-PHD region as well as the full-length protein (Figure 4-1C). Transfer of 
the linker insertion into UHRF1 TTD-PHD domain also led to reduced interaction with 
H3K9me3 peptides. Importantly, our fluorescence polarization binding experiments 
reveal an essential role of the proline patch (P293-P294-P295) and the center arginine 
residue (R298) in blocking the binding of the TTD to H3K9me3. Mutagenesis of these 
residues to alanine results in release of the TTD and to a gain in H3K9me3 binding in 
context of the TTD-PHD-fragment of NP95 I. Therefore, NP95 I TTD-PHD linker 
resembles the mode of action of the PBR in UHRF1 (Figure 4-1 A, C).  
In context of the full-length NP95 I the same mutations do not change the binding to 
H3K9me3 to the same extent as seen in the TTD-PHD fragment, suggesting an additional 
intramolecular interaction stabilizing the TTD/linker interaction. Our intramolecular 
crosslinking experiments revealed interactions of the TTD domain with the PBR region, 
the SRA domain and the N-terminus of NP95 I. These interactions might stabilize the 
TTD-PHD linker in context of the full-length protein and thus retain the block of the TTD 
domain.  
In contrast to NP95 I, the TTD-PHD linker of NP95 II did not impair the TTD target 
interaction. The TTD-PHD linker of NP95 II has higher sequence similarity with the  
TTD-PHD linker in UHRF1 including the essential R-K-S motif. Previous studies revealed 
an essential contribution of this R-K-S motif to the establishment of a multivalent binding 
mode of TTD and PHD in UHRF1. This multivalent binding was dependent on the 




affinity of UHRF1 TTD-PHD to a N-terminally unmodified H3K9me3 peptide (Arita et al., 
2012; Rothbart et al., 2013). In context of the TTD-PHD region and full-length NP95 II, the 
mutation of the R-K-S (R293-K294-S295) motif to alanine impaired multivalent binding of 
TTD and PHD domain. I reasoned that the mutation might uncouple of both domains. 
According to that, the TTD-PHD linker might be a scaffold for the concerted binding of 
TTD and PHD. This is supported by the results of SAXS and NMR experiments that 
demonstrate similar behavior of the TTD-PHD linker in context of the TTD-PHD domain 
of UHRF1 and NP95 II. Therefore I reasoned that the multivalent binding mode found in 
UHRF1 also exists in NP95 II (Figure 4-1B, D).  
We found comparable binding states of UHRF1 and NP95 concerning the H3 tail. Yet, 
DNA binding by the SRA domain strongly influenced H3K9me3 binding UHRF1 but not 
NP95. Thus, the similarities of the different binding states of the protein in mouse and 
human are limited to the binding of H3K9me3. Since it was shown that nuclear 
localization of UHRF1, NP95 I and II is dependent on TTD, PHD and SRA domain in all 
three proteins, I deduced they have to be regulated in a different manner, due to their 
differential intramolecular interactions of the TTD with inter-domain linker regions  
(Rajakumara et al., 2011; Rothbart et al., 2013; Rottach et al., 2010). 
4.3 Inter-domain linker regions regulate the multivalent read 
out of chromatin marks in UHRF1 and NP95 
4.3.1 TTD/linker interaction is a prerequisite for a cooperative binding 
event in UHRF1 but not in NP95 
Emerging evidence indicates that the chromatin binding modules of UHRF1 do not act 
independently of each other but establish interactions with patterns of chromatin 
modifications (Arita et al., 2012; Bartke et al., 2010). Indeed, I show that the TTD/PBR 
interaction in UHRF1 is not only a simple mechanism to block the TTD binding to 
H3K9me3, but it is more importantly generating the basis of a cooperative binding event 
of TTD and SRA to H3K9me3 and DNA methylation (Figure 4-1 B). Unlike UHRF1, the 
cooperative binding of DNA and H3K9me3 is not conserved in NP95. This might be 
connected with the different role of the PBR in NP95 (Figure 4-1 C, D; Chapter 4.2.1). 
In NP95, binding measurements did not detect improved binding of the TTD domain to 
H3K9me3 in the presence of hemimethylated DNA. Nevertheless, it was shown before 
that NP95 I binding to H3K9me3 peptide is improved upon addition of hemimethylated 




20 of the H3 tail and were C-terminally labeled with TAMARA. Thus, I reasoned that the 
increased binding of NP95 I to the H3(1-20)K9me3-TAMARA might be due to the 
interaction of the PHD domain with the unmodified N-terminus of H3. The TTD binding 
to H3K9me3 was unaffected. 
In UHRF1, I demonstrated that the presence of hemimethylated DNA restores the 
TTD/H3K9me3 interaction that was blocked by the PBR region in vitro. Therefore, I 
reasoned that the binding of the SRA domain to DNA leads to a conformational change in 
the protein that abrogates the TTD/PBR interaction. Given that the interaction of the TTD 
with PBR involves a polybasic patch, the interaction could be interfered by the negative 
charge introduced upon DNA binding. Hence, the weakened TTD/PBR interaction might 
lead to enhanced binding of TTD to H3K9me3. In this way, UHRF1 establishes a binding 
mode where it interacts with both the hemimethylated oligonucleotide and H3K9me3. 
This clearly demonstrates that the inter-domain linker regions are not passive and flexible 
domain linkage, but are important regulators of UHRF1 binding specificity. 
Based on this rational, I reasoned that the interaction of UHRF1 with a regulator that 
improves binding of the TTD to H3K9me3 might affect the TTD/PBR interaction and 
increase the binding to DNA methylation by the SRA domain. 
 




(A) Schematic representation of UHRF1 binding state A, PBR is interacting with the TTD surface, only the 
PHD domain can interact with the H3 tail peptide, SRA domain is not interacting with DNA. (B) Schematic 
representation of UHRF1 binding state B, PBR is not interacting with the TTD surface, the TTD and PHD 
domain can interact with the H3 tail peptide, SRA domain is interacting with DNA. (C) Schematic 
representation of NP95 I binding state, TTD-PHD linker is interacting with the TTD surface, only the PHD 
domain can interact with the H3 tail peptide, SRA domain is interacting with DNA. (D) Schematic 
representation of NP95 II binding state, TTD-PHD linker is interacting with the TTD surface, the TTD and 
PHD domain can interact with the H3 tail peptide, SRA domain is interacting with DNA. 
4.3.2 Inter-domain linker regions improve binding specificity for 
multivalent targets 
In presence of high local concentrations of the H3K9me3 tail at heterochromatic loci, the 
simultaneous interaction of H3K9me3 and TTD-PHD linker could overcome the PBR 
dependent blocking of the TTD. Therefore, the interplay of the different inter-domain 
linker regions on the TTD surface might be a mechanism to increase the specificity of 
UHRF1 for the modification. Thus, it prevents incorrect readout of histone marks by 
UHRF1. Similar effects were already shown for the Nck multidomain adapter protein. 
Similar to UHRF1, the binding specificity of the protein is regulated by the interplay of 
two linker regions (Takeuchi et al., 2010). This interplay improved the specificity of the 
protein and as a result it favored bivalent target sites. 
Since NP95 I also shows blocking of the TTD binding to H3K9me3 in vitro, similar 
mechanisms could exist in this isoform of NP95. Nevertheless, the exact regulation of 
NP95 I binding specificity remains elusive and might involve secondary interactions 
targeting the TTD-PHD linker region.  
4.4 Linker influence the nuclear localization of UHRF1/NP95  
4.4.1 Similar cellular roles of UHRF1 and NP95 I 
Many studies have emphasized the important role of UHRF1 and NP95 I in the 
maintenance of DNA methylation and other heterochromatic marks during continuous 
cell divisions (Bronner et al., 2010; Cartron et al., 2013; Jin et al., 2010). UHRF1 and NP95 I 
were both shown to be involved in DNMT1 recruitment to replicating loci. However, it 
was also found that UHRF1 binds to promoter regions of euchromatic genes and regulates 
their expression (Rajakumara et al., 2011; Yao et al., 2016). Some of these loci lack 
H3K9me3 but exhibit DNA methylation paired with H3 unmodified at the N-terminus 
(i.e. absence of H3R2 symmetric dimethylation) (Rajakumara et al., 2011). It is conceivable 




SRA domains with the unmodified N-terminal H3-tail and methylated DNA. NP95 I 
exhibits a similar binding mode. It was shown to bind to methylated DNA and the N-
terminus of H3 in vitro, while it was not binding to H3K9me3. Therefore, we expect that 
NP95 I might be recruited to such loci in the cell, comparable to UHRF1.  
It was found that NP95 I interacts with the de novo DNA methyltransferases DNMT3a 
and DNMT3b and that this complex mediates epigenetic silencing in a histone H3 lysine 9 
methyltransferase (i.e. G9a, Suv39h1/2) dependent manner (Meilinger et al., 2009). 
Depletion of NP95 in mouse embryonic stem cells results in severe global DNA 
hypomethylation (Sharif et al., 2007). A similar DNA methylation defect is caused by 
depletion of all three DNMTs (Tsumura et al., 2006) or of histone methyltransferases (G9a, 
Suv39h1/2) (Dong et al., 2008; Lehnertz et al., 2003). Hence, there is circumstantial 
evidence that NP95 I is not only involved in replication-coupled maintenance of DNA 
methylation, but also in de novo DNA methylation in an H3K9me3-dependent manner. 
This was so far not reported for UHRF1. 
Others and we showed that UHRF1 and NP95 I were very highly abundant in thymus 
and intestine (Chapter 3.3.2) (Hopfner et al., 2000). Thymus and intestine are important 
parts of the human and murine immune system and an important site of T-lymphocyte 
proliferation and maturation. A key process of T-cell maturation is V(D)J recombination, 
that was shown to involve reorganization of heterochromatic regions (Proudhon et al., 
2015; Su et al., 2004). Recent reports reveal a central role of UHRF1 in transcriptional 
regulation of the macrophage migration inhibitory factor in monocytes, B- and T-
lymphocytes and the importance of NP95 in maturation of colonic regulatory T-cells 
(Obata et al., 2014; Yao et al., 2016). The high similarity of expression levels of NP95 I and 
UHRF1 in these tissues and the very low abundance of NP95 II mRNA in the murine 
intestine, suggests that immune system related functions of UHRF1 in human might be 
resumed by NP95 I in mouse. 
4.4.2 Potential cellular role of NP95 II  
The expression of NP95 II mRNA is much lower than NP95 I mRNA. NP95 II shows 
highest expression in adult ovary, thymus and duodenum, suggesting an important 
function in these tissues. In this study I demonstrated that the protein establishes a 
multivalent binding mode to a H3 tail with an unmodified N-terminus and K9me3 
comparable to the UHRF1 B state (Figure 4-1B, D) (Arita et al., 2012; Cheng et al., 2013; 
Rothbart et al., 2013; Xie et al., 2012). While the functions of UHRF1 and NP95 I are 
extensively studied, there is nothing known about the NP95 II isoform of the protein. In 




nor by the TTD-PHD linker. In contrast to UHRF1 the protein lost the consensus 
recognition motif of PKA (R-X-X-S) in the TTD-PHD linker. Therefore, I think this isoform 
adopts a constant multivalent binding mode and targets a special subset of loci. The 
nature of NP95 II action in vivo will be the subject of future experiments. 
4.5 Regulation of the TTD interaction by different inter-domain 
linker regions 
In cells, UHRF1 and NP95 are localized to pericentromeric heterochromatin in the S-phase 
of the cell cycle (Bostick et al., 2007; Miura et al., 2001; Papait et al., 2007; Sharif et al., 
2007). Pericentromeric heterochromatin is generally thought to be rich in DNA-
methylation and H3K9me3 (reviewed in (Dejardin, 2015)). It was previously reported that 
the TTD, PHD and SRA domains are all participating in targeting of UHRF1 and NP95 I to 
heterochromatin (Liu et al., 2013; Rothbart et al., 2013; Rottach et al., 2010). 
I show that in NIH3T3 cells UHRF1 localization to this region is dependent on the 
domains that bind these modifications, the SRA and the TTD domain. In vitro, the  
C-terminal PBR region blocks the interaction of the TTD with H3K9me3 (Gelato et al., 
2014). Therefore we thought that TTD/PBR interaction influences the nuclear localization 
of the protein. Indeed, overexpression of the full-length protein together with the PBR-
RING region impaired co-localization with the pericentromeric heterochromatin while a 
mutant PBR-RING did not (Gelato et al., 2014). 
In NP95 I, we found a similar linker dependent mechanism to block the TTD aromatic 
cage and thus impair the interaction with H3K9me3. It was described earlier that the TTD 
is essentially contributing to the co-localization of NP95 I with pericentromeric 
heterochromatin (Rottach et al., 2010). Given the importance of the TTD in the nuclear 
localization of UHRF1 as well as NP95 I, it is crucial to tightly control the TTD interactions 
with the different inter-domain linker regions in UHRF1 as well as NP95. 
In agreement with former studies I show that the nuclear localization of UHRF1 to 
pericentromeric heterochromatin is also dependent on the interaction of the SRA domain 
with hemimethylated DNA (Gelato et al., 2014; Liu et al., 2013). Similar dependency on 
the SRA domain was demonstrated for NP95 (Rottach et al., 2010). Hence, UHRF1 as well 
as NP95 need the combined read out of DNA-methylation and H3K9me3 to faithfully 
localize to pericentromeric heterochromatin in the nucleus. It was already reported that 
the SRA domain alone does not co-localize with full-length protein in cells (Rottach et al., 
2010). Therefore, altering binding contribution of the TTD caused by intramolecular 




processes affecting the TTD/linker interaction might give rise to target site variation that 
can be important to fulfill the multitude of reported functions of UHRF1/NP95 in 
replication, transcriptional regulation, DNA-damage response and immune cell 
maturation. 
4.5.1 Characteristic features of linker regulations 
While intrinsically disordered, the linker regions might nevertheless adopt a series of 
limited, defined transitional states enabling interaction with different polar surfaces of 
UHRF1/NP95 and determining different conformational and binding states. The kinetic 
barrier for these transitions could be relatively low due to the intrinsic linker flexibility. 
As consequence, the protein might be able to rapidly change conformations in response to 
external stimuli and structural perturbations. This in turn would facilitate changes in the 
population of certain states therefore affecting UHRF1/NP95 target binding and cellular 
function (Ma et al., 2011; Tauber and Fischle, 2015). 
Sequence comparison of the linker regions regulating the binding behavior of UHRF1 and 
NP95 highlights the common characteristic features of regulatory linkers. All linker 
sequences comprise a K/R-rich basic patch or at least an essential basic residue, which is 
closely accompanied by a threonine or serine residue. The NP95 I TTD-PHD linker 
contains an additional Proline-rich region. All these linker regions interact with the 
surface of the TTD domain. This domain is formed by antiparallel β-sheets and contains a 
hydrophobic ligand pocket for the interaction with H3K9me3.  
Comparable intramolecular interactions of inter-domain linker regions with hydrophobic 
pocket containing domains are described for Src homology domain proteins (SH2, SH3). 
These proteins comprise SH3 domains that recognize a solvent exposed P-X-X-P motif 
(Freund et al., 2008). Comparable with UHRF1 TTD domain, the SH3 domain consists of 
β-strands that are arranged in two anti-parallel β-sheets and contain a hydrophobic ligand 
pocket. In Nck, a basic patch in a linker region accompanied by a serine residue, 
establishes interactions (Kd = 2 mM) with a SH3 domain masking its P-X-X-P binding site. 
This mechanism shows high similarity with the PBR-dependent blocking of the TTD in 
UHRF1. The Crk signaling protein shows intramolecular interactions of a proline 
containing linker with the surface of a SH3 domain that are modulating target interaction 
of the protein. In NP95 I, I revealed that a proline patch in the TTD-PHD linker is essential 
for blocking of the binding of the TTD to H3K9me3.  
In contrast, SH2 domains recognize phosphorylated tyrosin residues by a phosphate 




domains are separated by a 23 amino acid linker insertion that is thought to regulate its 
target interaction. This linker insertion is particularly rich in prolines, serines and basic 
residues. In UHRF1 and NP95 inter-domain linker regions we found same residues 
playing important roles in regulation of the binding specificity of the proteins. The 
similarities we found between linker regulated proteins might also give insights into 
common regulatory mechanisms to alter multidomain protein target binding. Given the 
common characteristics of the described mechanisms, these can be used to identify new 
putative linker regulated proteins.  
 
Figure 4-2 Regulation of TTD/ linker interactions 
Schematic representation of UHRF1 (A), NP95 I (B) and NP95 II (C) domain organization, highlighted are 
different regulatory linker regions affecting TTD interaction with H3K9me3, shown are regulatory 
mechanisms we and others described (black) and putative mechanisms (grey), grey dots show potential sites 
of post translational phosphorylation. 
4.5.2 Small molecule ligands: 
Previous work of our laboratory identified PI(5)P as a small molecule regulator of UHRF1 
TTD binding to H3K9me3, by interacting with the PBR region (Gelato et al., 2014). While 
we do not yet know how exactly PI(5)P is bound by UHRF1. It is interesting to note that 
the PBR resembles in sequence a previously defined consensus PIP interaction motif 




In this study, I show that manipulation of cellular PI5P levels affects UHRF1 subnuclear 
localization. Several links between the reported functions of UHRF1 and nuclear PI(5)P 
levels support the idea of allosteric control of the protein. It was shown previously that 
nuclear PI(5)P levels are tightly regulated during the cell cycle and in response to certain 
cellular signaling cascades. PI(5)P levels increase up to 20-fold during transition of G1- to 
S-phase (Clarke et al., 2001; Divecha et al., 1991; Jones et al., 2006; Jones et al., 2013). Cell 
cycle analysis of UHRF1 localization in relation to heterochromatic foci indicates changed 
distribution at the onset of S-phase (Papait et al., 2007), which might be caused by 
regulation of TTD/H3K9me3 interaction by PI(5)P. Also, UHRF1 interacts with several 
factors associated with the DNA damage response such as Eme1, TIP60, Ku70, and 
PARP1 (Achour et al., 2009; De Vos et al., 2014; Mistry et al., 2008; Sharif et al., 2007). 
PI(5)P levels are increased after irradiation and exposure to oxidative stress (Clarke et al., 
2001; Divecha et al., 1991; Jones et al., 2006; Jones et al., 2013). Indeed, recent studies 
revealed a role of UHRF1 in DNA damage response, as a sensor for DNA interstrand 
crosslinks (Liang et al., 2015; Tian et al., 2015). 
The role of PI(5)P in the regulation of UHRF1 binding behavior to H3K9me3 shows the 
importance of small molecules in timed and site-specific localization of the protein. This 
led us to investigate the potential of additional small molecule regulators. We identified 
two potential cyclic peptide regulators of UHRF1, D4 (PYNRILIKRHRVKII) and D5 
(PYVLIYVNNHKRPSR) and demonstrated that these peptides interact with the PBR-
RING region of UHRF1. In addition, the peptides caused a significant increase in the 
interaction of this region with the TTD-PHD region of the protein. Therefore, the peptides 
had opposite effects than PI(5)P. The cyclic peptides could thus be a tool to lock UHRF1 in 
state A (Figure 4-1A) and drastically decrease the interaction of the protein with 
H3K9me3 and putatively DNA methylation. Potentially, the peptide candidates resulting 
from our screening procedures might be relevant candidates for future medical 
approaches to target UHRF1 in cancerous tissues. 
In NP95 I, we found the TTD-PHD linker playing an important role in regulation of the 
binding to H3K9me3. It was proposed that the linker insertion in NP95 I harbors a 
ATP/GTP-binding site motif between A296 and S303 (Fujimori et al., 1998; Hopfner et al., 
2000). It is likely that binding of ATP or GTP to the TTD-PHD linker would impair the 
interaction between the linker and the TTD. As a result the TTD might be available to 
bind to H3K9me3 again. Indeed, GTP might be relevant in NP95 I regulation. GTP 
hydrolysis is essential for cell cycle progression (Avis and Clarke, 1996). NP95 I was 
shown to be essential progression of the S-phase and its depletion is linked to cell cycle 




even apoptosis (Meshkini and Yazdanparast, 2010). This suggests that NP95 I binding to 
H3K9me3 could be regulated by this molecule in the cell.  
4.5.3 Posttranslational modification 
The transitions between different conformational states of UHRF1 and NP95 conveyed by 
the linker regions might be further regulated by posttranslational modifications (PTM). 
Given the importance of basic patches or residues for the interaction between the linkers 
and the TTD domain, it is important to note that serine and threonine residues often 
accompany these. This amino acids are targets for posttranslational phosphorylation. 
Phosphorylation could impair binding of the linker to the peptide-binding groove of the 
TTD or putatively other regions of the protein by impairing their electrostatic interactions. 
Indeed, for UHRF1 it was shown previously that phosphorylation of a serine residue 
(S298) adjacent to R295-R296-K297 by PKA, decreases the binding affinity of the TTD-
PHD cassette for the H3K9me3-tail. The altered binding stoichiometry of the complex 
indicates that the coupling of TTD and PHD mediated by TTD-PHD linker is impaired by 
the PTM (Arita et al., 2012). Interestingly, the PKA consensus motif (R-X-X-S) is neither 
conserved in NP95 I nor NP95 II suggesting that the murine proteins are not 
phosphorylated at that position.  
A number of additional sites of serine phosphorylation and other posttranslational 
modifications have been identified in UHRF1 as well as NP95 by proteomics studies. 
Some of these map to highly conserved residues within the TTD-PHD linker and the PBR 
region (Dephoure et al., 2008; Ma et al., 2012; Olsen et al., 2006; Rigbolt et al., 2011). These 
events have the potential to regulate the proteins conformational states. In UHRF1 for 
example, phosphorylation of S651 that is found during human embryonic stem cell 
differentiation and mitosis, is next to the K648-R649-K650 element (Ma et al., 2012; Rigbolt 
et al., 2011). This might impair the interaction of the PBR with the peptide-binding groove 
of the TTD thereby enhancing a particular UHRF1 chromatin-binding mode.  
Similar effects of posttranslational phosphorylation were predicted for the linker 
dependent regulation of Nck and have been reported for Syk (Paris et al., 2010; Takeuchi 
et al., 2010). Syk is a target of PKC in cells and is phosphorylated at a serine residue in the 
center of the regulatory linker. Interestingly, the 9 amino acid insertion in the NP95 I TTD-
PHD linker matches the general PKC consensus motif (R/K)1-3–(X)0-2–T/S–(X)0-2–(R/K)1-3 
generating a putative binding site for PKC (Kennelly and Krebs, 1991). Therefore, NP95 I 
is a potential substrate and might get phosphorylated on a threonine residue (T300) 
located between R298 and K302. This phosphorylation could potentially impair the 




4.5.4 Prolyl isomerization 
In addition to the discussed PTMs, serine S287 of UHRF1 is posttranslationally 
phosphorylated during T-cell receptor signaling, mitosis and human embryonic stem cell 
differentiation (Olsen et al., 2006; Rigbolt et al., 2011). The same phosphorylation was 
reported in rat UHRF1 and might also exist in the murine protein (Lundby et al., 2012). 
This phosphorylation site is C-terminally accompanied by a proline residue (P288) that 
might be a target for Pin1 directed prolyl isomerization (Figure 4-2). Pin1 is known to 
specifically target the proline residues that are accompanied by a phosphorylated serine 
residue. It catalyzes cis-trans isomerization of proline imidic peptide bonds exclusively on 
phosphorylated target sites (Rostam et al., 2015). In UHRF1/NP95, this isomerization 
could impair or change the positioning of the TTD-PHD linker on the TTD surface and 
thus the multivalent binding of TTD and PHD in a phosphorylation signal dependent 
manner. Similar to UHRF1 and NP95, Pin1 is important for cell cycle progression between 
G1/G0- and S-phase and plays a key role in cellular signal transduction pathways (Rostam 
et al., 2015). This might be a versatile mechanism to regulate the target binding specificity 
of the protein during cell cycle or cellular differentiation processes.  
It has been shown that isomerization of proline bonds can tune the binding affinity of a 
protein. In MLL1 a proline in the linker between the PHD3 and the bromodomain is 
subject of CyP33 dependent prolyl isomerization that changes the relative spacing of the 
two domains. This results in a reduced affinity for its target H3K4me2/3 as well as the 
generation of a new interaction interface of the PHD3 domain (Wang et al., 2010). The 
relevance of proline switches for linker dependent regulation is also demonstrated for the 
SH3 containing Crk signaling protein (Sarkar et al., 2011). In Crk the cyclophilin A-
dependent proline cis-trans isomerization in a regulatory linker region affects target site 
specificity of the protein by releasing novel SH3 binding surfaces. 
4.5.5 Protein-protein interactions 
UHRF1/NP95 is known to interact with different proteins such as DNMTs, G9a and 
USP7. These interactions require distinct, specific surfaces that will or will not be available 
in the different conformational states of UHRF1/NP95. Conversely, it is expected that 
engagement of a particular protein partner will stabilize a certain conformation and 
therefore a certain chromatin mark-binding mode of UHRF1 or NP95. USP7 was recently 
found to interact with the SRA-RING linker region of UHRF1 engaging lysine residues 
K646 and K648 (Ma et al., 2012; Zhang et al., 2015). These lysines have also been shown to 




interaction with USP7 was shown to affect the TTD/PBR interaction in vitro as well as the 
UHRF1 recruitment to chromatin in vivo. It specifically interacts with UHRF1 in S-phase 
of the cell cycle and prevents its ubiquitinylation. In turn, mitotic phosphorylation at S651 
of UHRF1 dissociates the deubiquitylase from the PBR (Ma et al., 2012). Interestingly, the 
identified recognition motif of USP7 in the SRA-RING linker is also conserved in NP95 
(Zhang et al., 2015). Therefore, we expect similar interactions of USP7 with NP95. Since 
the TTD/PBR interaction is not conserved in NP95, the association of USP7 with the 
protein should not affect the binding of the TTD to H3K9me3. Nevertheless, TTD domain 
binding to this modification was shown to be essential for the recruitment of the protein 
to pericentromeric heterochromatin (Rottach et al., 2010).  
In this study we showed that UHRF1 SRA domain interaction with hemimethylated DNA 
enhances the interaction of the TTD with the H3K9me3 peptide, thus is impairing the PBR 
dependent blocking of the TTD aromatic cage. It is reported that the SRA is not only 
interacting with DNA, but is also establishing strong connections to DNMT1 (Achour et 
al., 2009; Bashtrykov et al., 2014). I reasoned that this interaction might influence the 
TTD/PBR interaction in UHRF1. While DNMT1 was shown to only interact with the SRA 
domain in UHRF1, a second interaction site of the protein was reported in NP95 I (Achour 
et al., 2009; Bashtrykov et al., 2014; Berkyurek et al., 2014; Bostick et al., 2007). This 
binding site of DNMT1 was mapped to the region of the TTD-PHD linker and the PHD 
domain of NP95 I (Bostick et al., 2007). Since we have shown here that the TTD-PHD 
linker is blocking the TTD interaction with H3K9me3, the interaction of DNMT1 with this 
region might be a regulatory mechanism to release this block. It is known that the TTD 
domain interaction with H3K9me3 is essential for proper localization of NP95 I to 
pericentromeric heterochromatin in vivo (Rottach et al., 2010). Therefore the binding of 
DNMT1 to the TTD-PHD linker might facilitate proper localization of the protein in vivo. 
The linker insertion in NP95 I comprises other features to putatively regulate the 
TTD/TTD-PHD linker interactions. proline-rich motifs (PRMs) are important hubs of 
protein-protein interactions that are bound by PRM recognizing domains (PRD) (Freund 
et al., 2008). The linker insert of NP95 I is especially rich in proline residues, which could 
be important for interactions with PRD comprising proteins. These proteins play key roles 
in a variety of cellular signaling events and their interaction with the proline patch could 
impair the TTD/ TTD-PHD linker interaction in NP95 I. This could regulate the NP95 I 




4.6 Alternative splicing of linker regions 
In mice, alternative splicing generates two isoforms of UHRF1. The difference of only nine 
amino acids between the isoforms give rise to two proteins that substantially differ in the 
binding behavior regarding K9 trimethylation of the H3 tail. The linker insertion 
introduces residues in the TTD-PHD linker that establish interactions with the TTD, 
blocking the H3K9me3 binding. At the same time NP95 II is able to establish a multivalent 
binding mode of TTD and PHD that was not shown for NP95 I. Since the two splicing 
variants of NP95 resemble the two binding states we found for UHRF1, the target 
interaction of the murine protein could also be regulated on a transcriptional level. How 
the differential splicing events are regulated during the cell cycle and cell differentiation, 
however, remains to be elucidated.  
I found notable similarities between the inter-domain linker dependent regulatory 
mechanisms in UHRF1/NP95 and the proteins of the Src homology domain proteins. Syk 
is a member of this protein family, resembling the described key features of the linker 
dependent regulation (Chapter 4.3.1). Similar to NP95, the Syk family of tyrosine protein 
kinases exemplifies the importance of alternative splicing events in inter-domain linker 
sequences. Alternative splicing events give rise to two different splicing variants of Syk 
proteins, Syk and SykB. The proteins only differ by a 23 amino acid insertion in the linker 
between the tandem SH2 domains and the catalytic domain of the proteins. This insertion 
is highly conserved in human, rat and mouse. As a consequence of the insertion, Syk 
exhibits a higher target affinity for phosphorylated immunoreceptor tyrosine-based 
activation motifs and is therefore much more efficiently mediates the immunoreceptor 
signaling (Latour et al., 1998). I found a similar alternative splicing event regulating the 
binding affinity of NP95. Additionally, the insertion found in NP95 I harbors putative 
regulatory features not found in NP95 II. Similar to Syk, the linker insert in NP95 I 
comprises a PKC binding motif. As described above, Syk function is modulated by PKC 
dependent phosphorylation, while SykB is not.  
Different isoforms are expressed from the same gene using specific alternative splicing 
mechanisms dependent on tissue or environmental conditions. Since the same coding 
sequence can be used to produce different proteins that fulfill different cellular functions, 
this mechanism improves the coding capacity of the genome. I reasoned that the 
alternative splicing events in inter-domain linker regions might in general give rise to 
differentially regulated multidomain proteins. In this way, proteins with slight variations 
in target specificity can be expressed. These different variants can be recruited to 




spliced linker regions might also carry different regulatory features. Thus proteins could 
be targeted to specific loci in response to different external stimuli. 
4.7 Using small molecules to target UHRF1 in cancer 
UHRF1 is found in a complex with enzymes catalyzing histone and DNA modifications 
that are mainly located in transcriptionally inactive chromatin (reviewed in (Almouzni 
and Probst, 2011; Bernstein et al., 2007; Dejardin, 2015), such as HDAC1, DNMT1 and G9a 
(Cartron et al., 2013; Jin et al., 2010), where it targets these catalytic proteins to 
heterochromatic loci using the TTD and SRA domain (Nady et al., 2011; Unoki et al., 
2004). UHRF1 is a central component of this complex ensuring the faithful copy of 
silencing epigenetic marks during replication, preserving gene repression (Bronner et al., 
2010; Cartron et al., 2013; Jin et al., 2010).  
UHRF1 expression was found to be aberrant in cancer cells (Mousli et al., 2003). Elevated 
levels of UHRF1 expression have been found in many human cancerous tissues including 
bladder, breast, cervix, kidney, lung, pancreas and prostate (Bronner et al., 2007; Unoki et 
al., 2009; Unoki et al., 2010). The high levels of the protein result in loss of contact 
inhibition and hypermethylation in tumor suppressor genes (Alhosin et al., 2011; 
Daskalos et al., 2011; Hopfner et al., 2002; Sabatino et al., 2012). The down regulation of 
UHRF1 in this context was shown to give rise to re-expression of tumor suppressors, cell 
cycle arrest and apoptosis (Alhosin et al., 2011; Jeanblanc et al., 2005; Qin et al., 2015; Tien 
et al., 2011). Therefore, UHRF1 is a versatile target for anti-cancer therapy in many tissues 
(Alhosin et al., 2011; Unoki et al., 2009). It was already proposed that small molecule 
compounds could be used to impair SRA binding to hemimethylated DNA and to reduce 
UHRF1-dependent hypermethylation at tumor suppressor genes (Unoki et al., 2009). A 
recent report has revealed small molecules that modify the binding of the domain to 
DNA, leading to inhibition of DNA-methylation in vitro (Myrianthopoulos et al., 2016). 
However targeting the SRA domain of UHRF1 is not an ideal approach due to the fact 
that UHRF2, another protein of the same family, comprises a similar domain. In contrast, 
the TTD/PBR interaction we described is UHRF1 specific (Gelato et al., 2014) and can be 
used to impair the interaction of the protein with its target sites. In this study we could 
show that UHRF1 binding to H3K9me3 and DNA methylation are not separate events but 
are closely interconnected. Small molecules targeting the TTD/PBR interaction will thus 
affect both binding events. In our cyclic peptide screening we found that D4 and D5 
peptides are promising small molecule regulators of UHRF1 and could be used to target 





Ubiquitin-like with PHD and RING Finger domains 1 (UHRF1 in human, NP95 in mouse) 
is an important epigenetic regulator connected to apoptosis and tumor development. 
UHRF1/NP95 integrates different chromatin modifications and is essential for their 
maintenance throughout the cell cycle. UHRF1/NP95 comprises domains for interaction 
with histones of different modification states (TTD and PHD) and methylated DNA (SRA) 
coupled to a catalytically active E3 Ubiquitin ligase domain (RING). While multivalent 
binding of multidomain proteins to complex patterns of chromatin modifications is a 
hallmark of the histone code, the regulation of such factors has not been fully 
investigated. Emerging evidence indicates that the chromatin binding modules of 
UHRF1/NP95 do not act in isolation but in concert to orchestrate coordinated interaction 
with different histone and DNA modifications. Here, we dissected the molecular details of 
regulation of chromatin binding by UHRF1/NP95. Using intramolecular crosslinking 
analysis and NMR studies we show that flexible inter-domain linker regions establish 
contacts between the different chromatin-binding modules and globally direct the overall 
folding and spatial domain arrangement of the protein. These contacts are modulated by 
ligand binding (histones, DNA) as well as by the allosteric regulator phosphatidylinositol 
5-phosphate (PI5P). Indeed, in vitro binding experiments imply that the unstructured 
linker regions of the protein can alter binding behavior of the chromatin interaction 
domains and therefore control specificity of UHRF1/NP95. Interestingly, we found that 
murine NP95 has two splice variants, which only differ in a nine amino acid insertion in 
one of the inter-domain linker regions. In agreement with our hypothesis, this insertion is 
sufficient to facilitate differential regulation of chromatin binding by the two isoforms.  
Overall, our results show that flexible inter-domain linkers are versatile tools to 
dynamically regulate the interplay of several domains. We therefore propose a general 
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7.1 cDNA sequences 
The coding sequence of homo sapiens UHRF1/ICBP90 was used as published in (Gelato et 
al., 2014) 
















































The coding sequence of mus musculus NP95 variant I matching the annotated sequence 
BC022167 was obtained from Source bioscience as I.M.A.G.E. fully sequenced cDNA clone 
IRAVp968C1122D (ImageID: 4017286) 

















































The coding sequence of mus musculus NP95 variant II matching the annotated sequence 
AK153083 was obtained from Source bioscience as RIKEN Mouse FANTOM full length 
cDNA clone I830121L22 















































7.2 Primer list 
7.2.1 Cloning Primers 
Table 7-1 Names and sequences of the used cloning primers 
Oligo name Sequence 
NP95 for KpnI pcDNA3.1 gatcatggatccgcatgtggatccaggttcgaac 
NP95 rev NotI pcDNA3.1 tacatgcggccgcccggccgctgccatagccag 
pmCherry UHRF1 fwd XhoI  catcgtctcgagctatgtggatccaggttcgg 
pmCherry UHRF1 rev XbaI  catcgttctagatcaccggccattgccgtagcc 
pmCherry NP95 fwd XhoI gatcatctcgag ct atgtggatccaggttcgaac 
pmCherry NP95 rev XbaI gatcattctaga tcaccggccgctgccatagc 
 pEGFP PBR-RING/NLS rev KpnI atatgcggggtaccttaccggtccttgagtgacgcc 
 pEGFP PBR-RING/NLS fwd XhoI aggatgccctcgagctgatgatgagcctggcccttg 
petM13 NP95 fwd BamHI  agctatgtggatccaggttcgaactatggatg 
 petM13 NP95 rev XhoI gtggtgctcgagccggccgctgccatagc 
 pRuth NP95 V2 KpnI fwd agatctgggtacctggatccaggttcgaactatggatg 
 pRuth NP95 V2 HindIII rev gcggccgcaagctttcaccggccgctgccatagccag 
pcDNA3.1 NP95 fwd KpnI  gatcatggtaccgcatgtggatccaggttcgaac 
petM13 NP95 longPHD BspHI fwd gatactgatcatgaagagcggcccatcctg 
petM13 NP95 longPHD XhoI rev cagaattactcgagctcccctgcttgtaccac 
petM13 NP95 TTD XhoI rev cagaattactcgagcctcctctctttagg 
petM13 NP95 longRING BspHI fwd gagatatatcatgattctggggctcactatg 
petM13 NP95 TTD BspHI fwd gagatatatcatgattgtgtgggaggacacg 
7.2.2 Sequencing primer 
Table 7-2 Names and sequences of the used sequencing primers 
Oligo name Sequence 
SRA seq Primer  ctaccttctgcggagggacgatg 
NP95 N-term rev tgaaacacttcctcaatctt 
NP95 N-term fwd aag att gag gaa gtg ttt ca 
NP95 C-term rev aagagctggttgagaatggt 
NP95 C-term fwd accattctcaaccagctctt 





7.2.3 Mutagenesis primers 
Table 7-3 Names and sequences of the used mutagenesis primers 
Oligo name  Sequence 
fwd UHRF1 YT478/479AA ggg aat ttt ttc aca gcc gcg ggt agt gg 
rev UHRF1 YT478/479AA tcg acc acc act acc cgc ggc tgt gaa 
fwd UHRF1 R491A cc ggc aac aag gca acc gcg g 
rev UHRF1 R491A ctg ttc cgc ggt tgc ctt gtt g 
UHRF1 K648A fwd ggc aag ggc aag tgg gcg cgg aag tcg 
UHRF1 K648A rev tcc tgc cga ctt ccg cgc cca ctt gcc 
PIP4Ka G131L/Y138F fwd cgcagtctagctcgttttcacacttccttcgac 
PIP4Ka G131L/Y138F rev ttgtcgaaggaagtgtgaaaacgagctagactg 
PIP4Kb D278A fwd gatcatggcctacagcctg 
PIP4Kb D278A rev ccagcaggctgtaggccatg 
PIPKb D278A rat fwd gatcatggcctacagcctcctgg 
PIPKb D278A rat rev ggctgtaggccatgatcttcagc 
PIPKa fwd G131L/Y138F gcagcctggctcggtttcacacgtcctttgacaaaag 
PIPKa rev G131L/Y138F  tgtcaaaggacgtgtgaaaccgagccaggctgcgagc 
petM13 UHRF1 fwd His10 ctacggcaatggccggcaccaccaccacctcgagcacc 
petM13 UHRF1 rev His10 gtggtgctcgaggtggtggtggtgccggccattgc 
NP95 PBR-RING myc tag muta fwd ctggctatggcagcggccgggaacaaaaactcatctcagaagagg
atctgctcgagcaccaccac 
NP95 PBR-RING myc tag muta rev gtggtggtggtggtgctcgagcagatcctcttctgagatgagtttttgttc
ccggccgctgccatag 
UHRF1 TP linker Insertion NP95 I fwd  cccatggttgacaaccccatgagaccccctcctgccctccggaacac
agggaagagcgggccgtcc 
UHRF1 TP linker Insertion NP95 I rev gcttgcaggacggcccgctcttccctgtgttccggagggcaggaggg
ggtctcatggggttgtc 
NP95 V1 PPP linker mut fwd gatcgctagcccctcgcaagccgctgctgccctccggaac 
NP95 V1 PPP linker mut rev cttccctgtgttccggagggcagcagcggcttgcgaggg 
NP95 V1 R298 linker mut fwd gcaaccccctcctgccctcgcgaacacaggg 
NP95 V1 R298 linker mut rev gccgctcttccctgtgttcgcgagggcaggagg 
NP95 V2 RKS-AAA mutag fwd ttgatcgctagcccctcgcaagcggcagctggcccatcctgccgg 
NP95 V2 RKS-AAA mutag rev ccttgcagaaccggcaggatgggccagctgccgcttgcgaggggct
agc 
NP95 V1 KS-AA mutag fwd gccctccggaacacaggggcagctggcccatcctgccgg 
NP95 V1 KS-AA mutag rev ccttgcagaaccggcaggatgggccagctgcccctgtgttccg 
NP95 TTD 3xFlag fwd agaaggagatataccatggactacaaggaccacgacggtgactac
aaggaccacgacatcgactacaaggacgacgacgacaaggtgtg
ggaggacacggacctggggctgtac 






NP95II consensus fwd gcagctgaagcggatgacaagactgtgtgggaggacac 
NP95II consensus rev cccacacagtcttgtcatccgcttcagctgccccttcacc 
NP95 YY-AA TTD mt fwd ccatgtcaaggcagatgacgcaccagagcatggagtggaca 
NP95 YY-AA TTD mt rev gctctggtgcgtcatctgccttgacatggtacatgatgtc 
NP95 DE-AA PHD mt fwd gctgttgtgtgctgcgtgtgacatggccttccacctgtac 
NP95 DE-AA PHD mt rev gccatgtcacacgcagcacacaacagctgtttctcaggagc 
NP95I consens fwd ggcctgtcgctttgagctggaccacagctcc 
NP95I consens rev ggtccagctcaaagcgacaggccgggcagctg 
NP95 K628/632A fwd gagaagagcagggctcgcccggccgcagccttggagcagggacc
ctca 
NP95 K628/632A rev ctgctccaaggctgcggccgggcgagccctgctcttctccttgttagc 
NP95 K649A fwd ggcaaaagcaagcaggcatccacagggccgaccctct 
NP95 K649A rev ggccctgtggatgcctgcttgcttttgcctgtcttgga 
NP95 K645/647/649A fwd cttccaagacaggcgcaagcgctcaggcatccacagggccgaccc
tctcc 
NP95 K645/647/649A rev ggccctgtggatgcctgagcgcttgcgcctgtcttggaagatgaggg 
NP95 K623/K625/R627/K628/R629A fwd gaggccttggctaacgcagaggctagcgcagctgcgccggccaag
gccttggagcagggaccc 
NP95 K623/K625/R627/K628/R629A rev caaggccttggccggcgcagctgcgctagcctctgcgttagccaag
gcctccaagtagccttcagg 
7.3 Mass spectrometry results 
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Conserved linker regions and their regulation determine multiple
chromatin-binding modes of UHRF1
Maria Tauber and Wolfgang Fischle*
Laboratory of Chromatin Biochemistry; Max Planck Institute for Biophysical Chemistry; G€ottingen, Germany
Ubiquitin-like with PHD and RINGFinger domains 1 (UHRF1) is an
important nuclear protein that is
mutated and aberrantly expressed in
many tumors. The protein integrates dif-
ferent chromatin modifications and is
essential for their maintenance through-
out the cell cycle. Separate chromatin-
binding modules of UHRF1 have been
studied on a functional and structural
level. The unmodified N-terminus of his-
tone H3 is recognized by a PHD domain,
while a TTD domain specifically inter-
acts with histone H3 Lysine 9 trimethyla-
tion. A SRA region binds hemimethylatd
DNA. Emerging evidence indicates that
the modules of UHRF1 do not act inde-
pendently of each other but establish
complex modes of interaction with pat-
terns of chromatin modifications. This
multivalent readout is regulated by allo-
steric binding of phosphatidylinositol 5-
phosphate to a region outside the PHD,
TTD and SRA domains as well as by
phosphorylation of one of the linker
regions connecting these modules. Here,
we summarize the current knowledge on
UHRF1 chromatin interaction and intro-
duce a novel model of conformational
transitions of the protein that are
directed by the flexible and highly
charged linker regions. We propose that
these are essential in setting up defined
structural states of the protein where dif-
ferent domains or combinations thereof
are available for binding chromatin mod-
ifications or are prevented from doing so.
Lastly, we suggest that controlled tuning
of intramolecular linker interactions by
ligands and posttranslational modifica-
tions establishes a rational framework for
comprehending UHRF1 regulation and
putatively the working mode of other
chromatin factors in different physiologi-
cal contexts.
Introduction
DNA methylation is an important epi-
genetic modification to establish and
maintain cell-type-specific gene expression
profiles as well as to ensure genome stabil-
ity. In mammals, the majority of genomic
DNA methylation occurs on the 5-posi-
tion of cytosine bases within CpG dinu-
cleotides. Within the short palindromic
sequence DNA nucleotide methyltransfer-
ases (DNMTs) modify both strands (so
called symmetric or full methylation).
CpG methylation (meCpG) does not
operate in isolation but is closely intercon-
nected with specific repressive histone
Lysine methylation marks and in particu-
lar histone H3 Lysine 9 trimethylation
(H3K9me3). Histone modifications seem
to be involved in targeting DNMTs to
specific regions of the genome for regional
methylation of DNA. In turn, DNA
sequence and methylation state have a
great influence on the Lysine methylation
status of histones. The interplay between
both epigenetic marks and how these are
established is depending on the physiolog-
ical and developmental cellular context.
Since both modifications are associated
with transcriptional repression and hetero-
chromatin formation, their faithful dupli-
cation and transmission during cell
division is crucial to preserve genome
integrity (reviewed in ref.1)
Ubiquitin-like with PHD and RING
Finger domains 1 (UHRF1) is a nuclear
factor essential for the maintenance of
meCpG and putatively H3K9me3 pat-
terns during replication. The protein is
Keywords: allosteric, chromatin, coopera-
tive, DNA methylation, domains, epige-
netic, histone, modifications, multivalent,
multiple protein conformations, UHRF1
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EXTRA VIEW
preferentially localized to pericentric het-
erochromatin but can also be found in
euchromatic regions.2-4 Via multiple
chromatin binding domains UHRF1 tar-
gets enzymes catalyzing meCpG and
H3K9me3, DNMT1, DNMT3a/b and
G9a, to genomic loci.5-8 Since the protein
besides maintenance of epigenetic marks
is also implicated in gene expression regu-
lation, particularly in silencing of tumor
suppressor genes, understanding how it
affects chromatin regulatory processes
through histone and DNA methylation is
of great interest.2,9,10
Based on results of functional and
structural studies, we recently proposed a
role of phosphatidylinositol 5-phosphate
(PI(5)P) in allosteric regulation of
UHRF1 binding to H3K9me3.11 Here,
we summarize findings that indicate mul-
tiple conformational states of UHRF1
that expose different domains providing
distinct overall chromatin-binding proper-
ties. We suggest these different states of
UHRF1 are dependent on conserved
linker regions. Lastly, we provide rationale
how the different interaction modes of the
protein with chromatin might be regu-
lated by the interplay of allosteric ligands,
posttranslational modifications and pro-
tein binding partners.
Domain structure of UHRF1
Human UHRF1 is also referred to as
ICBP90, while the mouse ortholog is
known as Np95. Most vertebrates also
contain a highly similar factor, UHRF2
(mNp97). Since hUHRF1 has been most
extensively studied, we will, unless other-
wise stated, refer to this protein in our dis-
cussions. The five conserved domains of
UHRF1 (Fig. 1) comprise an N-terminal
ubiquitin-like domain (UBL), which is
also referred to as NIRF_N (novel Np95/
ICBP90-like RING finger protein N-ter-
minus). This domain has the classic a/b
ubiquitin fold and contains conserved sur-
face Lysines K31 and K50, which are
putative targets of mono- or poly-ubiqui-
tination (pdb entry 2FAZ, unpublished
structure). While UHRF1 protein func-
tion and/or proteasomal protein turnover
might be regulated by the UBL domain,
the exact biological role of this region is
not yet fully understood.12
At the C-terminus of UHRF1 is a
Really Interesting and New Gene (RING)
domain that has E3 ubiquitin ligase activ-
ity. It is composed of 2 zinc-fingers and a
novel, unique a-helix bundle structure,
which is formed by 3 helices localized
upstream and one helix localized down-
stream of the Zn-fingers (pdb entry 3FL2,
unpublished structure). According to a
recent report the RING domain estab-
lishes histone H3 Lysine 23 (H3K23)
monoubiquitination during S-phase. It
was proposed that this mark serves as a
prerequisite for recruitment of the mainte-
nance DNA methyltransferase DNMT1
to target sites of UHRF1.13
Three central domains of UHRF1 are
implicated in specific recognition of chro-
matin modifications, the unmodified N-
terminal region of histone H3 (H3unmod
(N-term)), the H3K9me3 mark and
hemi-methylated DNA (me1/2CpG)
(Fig. 1). The tandem tudor domain
(TTD) is composed of 2 subdomains
(TTDN:TTDC) that are tightly packed
together and that both have a typical tudor
family 5-stranded b-barrel fold.14 An aro-
matic cage that is built by residues F152,
Y188 and Y191 of TTDN recognizes di-
and tri-methylated Lysine residues. Speci-
ficity for binding H3K9me3 is provided
by a peptide-binding groove formed
between the 2 individual tudor domains
establishing specific and tight contacts to
the residues upstream and downstream of
the methylated Lysine. Binding of the
TTD to an H3K9me3 peptide is not sen-
sitive to adjacent Serine 10 phosphoryla-
tion (H3S10ph).14,15 In contrast, H3
Lysine 4 trimethylation (H3K4me3) and
Threonine 6 phosphorylation (H3T6ph)
impair affinity for H3K9me3. These post-
translational modifications disrupt the
important interactions of the K4 and T6
side chain and backbone residues with the
peptide-binding groove between TTDN
and TTDC.
14
The adjacent Plant Homeo Domain
(PHD) is a Zn-finger domain; 3 zinc
atoms coordinate its rod-shape structure.
It recognizes the N-terminus of the H3-
tail solely when unmodified (H3unmod
(N-term)).2 Accordingly, the crystal struc-
ture of the PHD with bound H3-tail pep-
tide revealed that Alanine 1 (H3A1) and
Arginine 2 (H3R2) make hydrogen bond-
contact to specific residues of the
domain.16 Remarkably, the first zinc atom
coordinates a loop, the so-called prePHD
that precedes the canonical PHD-fold.
This structural feature was first identified
in the UHRF1 PHD domain and its
detailed function still needs to be deter-
mined.16,17 It was suggested that the
prePHD might be essential for the right
orientation of residue C316, which makes
contact with H3K4.16 However, if ana-
lyzed in isolation the PHD does not much
discriminate the modification status of
H3K4. In contrast, phosphorylation of
H3 Threonine 3 (H3T3ph), symmetric as
well as asymmetric dimethylation of
H3R2 (R2me2s/a) and H3A1 N-terminal
acetylation (H3A1ac) strongly interfere
with binding of the PHD to the H3-tail.2
C-terminal to the PHD is a SET and
RING-associated domain (SRA). It con-
sists of a b-barrel flanked by a-helical ele-
ments forming a half moon-like structure
with a basic inner surface.18 Two loops
sticking out of this structure grasp into the
major and the minor groove of DNA.
R491 is part of the so-called N-K-R fin-
ger, which specifically forms hydrogen
bonds with CpG sequences. These con-
tacts flip out a cytosine from the double
helix placing it in a binding pocket that is
tailored for the recognition of 5-methylcy-
tosine (5mC).19 In this pocket 5mC is
sandwiched by stacking interactions with
2 aromatic residues (Y478, Y466). The
SRA domain exhibits significant specific-
ity for hemi-methylated DNA (me1/
2CpG). This is facilitated by N489, which
is a part of the N-K-R finger and makes
contacts to the non-methylated adverse
cytosine on the second DNA strand.
Methylation of this cytosine disturbs posi-
tioning of the N-K-R finger and therefore
impairs SRA binding.18
Interplay of UHRF1 chromatin-
binding domains
Given that UHRF1 contains 3 separate
domains that can recognize different chro-
matin modifications, the question arises
whether these work independently or in
concert. The combinatorial interaction of
different domains of one protein with a
complex target containing multiple
ligands is generally referred to as multiva-
lent binding. Several chromatin factors
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such as TRIM24 and BPTF have been
shown to recognize patterns of histone
modifications in a multivalent mode.20,21
In these proteins different binding
domains simultaneously engage in interac-
tion with separate histone modifications
Such cross-talk in interaction on the same
or distinct histone tails is considered a
fundamental element of the so-called his-
tone code theory that postulates that pat-
terns of chromatin marks constitute a
complex signaling system.22 To this point,
multivalent chromatin interactions have
been rationalized in a static manner, with
recognition domains acting independently
of each other.23,24 Several observations
indicate that multivalent binding of
UHRF1 to chromatin is more complex.
TTD-PHD interplay in recognizing
the H3-tail
Different biophysical studies have
quantified the interaction strength of
the isolated TTD of UHRF1 with
H3K9me3 peptides. Depending on the
experimental conditions the dissociation
constant (KD) was determined within a
range of 1.0 mM to 2.5 mM.11,15,25,26
Similarly, binding of the isolated PHD
domain to H3unmod(N-term) was
mapped at a KD of 0.7 mM to 2.5
mM.2,17,26,27 In contrast, a UHRF1
TTD-PHD cassette showed around 5-
fold enhanced binding (KD between
0.15 mM and 0.5 mM) to a histone H3
peptide containing both, an unmodified
Figure 1. UHRF1 is a multi-domain factor with several conserved protein motifs connected by linker regions. Schematic representation of the domain
structure of human UHRF1 isoform 1 is shown (UniProtKB: Q96T88). Top: The structures of the individual domains of UHRF1 as determined by X-ray crys-
tallography and NMR spectroscopy visualized and rendered using MacPyMOL v 1.7.0.3 (pymol.org). Middle: Domain boundaries are given by respective
starting and ending amino acid positions. Conserved stretches of low complexity and high content of basic amino acids within the linker regions are indi-
cated (red boxes). Bottom: Chromatin ligands of the different domains of UHRF1; schematic representation of a single nucleosome in interphase (left)
and immediately after replication in S-phase (right). For simplicity only one H3-tail is shown. UBL, ubiquitin like; TTD, tandem tudor domain; PHD, plant
homeodomain; SRA, SET and RING associated; PBR, polybasic region; RING, really interesting and new gene. pdb entries are: UBL, 2FAZ; TTDN:TTDC,
3DB3; PHD, 3SHB; SRA, 2PB7; RING, 3FL2.
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N-terminus and the K9me3 mark,
implying a multivalent binding
modus.11,25,26,28
Since the H3-tail is embedded in the
peptide-binding groove of the TTD in the
isolated structure of this complex, how
can the PHD get access to the ultimate N-
terminus of H3 in the context of the
TTD-PHD cassette? Fluorescence/F€orster
Resonance Energy Transfer (FRET)
experiments revealed a conformational
shift induced in the TTD-PHD cassette
upon interaction with the H3-tail.25 In
agreement, structural studies using cocrys-
talization as well as NMR measurements
indicate that the H3-binding mode of the
TTD-PHD cassette is different from that
of the isolated TTD (Fig. 2A). Obviously,
the short region connecting TTD and
PHD (linker 2, Fig. 1) replaces the H3-
tail from the peptide-binding groove of
the TTD and itself occupies this interface.
The resulting arrangement has the H3-tail
connecting the PHD, which binds the
ultimate N-terminus, with the TTD,
which binds K9me3. Two Arginine and a
Lysine residue (R295-R296-K297) in
linker 2 are crucial for stabilizing this
TTD-PHD conformation. Indeed, muta-
tion of R295 and R296 results in loss of
multivalent binding.26,28 In contrast,
dynamic NMR studies indicate multiple
modes of PHD linkage in relation to
linker 2 and TTD.28 Also, the TTD-
PHD cassette only crystalized in presence
of the H3K9me3-tail peptide.26 The find-
ings imply that the 2 domains do not
directly interface but that their relative
localization is variable without ligand.
The reduced binding surface of the
TTD with the H3-tail in the TTD-PHD/
H3K9me3 complex as well as the flexible
linkage of the ligand and between
the domains explain the observed relative
weak enhancement of interaction by
the multivalent binding mode. Indeed,
the PHD domain is dominating the inter-
action of the TTD-PHD cassette with the
H3K9me3-tail. If binding of the PHD to
the H3-tail is abolished by mutation of
D334 or modification of the N-terminus
of the H3 peptide (A1ac, T3phos), the
binding of the neighboring TTD to meth-
ylated K9 is drastically weakened or
completely lost. Conversely, PHD interac-
tion with the unmodified N-terminus of
H3 in the context of the PHD-TTD cas-
sette is largely unaffected by mutation of
the TTDN aromatic cage (F152, Y188) or
histone modifications such as H3K4me3,
which abolish the binding of the isolated
TTD to the H3-tail.15,25,26,28
Control of TTD/H3K9me3
interaction by a C-terminal polybasic
region
While reductionistic approaches study-
ing isolated domains and combinations
thereof have provided detailed insights
into the chromatin interaction potential
of UHRF1, other studies looked directly
at the full-length protein. Here, striking
differences in interaction specificity for
the H3-tail were observed. While native
UHRF1 analyzed in the context of mam-
malian cell extracts shows clear preferences
for H3K9me3, the recombinant protein
expressed in bacteria or insect cells binds
similarly to unmodified H3 and
H3K9me3 peptides.2-4,11,29 We recently
showed that this discrepancy is due to
intramolecular interaction of the TTD
with a polybasic region (PBR) located
between the SRA and RING domains of
UHRF1 (Fig. 2B).11 Our studies imply
that in the absence of ligands (i.e. the
recombinant purified protein) the PBR
but not linker 2 occupies the peptide-
binding groove of the TTD. This prevents
interaction with H3K9me3, whereas the
PHD is unaffected and can bind the ulti-
mate unmodified H3-tail.
NMR experiments have revealed that a
K-R-K motif (K648-R649-K650) is essen-
tial for placing the PBR in the peptide-
binding groove of the TTD surface. Com-
petition experiments with isolated domains
indicate that this interaction is stronger
than the similar TTD-linker 2 interplay. It
also fully blocks the binding of the
H3K9me3-tail. In the context of the recom-
binant, full-length protein mutagenesis of
the K-R-K motif is necessary to release the
PBR from the TTD.11 The resulting
mutant UHRF1 protein appears to be in an
intermediate state as the TTD and PHD
both can bind their respective K9me3 and
H3unmod(N-terminus) ligands.
Dialysis of recombinant UHRF1
against nuclear extract isolated from HeLa
cells induced yet another UHRF1 binding
state. Interestingly, this form resembles
the native cellular protein in preference
for H3K9me3 over H3K9me0
(Fig. 2C).11 The results not only infer an
allosteric regulatory mode of UHRF1, but
also indicate that states of the protein exist
where the PHD domain is prevented from
binding H3unmod(N-term).
Multivalent binding to histone H3
and DNA methylation
The isolated SRA domain of UHRF1
binds me1/2CpG with a dissociation con-
stant of around 200 nM.30 Of the 3 chro-
matin-binding domains it therefore has
the tightest interaction with a ligand.
While life cell imaging and fluorescence
recovery after photobleaching have
revealed that the SRA domain dominates
targeting of mNp95 to pericentromeric
heterochromatin in vivo, mutagenesis
studies imply that the PHD and/or TTD
domains are also required in this con-
text.29 Indeed, in vitro binding experi-
ments with mNp95 protein isolated from
cells show that presence of histone
H3K9me3 peptide promotes interaction
of the SRA with hemi-methylated DNA.
Conversely, interaction with histone pep-
tides is enhanced in presence of un-/meth-
ylated DNA.31 While the mechanistic
details of this interplay have not yet been
unveiled, the findings suggest that the
SRA domain cooperates with the TTD
and/or PHD in binding to multiple-mod-
ified chromatin targets.
A conformational transition model
for UHRF1 chromatin binding
It has not been possible to deduce a
simple, coherent picture of UHRF1 mul-
tivalent chromatin binding on the basis of
the research on cassettes composing more
than one of the chromatin binding
domains, our molecular analysis of the
full-length protein as well as based on the
multiple studies of deletion and point
mutants of the protein in recombinant
form, extracted from cells, or in different
cellular context (see for example
refs.3,29). A putative explanation might
come from the idea that the TTD, PHD,
and SRA (and possibly UBL and RING)
domains do not work independently.
Indeed, we favor the view that engagement
of the different binding domains of
UHRF1 with ligands influences the
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interaction properties of each other.
Since the structural analysis of the iso-
lated domains has not indicated any
conformational changes of the binding
pockets induced by ligand, the coopera-
tive mode of interaction must be medi-
ated on another level. We suggest that
UHRF1 exists in multiple protein con-
formations where different, structurally
invariable binding domains or
combinations thereof are either exposed
and available for interaction with chro-
matin marks or where these are
occluded and prevented from ligand
binding (Fig. 2). We postulate that
these conformational states are in con-
stant exchange with each other and that
the actual equilibrium between the dis-
tinct forms determines the apparent
binding properties of UHRF1.
Conserved linker regions likely
establish different UHRF1
conformational states
How are different conformational
states of UHRF1 established? The regions
connecting the conserved and easily recog-
nized chromatin modification-binding
domains might play a major role (Figs. 1
and 2). These contain the linker 2
between the TTD and PHD (26 aa in
hUHRF1), linker 3 between the PHD
and SRA (51 aa in hUHRF1), and the
PBR containing region between the SRA
and RING (linker 4, 138 aa in hUHRF1).
Algorithms that predict secondary struc-
tures fail to assign particular folds to these
regions. The linkers might therefore form
random, intrinsically disordered
structures.
Despite the lack of conserved folds,
short (ca. 20 aa) sequence stretches are
highly conserved within linker 2, linker 3
and PBR (Fig. 3A). For example, the
region between aa 372 and 391 of linker 3
shows sequence identity of around 90% in
all analyzed UHRF1 proteins.12 Besides
the conserved sequences, these stretches of
the linker regions are of relative low com-
plexity, enriched in basic amino acids (i.e.,
Lysine and Arginine residues). This seems
to be functionally important as for
hUHRF1 the R-R-K element in linker 2
and the K-R-K element in the PBR have
been shown to be crucial for binding of
these regions to the peptide-binding
groove of the TTD.11,26,28 Since the inter-
acting polar residues on the surface of the
TTD domain also exhibit conservation
throughout all analyzed species (Fig. 3B),
the competition of linker 2 and PBR for
binding the TTD seems to constitute a
major element for establishing different
UHRF1 conformational states. Due to
the high sequence conservation and a cen-
tral K-K-K element we further hypothe-
size that linker 3 might also interface with
the peptide-binding groove of the TTD
(Fig. 2C). We think that depending on
which linker associates with the TTD, dif-
ferent overall conformations of UHRF1
are established. Lastly, we theorize that
other regions of UHRF1 might contain
polar surfaces similar to the peptide-bind-
ing groove of the TTD for accommodat-
ing linker 2, linker 3 or PBR in the
different conformational states.
Figure 2. Conformational transition model for UHRF1 binding to chromatin marks. The three con-
formational states shown (A, B, C) correspond to binding modes deduced by different studies.
While some parameters of domain and ligand interaction are known, others are hypothetical. For
example, the exact coupling of H3unmod(N-term), H3K9me3, and me1/2CpG binding is not known.
Also, the mechanism of PHD inhibition in state (C) has not been resolved. Additional other binding
states and relative orientations of the domains might exist. For representation purposes, linker
regions are not drawn to scale. Linker regions that are involved in setting up different conforma-
tional states via interaction with the peptide-binding groove of the TTD are highlighted. Note that
the role of linker 3 has not been determined. Binding of the allosteric regulator PI(5)P to the PBR
region releases linker 4 from the TTD peptide-binding groove.
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As linker 2 and its interaction with the
peptide-binding groove of the TTD might
be elementary in setting up distinct con-
formational states of UHRF1, it is inter-
esting to note that in mouse as well as in
chicken splicing variants of the protein
exist that only differ in this region. Even
more perplexing is the fact that both inser-
tions occur right at the R-R-K element
important for the interaction with the
peptide-binding groove of the TTD
(Fig. 3A). While the linker 2 of mNp95
variant 2 is very similar to the correspond-
ing region of the single human UHRF1
protein, variant 1 contains an insertion of
9 aa, which eliminates the first Arginine of
the motif. And whereas the chicken
sequences are only predicted but lack
experimental validation, variant 1 of this
organism has a 54 aa insertion just ahead
of the R-R-K element.
Unfortunately, work on mNP95 did so
far not discriminate between variants 1
and 2 (note that chicken UHRF1 has not
yet been studied). Nevertheless, careful
reevaluation of the available data indicates
that the linker insertion in variant 1 might
block multivalent binding of the TTD-
PHD cassette to the H3K9me3-tail.31 We
therefore think that the combinatorial
binding of both domains is strongly
dependent on the sequence and length of
linker 2 that could alter the spacing and
orientation of the TTD and PHD. On
the basis of our conformational transition
model of UHRF1, we predict that certain
states are not or less populated by the dif-
ferent splicing variants of UHRF1 in
mouse and chicken. These should there-
fore have non-overlapping roles. Detailed
analysis of the expression and function of
the splicing variants in mouse and/or
chicken might be a fruitful avenue for fur-
ther dissecting the molecular working
mode and regulation of UHRF1.
Regulation of UHRF1 conformational
states
While intrinsically disordered, the
linker regions might nevertheless adopt a
series of limited, defined transitional states
enabling interaction with different polar
surfaces of UHRF1 and determining dif-
ferent conformational and binding states.
The kinetic barrier for these transitions
could be relatively low due to the intrinsic
linker flexibility. As consequence, the pro-
tein might be able to rapidly change con-
formations in response to external stimuli
and structural perturbations. This in turn
would facilitate changes in the population
of certain states therefore affecting
UHRF1 target binding and cellular
function.32
Different events might affect the equi-
librium of the conformational states of
UHRF1. If forms of the protein exist that
enable more than one of the chromatin
binding domains to interact with their
ligand (Fig. 2), engagement of one of the
exposed regions with its target will facili-
tate a secondary binding event of the other
available domain in a cooperative fashion.
While we do not (yet) know how many
different forms and binding states of
UHRF1 might exist, such interpretation is
in full agreement with the observed
enhancement of H3K9me3-tail binding
of mNP95 by DNA and vice versa.31
Allosteric ligands provide another level
of regulating UHRF1 conformational
Figure 3. The different linker regions and the peptide binding-groove of the TTD are highly conserved. Multiple sequence alignments of sequence
stretches within the linker regions (A) and the peptide-binding groove of the TTD (B) of UHRF1. Alignments were prepared using the PRALINE alignment
tool at http://www.ibi.vu.nl/programs/pralinewww/. Numbers correspond to amino acid positions at the beginning and end of the respective protein
sequences of the different species. Sequences of insertions found in splicing variants of mouse and chicken proteins are given. Symbols indicate residues
implied in the interaction of the TTD peptide-binding groove with linker 2 (dots) or the PBR region within linker 4 (squares). Triangles mark known sites of
phosphorylation. Asterisks mark positions corresponding to a putative PIP binding consensus motif within the PBR. Boxes highlight elements of basic res-
idues found in linkers 2, 3 and 4. UHRF1 amino acid sequences according to NCBI: Homo sapiens, NP_001276981.1; Mus musculus v1, NP_001104550.1,
Mus musculus v2, NP_001104548.1, Gallus gallus v1, XP_418269.4, Gallus gallus v2, XP_004949013.1; Xenopus laevis, F6UA42.2; Danio rerio, NP_998242.1.
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states. Based on our observations that
recombinant UHRF1 behaved differently
from cellular protein but could be con-
verted to a state with similar H3K9me3-
binding properties after dialysis against
nuclear extract, we biochemically defined
the cofactor and regulator as phosphatidy-
linositol 5-phosphate (PI(5)P).11 PIPs are
amphiphilic glycerophospholipids that
consist of a polar inositol head group
linked by a phosphodiester bridge to a
glycerol backbone branching 2 non-polar
fatty acids (Fig. 4). PI(5)P is a low abun-
dance PIP present primarily in mamma-
lian cytoplasmic cell membranes with a
smaller population in the cell nucleus.33
While its nuclear functions are not fully
clear, its presence in this compartment is
highly conserved throughout eukar-
yotes.34-36 We could show that PI(5)P
binding to UHRF1 specifically requires
the PBR region and that this interaction
releases the latter from the peptide-bind-
ing groove of the TTD. In consequence, a
conformation of UHRF1 is established
that allows the TTD to bind H3K9me3
independent of the PHD.11
While we do not yet know how exactly
PI(5)P is bound by UHRF1 – the protein
has to accommodate both, the polar head
group as well as the hydrophobic acyl
chains – it is interesting to note that the
PBR resembles in sequence a previously
defined consensus PIP interaction motif
(R/K-(Xn D 3–7)-K-X-K/R-K/R) shared by
several PIP interacting factors.37 Given
that the linker 2 and linker 3 are also
highly conserved and enriched in basic
amino acids, we are wondering whether
other ligands modulate the behavior of
these regions. We think this is an idea
worth entertaining, particularly since syn-
thetic PI(5)P did not fully recuperate all
changes of recombinant UHRF1 observed
after dialysis against cellular extract.11
The transitions between different con-
formational states of UHRF1 l conveyed
by the linker regions might be further reg-
ulated by posttranslational modifications
(PTM). These could impair binding to
the peptide-binding groove of the TTD or
putatively other regions of the protein
(Fig. 4). Indeed, it was shown previously
that phosphorylation of a Serine residue
(S298) adjacent to R295-R296-K297,
decreases the binding affinity of the TTD-
PHD cassette for the H3K9me3-tail. The
altered binding stoichiometry of the
complex indicates that the coupling of
TTD and PHD mediated by linker 2 is
impaired by the PTM.26
A number of additional sites of Serine
phosphorylation and other posttransla-
tional modification have been identified
in UHRF1 by proteomics studies. Some
of these map to highly conserved residues
within the linker 2, linker 3 and PBR
regions (Fig. 3A).38-43 These events have
the potential to regulate UHRF1 confor-
mational states. For example, phosphory-
lation of S651 that is found during
human embryonic stem cell differentia-
tion and is next to the K648-R649-K650
element40 might impair the interaction of
the PBR with the peptide-binding groove
of the TTD thereby enhancing a particu-
lar UHRF1 chromatin-binding mode.
Finally, we point out that binding of
UHRF1 to other proteins such as
DNMTs, G9a, USP7, etc. will affect the
equilibrium of the various forms of the
protein. These interactions require dis-
tinct, specific surfaces that will or will not
be available in the different conforma-
tional states of UHRF1. Conversely, it is
expected that engagement of a particular
protein partner will stabilize a certain
Figure 4. Regulation of the conformational transitions of UHRF1. The interplay of the chromatin-binding domains of UHRF1 and therefore the conforma-
tional states of the protein are affected by binding of different ligands, the allosteric regulator phosphatidylinositol 5-phosphate (PI(5)P) as well as post-
translational modifications (PTM) within the linker regions. Enhancing as well as suppressing effects on chromatin modification-binding properties of the
TTD, PHD and SRA domains have been described. Dashed lines indicate domain interplay that has not been fully resolved. The regulation of linker 3 is
hypothetical (question mark).
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conformation and accompanying chroma-
tin mark-binding mode of UHRF1
(Fig. 4).
Cellular role of the different
chromatin binding states of UHRF1
Many studies on UHRF1 have empha-
sized the importance of the 3 chromatin-
binding domains in facilitating specific
chromatin association and multiple func-
tions in cellular context. We think that
the fact that defined functions could not
be pinpointed exclusively to particular
domains agrees with extensive collabora-
tion and interplay of these regions. It was
shown that the TTD, PHD and SRA
domains are all participating in targeting
of UHRF1 to heterochromatin,3,28 a pro-
cess that might be dependent on
H3K9me3 and meCpG. The TTD,
PHD, and SRA regions are also necessary
for recruitment of DNMT1 to replicating
foci and thus for proper maintenance of
DNA-methylation.3,13,28 However, it was
also found that UHRF1 binds to pro-
moter regions of euchromatic genes and
regulates their expression. Interestingly,
these loci lack H3K9me3 but exhibit
DNA methylation paired with H3unmod
(N-term) (i.e. absence of H3R2 symmet-
ric dimethylation).2 It is conceivable that
UHRF1 binds to these genomic regions
by multivalent interaction of the PHD
and SRA domains with the unmodified
N-terminal H3-tail and methylated DNA,
respectively.
Additionally, it was found that
UHRF1 interacts with the de novo DNA
methyltransferases DNMT3a and
DNMT3b and that this complex mediates
epigenetic silencing in a histone H3
Lysine 9 methyltransferase (i.e., G9a,
Suv39h1/2) dependent manner.8 Deple-
tion of Np95 in mouse embryonic stem
cells results in severe global DNA hypo-
methylation.44 A similar DNA methyla-
tion defect is caused by depletion of all 3
DNMTs45 or of histone methyltransfer-
ases (G9a, Suv39h1/2).46,47 Hence, there
is circumstantial evidence that UHRF1 is
not only involved in replication-coupled
maintenance of DNA methylation, but
also in de novo DNA methylation in an
H3K9me3-dependent manner. Since de
novo methylation has no hemimethylated
DNA template, UHRF1 targeting to these
chromatin regions might be dependent on
interaction of the TTD or TTD-PHD
cassette with H3K9me3.
Our work showed that manipulation of
cellular PI(5)P levels affects UHRF1 sub-
nuclear localization.11 Several links
between the reported functions of
UHRF1 and nuclear PI(5)P levels support
the idea of allosteric control of the pro-
tein. It was shown previously that nuclear
PI(5)P levels are tightly regulated during
the cell cycle and in response to certain
cellular signaling cascades. PI(5)P levels
increase up to 20-fold during transition of
G1- to S-phase.34,48-50 Cell cycle analysis
of UHRF1 localization in relation to het-
erochromatic foci indicates changed distri-
bution at the onset of S-phase,51 which
might be caused by regulation of TTD/
H3K9me3 interaction by PI(5)P. Also,
UHRF1 interacts with several factors asso-
ciated with the DNA damage response
such as Eme1, TIP60, Ku70, and
PARP1.44,52-54 PI(5)P levels are increased
after irradiation and exposure to oxidative
stress.34,49,50,55 Since H3K9me3 has an
important role in repair mechanisms of
DNA damage,56 we speculate that
UHRF1 might in a specific context target
the repair factors to H3K9me3 enriched
loci (Fig. 5).
While nothing is known about the in
vivo significance of the PTMs of UHRF1
within the linker region, we note that this
essential effector protein is incorporated
into various complexes involved in differ-
ent chromatin regulating processes (i.e.
maintenance of DNA methylation, de
novo DNA methylation, histone H3
methylation, and histone H4 deacetyla-
tion).7,8,44,51,57,58 Thus, it was shown to
be an important factor to facilitate DNA
replication, cell cycle progression, tran-
scriptional repression, and DNA damage
response.2,53,59-61 This variety of func-
tions argues for different states of the pro-
tein that provide distinct binding
interfaces not only for histone and DNA
modifications but also for specific protein
interaction partners (Fig. 5).52,53,57,62
Concluding Remarks
Here, we discussed in detail the modifi-
cation binding behavior of UHRF1 that
reveals novel features of a chromatin bind-
ing protein. First of all, the different
regions of the protein appear not to func-
tion in isolation. We expect that further
functional and structural analysis of the
full-length protein or of cassettes contain-
ing more than one of the TTD, PHD and
SRA chromatin-binding domains will
uncover that these generally do not inter-
act with their targets independent of each
other. We think their interplay induces
complex binding modes that cannot sim-
ply be explained by static multivalent and
simultaneous engagement of different pro-
tein surfaces with complex ligands (i.e.,
key and lock behavior). Instead, UHRF1
might exist in multiple, distinct but con-
stantly exchanging conformations. We
propose that these are brought about by
flexible linkers that intramolecularly
Figure 5. Regulation of interaction of UHRF1 with chromatin and multiple interaction partners. The
allosteric regulator phosphatidylinositol 5-phosphate (PI(5)P), different chromatin marks as ligands
and posttranslational modifications regulate the postulated different conformations of UHRF1. This
impacts on interaction with different protein partners in distinct physiological pathways of chroma-
tin control. Conversely, the protein-binding partners of UHRF1 putatively affect interaction with
ligands, allosteric regulators as well as establishment of post-translational modifications.
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compete for a limited number of different
sites thereby inducing and stabilizing folds
of the protein that expose or occlude the
different chromatin-binding interfaces.
Besides cooperativity in interaction with
chromatin marks, a major consequence of
these considerations is a general rationale
for comprehending regulation of UHRF1
by allosteric ligands such as PI(5)P and
posttranslational modifications that both
target linker regions outside of the actual
chromatin-binding modules.
The transitions between the different
conformations and binding states of
UHRF1 are dynamically regulated in a
physiological context and in response to
external stimuli. This in turn controls spe-
cific localization of UHRF1 to defined tar-
get loci of the genome as well as
interaction with different protein partners
such as chromatin modifying enzymes.
Any perturbation of these regulatory pro-
cesses will have profound consequences on
chromatin structural organization and
subsequently lead to developmental aber-
rations, chromosome instability and onco-
genesis – a major outcome of UHRF1
mutation or abnormal expression.63,64
UHRF1 might be a paradigm for com-
prehending chromatin interaction and
regulation of other factors in response to
cellular internal or external stimuli. We
note that other related multi-domain pro-
teins as for example DNMT1 and PARP1
also comprise flexible linkers between
their functional domains. Interestingly,
these might putatively also interact with
PIPs via polybasic regions.37 We expect
that future studies will not only reveal a
more general influence of small cellular
metabolites such as PIPs onto chromatin
binding factors but also provide a general
framework for the role of interchanging,
transient conformational states in protein
regulation.
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UHRF1 is a multidomain protein crucially linking his-
tone H3 modification states and DNA methylation.
While the interaction properties of its specific do-
mains are well characterized, little is known about
the regulation of these functionalities. We show that
UHRF1 exists in distinct active states, binding either
unmodified H3 or the H3 lysine 9 trimethylation
(H3K9me3) modification. A polybasic region (PBR)
in the C terminus blocks interaction of a tandem
tudor domain (TTD) with H3K9me3 by occupying
an essential peptide-binding groove. In this state
the plant homeodomain (PHD) mediates interaction
with the extreme N terminus of the unmodified H3
tail. Binding of the phosphatidylinositol phosphate
PI5P to the PBR of UHRF1 results in a conformational
rearrangement of the domains, allowing the TTD to
bindH3K9me3. Our results define an allostericmech-
anism controlling heterochromatin association of an
essential regulatory protein of epigenetic states and
identify a functional role for enigmatic nuclear phos-
phatidylinositol phosphates.
INTRODUCTION
A major concept that has emerged for the readout of his-
tone modifications is the recruitment of proteins containing
conserved domains that specifically interact with defined modi-
fications. Systematic proteomic approaches have implied that
individual chromatin modifications are usually recognized by
multiple competing proteins (Patel and Wang, 2013). To under-
stand the readout of chromatin marks, it is therefore imperative
to dissect how the interplay between modifications and binding
factors is regulated. The exact context appears to matter, asM
neighboring modifications can influence interaction in a nega-
tive or positive manner. Posttranslational modifications of chro-
matin-associated proteins can directly affect the modification
binding properties of chromatin proteins. Further, the expression
of specific binding factors is modulated in cell differentiation and
development (reviewed by Fischle, 2012).
Since transient changes in cellular states (e.g., nutrition levels)
can have a lasting effect on gene expression patterns, it has been
suggested that metabolites and small cellular molecules have an
immediate impact on the condition of chromatin and the epige-
netic state of cells (Lu and Thompson, 2012). Phosphatidylinosi-
tol phosphates (PIPs) are particularly interesting in the context of
chromatin. A pool of these lipids exists in the cell nucleus, sepa-
rately regulated from the cell membrane and cytoplasm by dedi-
cated enzymes. However, the exact biochemical state of PIPs in
this compartment is still unclear (Barlow et al., 2010; Fiume et al.,
2012). The bulk of nuclear phospholipids copurifies with nonhis-
tone chromosomal proteins (Manzoli et al., 1976). Interestingly,
analysis of isolated chromatin fractions revealed that lipids
associated with hetero- and euchromatin each showed distinct
turnover rates (RoseandFrenster, 1965). Furthermore, hydrolysis
of nuclear phospholipidsbyphospholipaseC (PLC)wasshown to
change chromatin structure (Maraldi et al., 1984).
Few nuclear proteins have been found to associate with PIPs
so far (Barlow et al., 2010; Fiume et al., 2012). PI4,5P2 has been
shown to activate and stabilize the chromatin remodeling
complex BAF (Burgio et al., 2010). The H3K4me3-binding plant
homeodomain (PHD) and adjacent polybasic region of ING2
and several related proteins associate with chromatin through
a PI5P-mediated mechanism (Bua and Binda, 2009; Gozani
et al., 2003; Jones et al., 2006). While this pathway is important
in controlling ING2-dependent genes, especially in DNA damage
pathways, interaction of H3K4me3 and PI5P are independent of
each other (Bua et al., 2013). Binding of PI5P to a PHD domain
causes ATX1 to detach from promoters and translocate from
the nucleus to the cytosol (Ndamukong et al., 2010). Whereas
major biochemical screens have been conducted for PIP-bind-






Figure 1. UHRF1 Binding to the Modified or Unmodified H3 Tail Is Regulated by Cellular Cofactors
(A) Domain structure of UHRF1. UBL, ubiquitin-like (aa 1–76); TTD, tandem tudor domain (aa 126–285); PHD, plant and homeodomain (aa 310–366); SRA, SET-
and RING-associated (aa 435–586); PBR, polybasic region; RING, really interesting new gene (aa 724–763).
(B) Cellular lysates (NE, nuclear extract) and purified cellular or recombinant proteins were incubated with the specified biotinylated H3(1–20) peptides immo-
bilized on streptavidin magnetic beads. Recovered material was analyzed by western blot. Input, 2%.
(C) Flow scheme for dialysis experiments as analyzed in (D)–(H).
(legend continued on next page)
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nuclear interactome of a PIP, namely PI4,5P2. There, lysine/argi-
nine-rich patches with the consensus K/R-(X)n = 3–7-K-X-K/R-K/
R emerged as major interaction motifs (Lewis et al., 2011).
Ubiquitin-like with PHD and RING finger domains 1 (UHRF1),
also known as inverted CCAAT box protein of 90 kDa (ICBP90)
and NP95 in mouse, is a nuclear multidomain factor impli-
cated in the maintenance of DNA methylation patterns during
replication. Deletion of UHRF1 in mice is embryonic lethal. The
knockout embryonic stem cells show loss of DNA methylation,
enhanced susceptibility to DNA replication arrest, increased
sensitivity to DNA damaging agents, impaired maintenance of
higher-order chromatin structure, and spurious transcription
of repetitive DNA elements (Bostick et al., 2007; Sharif et al.,
2007). UHRF1 is upregulated in various cancer cells, including
breast, prostate, and lung cancer, where it plays a key role in
promoting proliferation (Bronner et al., 2010).
UHRF1 is composed of at least five domains: an N-terminal
ubiquitin-like domain (UBL), followed by a tandem tudor domain
(TTD), a plant homeodomain (PHD), a SET and RING-associated
(SRA) domain, and a C-terminal really interesting new gene
(RING) domain (Figure 1A). The SRA domain preferentially binds
to hemimethylated CpG, which during semiconservative replica-
tion of DNA recruits DNMT1 to copy themethylation pattern onto
the daughter strand (Berkyurek et al., 2014; Rottach et al., 2010;
Sharif and Koseki, 2011). This process appears to also involve
H3K23 ubiquitylation by the RING (Nishiyama et al., 2013). The
isolated TTD binds H3K9me3 (Nady et al., 2011), while the iso-
lated PHD recognizes the unmodified extreme H3 N terminus
(Rajakumara et al., 2011). Functional cooperation by these
modules was recently suggested by structural and functional
studies on isolated TTD-PHD fragments (Arita et al., 2012; Cheng
et al., 2013; Rothbart et al., 2013). Both DNA methylation and
H3K9me3 are hallmarks of pericentric heterochromatin where
UHRF1 is preferentially localized (Liu et al., 2013). UHRF1 is
also found in euchromatin and regulates gene expression,
particularly the silencing of tumor suppressor genes, possibly
through affecting DNA methylation and histone modifications
(Bronner et al., 2010; Wang et al., 2012). Posttranslational modi-
fication of UHRF1 has been implicated in regulating its stability
and possibly directing its interaction with chromatin components
(Arita et al., 2012; Ma et al., 2012).
While the interactions of many histone modification-binding
domains with their target sites are well studied, it is not always
clear if and how the findings on the isolated modules pertain to
the proteins and complexes containing them. Here, we analyzed
the histone modification binding properties of intact, full-length
UHRF1. We found that the protein is allosterically regulated for(D) Cellular lysates or recombinant proteins (top) were dialyzed against the indic
(E) Fluorescence polarization binding experiment using purified recombinant 63
(FAM-H3[1–15]) via an amide bond.
(F) Fluorescence polarization binding experiment using purified recombinant 63
labeled with fluorescein at the ε-amino group (H3[1–15]-K[FAM]).
(G) Fluorescence polarization binding experiment using purified recombinant 63
rescein at the N terminus (FAM–H3[1–15]) via an amide bond.
(H) Fluorescence polarization binding experiment using purified recombinant 63H
was added and labeled with fluorescein at the ε-amino group (H3[1–15]-K[FAM])
M
interaction with unmodified H3 versus H3K9me3, principally by
PI5P, which controls access to the TTD and PHD domains.
Our results imply that this mechanism contributes to directing
UHRF1 heterochromatin localization and function.
RESULTS
UHRF1 Exists in Different Functional States
To obtain insights into the recognition of histone marks by
UHRF1, we performed histone peptide pull-down experiments
using the lysate or purified form of the FLAG- or 63HIS-
tagged protein from different expression systems. Endogenous
UHRF1 in HeLa cell nuclear extract (NE) exhibited preference
for H3K9me3 over the unmodified form (H3K9me0) (Figure 1B).
Similar binding specificity was observed for UHRF1-FLAG
in vitro translated in rabbit reticulocyte extract or in NE prepared
from HEK293 cells overexpressing the fusion protein and for
63HIS-UHRF1 in total lysate of Sf9 insect cells programmed
for expression. In contrast, recombinant 63HIS-UHRF1 from
E. coli bound the H3K9me0 and H3K9me3 states equally well.
Similarly, the UHRF1-FLAG or 63HIS-UHRF1 proteins affinity
purified from the overexpressing human embryonic kidney 293
(HEK293) or Sf9 cell extracts, respectively, displayed compara-
ble interaction with both H3 tail peptides. Bacterial, recombi-
nant 63HIS-UHRF1 preferentially bound H3K9me3 when put
into HeLa NE. As we observed distinct behavior in multiple
expression systems and with different affinity tags at the N and
C terminus, we concluded that the proteins in the NE and
those that are affinity purified likely exist in different functional
states.
UHRF1 Interaction with the Modified or Unmodified H3
Tail Is Regulated by Cellular Cofactors
Similar to previous findings (Nady et al., 2011), we observed that
the isolated TTD of UHRF1 specifically binds to H3K9me3 (Fig-
ure S1A available online). In contrast, the PHD domain interacted
with the extreme H3 tail irrespective of the modification status of
the K9 site (Hu et al., 2011; Lallous et al., 2011; Rajakumara et al.,
2011; Wang et al., 2011). This behavior was reflected in quanti-
tative fluorescence polarization binding experiments (FP). We
used two sets of peptides corresponding to residues 1–15 of
the H3 tail with fluorescein attached to either the N or C terminus.
Both types of peptides carrying the K9me3 mark bound to the
TTD with similar affinity, while no interaction with the unmodified
counterpart was observed (Figures S1B and S1C; see Tables S1
and S2 for a listing of all KD values measured in this study). In
contrast, the PHD only bound the C-terminally labeled peptides
irrespective of the modification status of K9, but not theated sources (bottom) and analyzed by histone peptide pull-down as in (B).
HIS-UHRF1 directly. H3 peptides were linked to fluorescein at the N terminus
HIS-UHRF1 directly. A non-natural lysine at the C terminus was added and
HIS-UHRF1 after dialysis against HeLa NE. H3 peptides were linked to fluo-
IS-UHRF1 after dialysis against HeLa NE. A non-natural lysine at the C terminus
. See also Figure S1 and Tables S1 and S2.
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mental approach to quantitatively define the interaction proper-
ties of UHRF1 and to dissect the contributions of the TTD and
PHD within the full-length protein.
Since the observed H3 methylation-specific interaction of
UHRF1 in the cell extract resembled that of the TTD, while
the methylation nonspecific interaction of purified UHRF1 corre-
sponded to that of the PHD, we reasoned that cellular cofactors
direct differential binding modes relying on one or the other
module. To test this, we set up a dialysis experiment, consecu-
tively exposing recombinant 63HIS-UHRF1 purified from E.coli
to HeLa NE, but separated by a membrane with a very low
(3 kDa) molecular weight cutoff (Figure 1C). After one round of
dialysis, interaction with H3K9me0 was significantly decreased,
while binding to H3K9me3 appeared unaffected (Figure 1D).
After two rounds of dialysis, the interaction of the recombinant,
dialyzed protein fully resembled that of the endogenous UHRF1
in HeLa NE. In parallel, the endogenous UHRF1 protein in the
HeLa NE used for dialysis changed its properties, now binding
H3K9me0 and H3K9me3 peptides equally well. Similar behavior
was observed when NE from Sf9 insect cells instead of HeLa NE
was used, indicating a general phenomenon (Figure S1D).
Quantitative FP measurements confirmed this switch in bind-
ing behavior. Purified, recombinant 63HIS-UHRF1 did not bind
N-terminally labeledH3K9me0orH3K9me3peptides (Figure 1E).
Conversely, the protein interacted with C-terminally labeled
H3 peptides with a slight preference for the K9me3 over the
K9me0 state (Figure 1F). After two rounds of dialysis against
HeLa NE, the properties changed completely. Interaction with
H3K9me0 peptides irrespective of labeling at the N or C terminus
was lost, while the H3K9me3 mark on both substrates was
recognized, indicating that the TTD was responsible for the
interaction and that any PHD binding contribution was removed
(Figures 1G and 1H).We then performed consecutive dialysis ex-
periments using UHRF1 with different tags (Figure 1D). Recom-
binant, bacterially expressedMBP-UHRF1, which bound equally
well to H3K9me0 and H3K9me3 peptides, was dialyzed against
63HIS-UHRF1 that had been already dialyzed twice against
HeLa NE. Pull-down experiments showed that MBP-UHRF1
could be activated for specific H3K9me3 interaction using this
scheme. Overall, the results indicated that small cofactors are
transferred from HeLa NE to a recombinant protein, which can
also be transferred to another recombinant protein.
Different H3 Tail Binding Modes of UHRF1 Are Mediated
by the TTD and PHD Domains
We reasoned that the differential behavior of UHRF1 might be
the consequence of allosteric regulation inducing conforma-
tional changes of the protein. Therefore, we compared the hy-
drodynamic properties of purified recombinant UHRF1 before
and after dialysis against HeLa NE by analytical ultracentrifuga-
tion (Figure 2A). UHRF1 in a matched buffer control had a sedi-
mentation coefficient around 3.7 S. The fit in the continuous
c(s, ff0) model suggested that the majority of molecules dis-
played a frictional coefficient around 1.66 (Schuck and Rossma-
nith, 2000). After dialysis against HeLa NE, this distribution was
significantly shifted toward lower frictional coefficients, demon-
strating that the protein adopted a different overall conformation.908 Molecular Cell 54, 905–919, June 19, 2014 ª2014 Elsevier Inc.To gain further insights into the regulation of UHRF1, we
analyzed a series of mutant recombinant proteins (Figure 2B).
Deletion of the TTD had no effect on the interaction of UHRF1
with H3K9me0 and H3K9me3. Deletion of the PHD or mutagen-
esis of two key residues therein abolished H3 tail binding in pull-
down (Figure 2C) and FP experiments (Figures S2A and S2B).
The same mutations, however, had no effect on the interaction
of the protein dialyzed against HeLa NE with H3K9me3. The
results were consistent with the PHD mediating H3K9me0/
H3K9me3 interaction in the form of the recombinant protein
and the TTD mediating H3K9me3 binding after dialysis against
HeLa NE. They also implied that the TTD is unavailable for his-
tone binding in the state of the pure recombinant protein.
Deletion of the C-terminal region resulted in a recombinant
UHRF1 protein that specifically recognized the H3K9me3 pep-
tide in pull-down (Figure 2B) as well as FP (Figure 2D) experi-
ments, reminiscent of the wild-type recombinant protein after
HeLa NE dialysis. In this construct, the TTD is clearly available
for binding the H3K9me3 tail. While a fragment containing only
the TTD, PHD, and SRA domains showed similar preference
for H3K9me3, the isolated TTD-PHD fragment displayed inter-
mediate behavior. It bound to H3K9me3 and, somewhat weaker,
to H3K9me0. FP analysis indicated that this fragment could
interact with the C-terminally labeled H3K9me0 and H3K9me3
peptides and also with the N-terminally labeled H3K9me3
peptide, but not with the N-terminally labeled H3K9me0 peptide
(Figure S2C). Binding to the C-terminally labeled peptides was
overall stronger compared to the N-terminally labeled peptide,
and there was a slight preference for the H3K9me3 over
the H3K9me0 state. Recent work has suggested a cooperative
mode of interaction involving simultaneous recognition of the
extreme N terminus of H3 by the PHD and of the K9me3 mark
by the TTD in this context (Arita et al., 2012; Cheng et al.,
2013; Rothbart et al., 2013; Xie et al., 2012). However, since
the full-length protein dialyzed against HeLa NE did not bind
the C-terminally labeled H3K9me0 peptide (Figure 1H), meaning
that the PHD is not contributing to H3 interaction, but showed
binding to the N-terminally labeled H3K9me3 peptide similar
to the TTD (Figure S2D), we deduced that the behavior of the
isolated TTD-PHD could not explain the binding properties of
the full-length protein.
A PBR Sequence in the C-Terminal Domain of UHRF1
Binds to a Peptide-Binding Groove on the Surface of the
TTD
Because of the altered methylation specificity of the UHRF1
C-terminal deleted protein, we further investigated the role of
this region in regulating H3 tail binding. In immunoprecipitation
experiments, the isolated C terminus bound to the isolated
TTD (Figure S3A), but not the PHD domains of UHRF1 (Fig-
ure S3B) or the FYVE domain of the Eea1 protein (Figure S3C),
which belongs to the RING superfamily. Isothermal titration calo-
rimetry deduced a binding strength of the isolated C terminus to
the TTD of 4 mM (Figure S3D).
Additional mapping identified a short region within the pre-
RING region of the C terminus that was sufficient for binding
the TTD in pull-down experiments (Figure 3A). Due to its high





Figure 2. The C Terminus Blocks UHRF1
H3K9me3 Interaction
(A) Recombinant 63HIS-UHRF1 either dialyzed
against buffer (top) or against HeLa NE (bottom)
was analyzed by analytical ultracentrifugation.
Distribution of sedimentation coefficient (S, x axis),
concentration (c[S]; left y axis), and frictional ratio
(f/f0; right y axis; intensity of the corresponding
sedimentation coefficient is indicated by super-
position of the heatmap).
(B) Recombinant proteins were incubated with
the specified biotinylated H3 (1–20) peptides
immobilized on streptavidin magnetic beads.
Recovered material was analyzed by western blot.
Input, 2%.
(C) Mutant recombinant UHRF1 protein was either
analyzed directly or after dialysis against HeLa NE
by histone pull-down experiment as in (B).
(D) Recombinant UHRF1 lacking the C terminus
was analyzed in fluorescence polarization bind-
ing experiments. See also Figure S2 and Tables
S1 and S2.
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binding mode of the UHRF1 TTD-PHD fragment have implicated
the short linker region between these domains in directing the
synergistic recognition of H3K9me3 (Arita et al., 2012; Cheng
et al., 2013; Rothbart et al., 2013; Xie et al., 2012). A peptide
binding groove on the isolated TTD was found to bind to H3
tail peptides with low mM affinity (Nady et al., 2011) as well as
to the TTD-PHD linker with relatively weak affinity (KD >
100 mM). Interestingly, the PBR, the TTD-PHD linker region,
and the H3 tail all share an RKS sequence motif (Figure 3B).
We measured the KD for binding of the TTD to the PBR at
4 mM, which was much lower than that for the free TTD-PHD
linker peptide (Figure 3C) (Rothbart et al., 2013).
In order to further characterize the intramolecular interaction,
we performed a nuclear magnetic resonance (NMR) titration of
increasing concentrations of the PBR peptide into 15N-labeled
TTD. We observed significant chemical shift changes indicative
of an interaction in the micromolar range (Figure S3E). ChemicalMolecular Cell 54, 905–9shift changes larger than 0.094 ppm
were concentrated around the groove
formed at the interface between the
two tudor domains (Figure S3F). This re-
gion was previously shown to bind the
sequence N-terminal to the methylated
lysine in the complex of the TTD with
H3K9me3 (Nady et al., 2011). It also
accommodates the linker in the crystal
structure of the H3K9me3/TTD-PHD
complex, thereby directing the coopera-
tive bindingmode engaging bothmodules
(Arita et al., 2012; Cheng et al., 2013;
Rothbart et al., 2013; Xie et al., 2012).
We therefore refer to this region of the
TTD as the peptide-binding groove (Fig-
ure 3D). Although the PBR can bind to
the same TTD peptide-binding groove asthe histone H3 peptide and the TTD-PHD linker, the observed
chemical shift perturbations were more extensive, involving
extra surface residues such as K187, E193, L225, I211, and
D275 (Figures 3D and S3F).
To better understand how the PBR interacts with the TTD,
we performed docking calculations with HADDOCK, which
uses NMR chemical shift changes to guide the simulations (de
Vries et al., 2007; Dominguez et al., 2003). Two plausible models
of the docked PBRwere deduced. These differed in the direction
of the bound PBR peptide (Figure 3E). Model 1 suggested an
important contribution of PBR residues R649 and K650, while
model 2 implicated residues K648 and R649 for binding to the
TTD. Mutagenesis analysis of PBR peptides by FP indicated
an essential contribution of R649 (Figure 3F). Mutagenesis of
K648 had a stronger effect compared to mutagenesis of K650.
In contrast, mutagenesis of residues K644 and K646 had no
effect on the interaction. Similar results were obtained for the








Figure 3. The PBR Sequence of the Pre-RING Region Binds a Peptide Groove on the Surface of the TTD
(A) TTD or PHD domains of UHRF1 or the FYVE domain of Eea1 were incubated with a biotinylated PBR peptide immobilized on streptavidin magnetic beads or
beads alone (mock). Recovered material was analyzed by western blot. Input, 2%.
(B) Sequence comparison of the UHRF1 PBR and linker regions with the H3 tail.
(C) TTD of UHRF1 was analyzed in fluorescence polarization binding experiments with peptides corresponding to the UHRF1 linker or PBR (FAM at the
N terminus).
(D) Surfacemodel of the TTD (Protein Data Bank ID [PDB] 2L3R). Residues with chemical shift changes >0.094 ppm upon titration of the PBR peptide are shown in
purple; those lining the TTD peptide-binding groove (red box), which have disappeared upon titration of the PBR peptide, are shown in red.
(E) HADDOCKmodels of likely positions of the PBR peptide in the TTD peptide-binding groove. K648 is highlighted in yellow as a visual guide of the orientation of
the peptide; R649, K650, S651 is shown in cyan; the N andC termini of the peptide are shown in blue and dark blue, respectively. Color codes of residues showing
major changes upon addition of the PBR peptide are as in (D).
(F) TTD of UHRF1 was analyzed in fluorescence polarization binding experiments with the indicated wild-type (WT) or mutant FAM-PBR peptides.
(G) Overlay of the positioning of the H3 tail (red; K4 residue in green, K9 residue in purple) as determined in the TTD/H3K9me3 complex (PDB 2L3R) and the PBR
sequence in model 1 and model 2 (color code as in E). Images were generated by PyMOL.
(H)Wild-type (WT) or D142Amutant TTD of UHRF1was analyzed in fluorescence polarization binding experiments withWT FAM-PBR peptide. See also Figure S3
and Tables S1 and S2.
Molecular Cell
Allosteric Regulation of UHRF1
910 Molecular Cell 54, 905–919, June 19, 2014 ª2014 Elsevier Inc.
Molecular Cell
Allosteric Regulation of UHRF1unambiguously discriminate between the two binding modes for
the TTD/PBR interaction, themutagenesis results favored model
2. Comparison of the TTD/PBR complex with the TTD/H3K9me3
(Figure 3G) or the TTD/linker (Figure S3H) complexes indicated a
mutually exclusive binding mode.
While methylated K9 of H3 within the RKS motif binds in
a pocket formed in the TTD, the RKS sequence of the PBR
does not interact in the same region. Instead, the UHRF1 PBR
is centrally located in the TTD peptide-binding groove. Indeed,
mutagenesis of two caging aromatic acid residues implicated
in methyl-lysine binding in the TTD/H3K9me3 complex had
only a very limited effect on TTD/PBR interaction (Figure S3I).
In both NMR models, R649 engages in hydrogen bonding with
D142, and mutagenesis of this residue significantly impaired
binding of the PBR to the TTD (Figure 3H). In model 2, K648
engages in hydrogen bonding with D189 and D190. These are
critical residues in the TTD peptide-binding groove that interact
with R296 of the anchored TTD-PHD linker andwith T6 of the his-
tone H3K9me3 peptide, respectively (Arita et al., 2012; Nady
et al., 2011). While mutagenesis of R295 and R296 of the linker
within the TTD-PHD fragment had no effect on PBR interaction,
it resulted in a slight increase in binding to free linker peptide
(Figure S3J).
The PBR Sequence Is Sufficient for Blocking H3K9me3
Binding of the TTD
Next, we investigated the role of the C-terminal domain
of UHRF1 in regulating H3K9me3 binding of the TTD. While the
C terminus did not show specific interaction with H3K9me0 or
H3K9me3 peptides (Figures S4A and S4B), it severely reduced
recovery of the TTD on H3K9me3 beads when titrated into his-
tone peptide pull-down experiments (Figure 4A). Likewise, the
C-terminal domain of UHRF1, but not the FYVE domain of
Eea1, blocked TTD/H3K9me3 interaction in FP experiments
(Figure 4B). Similar results were obtained for the TTD-PHD,
TTD-PHD-SRA, and UBL-TTD-PHD-SRA recombinant frag-
ments of UHRF1 (Figures S4C–S4E).
Titration of H3K9me3, but not H3K9me0 peptide, into an
immunoprecipitation of the C terminus resulted in significantly
reduced recovery of the TTD (Figure 4C). These results were
confirmed using only the PBR region of the C-terminal domain.
In FP experiments, the PBR peptide blocked binding of the TTD
to the H3K9me3 peptide (Figure 4D). Mutagenesis of the K644
and K646 residues that were not implicated in the binding of
the PBR to the TTD peptide-binding groove had only a limited
effect. While mutagenesis of the K650 residue somewhat
reduced the blocking effect of the PBR peptide, changing the
individual K648 or R649, or the combined R649, K650, and
S651 sites, resulted in severe loss of blocking. Similar results
were obtained for the TTD-PHD (Figure S4F).
Only the PBR, but not the much weaker binding linker peptide,
blocked interaction of the TTD with H3K9me3 (Figure S4G). This
effect was abrogated in the D142A mutant (Figure S4H). More-
over, the PBR peptide competed with the N-terminally labeled
H3K9me3, but not the C-terminally labeled H3K9me3 or
H3K9me0 peptides, for binding to the TTD-PHD (Figures S4I–
S4K). The results supported the idea that binding of either the
H3K9me3 or PBR peptides to the TTD are mutually exclusiveM
and independent of linker function as well as PHD binding to
the extreme N terminus of H3. Presence of an H3K9me3 peptide
compromised the interaction of the TTD (Figure 4E) or TTD-PHD
(Figure S4L) with the PBR, while a H3K9me0 peptide had amuch
reduced effect.
Next, we designed multiple UHRF1 protein constructs with
mutations in the PBR region. While mutagenesis of K650 had
no effect, the R649A mutant showed increased binding to
H3K9me3 in FP experiments (Figure 4F). This effect was stronger
when, in addition, the K650 and S651 or the K644, K646, K648,
K650, and S651 residues were also mutated. The same muta-
tions had only little effect on the interaction of UHRF1 with an
H3K9me0 peptide (Figure S4M). Similarly, we found that the
UHRF1 K644A,K646A,K648A,R649A,K650A,S651A mutant pro-
tein had increased binding to H3K9me3 in pull-down experi-
ments (Figure 4G). While the results potentially implied that there
are additional interfaces between the TTD and C terminus, they
supported a blocking effect of the PBR in the context of the full-
length UHRF1 protein.
The PBR of UHRF1 Interacts with PI5P
To isolate the small cellular cofactor of UHRF1, we set up a
chromatographic purification scheme (Figures S5A and S5B).
Dialyzed, recombinant UHRF1 and the associated factors
from the HeLa NE (all presumably <3 kDa) were separated
by reversed-phase chromatography. Individual fractions were
lyophilized and then tested for their ability to induce
H3K9me3-specific binding of full-length recombinant UHRF1.
The activating factor(s) could be separated by step-wise
elution at 50% acetonitrile from a C8 column (Figure S5C).
While it was possible to further refine the purification scheme
and to combine different chromatography methods, several
attempts to identify the activating factors by mass spectrom-
etry failed.
In order to gain insights into the nature of the compounds
from another direction, we defined the region of UHRF1 binding
the NE factor(s). To this end, different domains of UHRF1 were
subjected to dialysis against HeLa NE. Material eluting at 50%
acetonitrile in our purification scheme was analyzed in his-
tone tail pull-down experiments with recombinant UHRF1. The
fragments of UHRF1 containing the C-terminal domain (WT,
UBL-TTDSRA-RING, C terminus), but not those without the
C terminus (UBL-TTDSRA, UBL-TTD-PHDSRA), were able
to recruit factor(s) that induced H3K9me3-specific binding (Fig-
ure 5A). Indeed, dialysis of the C terminus against HeLa NE
relieved its inhibition of the interaction between the TTD and
H3K9me3 (Figure 5B), while dialysis of the TTD itself had no
effect (Figure 5C).
Upon a closer look at the PBR sequence within the C terminus,
we realized that it contains a motif (K/R-(X)n = 3–7-K-X-K/R-K/R)
that had been implied in binding PIPs (Lewis et al., 2011). Indeed,
treatment with phospholipase A2 (PLA2) that hydrolyzes PIPs
abolished the capability of HeLa NE to activate H3K9me3-spe-
cific binding of recombinant UHRF1 (Figure 5D). We then tested
recombinant UHRF1 for interactionwith different PIPs, its precur-
sors, and related compounds in standard lipid dot blot assays
(Figures S5D and S5E). Similar to the PHD domain of ING1,







Figure 4. The PBRBlocksH3K9me3Binding
of the TTD
(A) TTD was incubated with increasing concen-
trations of the C terminus (molar ratio TTD:C
term. = 2:1, 1:1, 1:1.5) and analyzed in pull-down
(PD) experiments using an immobilized H3K9me3
peptide. Recovered material was analyzed by
western blot. Input, 2%.
(B) TTD alone (mock) or in the presence of the C
terminus of UHRF1 or the FYVE domain of Eea1
(1:2 molar ratio) was analyzed in fluorescence
polarization binding experiments with FAM-
H3(1–15)K9me3 peptide.
(C) C terminus was incubated with the TTD
in the presence of increasing concentrations
of the indicated H3(1–20) peptides (molar ratio
TTD:C term.:peptide = 1:1:1, 1:1:2.5, 1:1:5,
1:1:7.5) and immunoprecipitated using antibodies
against UHRF1. Recovered material was analyzed
by western blot. Running positions of proteins
recognized by the primary and/or secondary anti-
bodies are indicated. Input, 5%.
(D) TTD alone (mock) or in the presence of the
indicated PBR wild-type (WT) or mutant peptides
(1:5 molar ratio) was analyzed in fluorescence
polarization binding experiments with FAM-H3(1–
15)K9me3 peptide.
(E) TTD alone (mock) or in the presence
of the indicated H3(1–20) peptides (1:5 molar
ratio) was analyzed in fluorescence polarization
binding experiments with FAM-H3(1–15)K9me3
peptide.
(F) Wild-type (WT) UHRF1 or UHRF1 carrying the
indicated mutations was analyzed in fluorescence
polarization binding experiments with FAM-H3(1–
15)K9me3 peptide.
(G) Mutant UHRF1 K644A,K646A,K648A,R649A,
K650A,S651A was analyzed in a pull-down
experiment using the specified biotinylated H3(1–
20) peptides immobilized on streptavidin magnetic
beads or beads alone (mock). Recovered material
was analyzed by western blot. Input, 2%. See also
Figure S4 and Tables S1 and S2.
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PI3P=PA>PI3,5P2=PI4,5P2>PS)were alsoobserved. Asantic-
ipated, no interaction of the H3K9me3-binding HP1b protein with
any of the lipids was seen.912 Molecular Cell 54, 905–919, June 19, 2014 ª2014 Elsevier Inc.We then used a liposome flotation
assay to further define the PIP binding
properties of UHRF1 (Figure 5E) (Rusten
and Stenmark, 2006). As expected, the
PHD domain of ING1 was only retained
by liposomes containing PI5P, but not
any of the other PIPs, while the FYVE
domain of Eea1 was only retained on lipo-
somes containing PI3P (Figures 5F and
S5F) (Simonsen et al., 1998). Some back-
ground binding of both factors to PIP-free
liposomes was also seen. While UHRF1
showed a similar background with PIP-
free liposomes, it was only specifically re-tained on liposomes containing PI5P. No binding to liposomes
containing PI3P, PI4P, PI3,5P2, or PI4,5P2 was observed.
Mapping of the interaction using lipid dot blots as well as lipo-
some flotation assays defined the C terminus and, within that,
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of UHRF1 (Figures 5G, S5E, and S5F). Mutagenesis of R649,
K650, and S651 within the PBRwas sufficient to severely reduce
binding of full-length UHRF1 as well as the pre-RING region to
PI5P. Lastly, we compared binding of fluorescently labeled
wild-type and R649A,K650A,S651A mutant PBR peptides to
biotinylated PIPs immobilized on streptavidin beads (Figures
5H and S5G). A clear preference of the wild-type PBR for PI5P
over PI, PI3P, PI4P, PI3,5P2, and PI4,5P2 was observed.
PI5P Regulates UHRF1 Interaction with the Modified or
Unmodified H3 Tail
When titrated into immunoprecipitations of the C-terminal
domain with the TTD, PI5P, but not PI4P, blocked the interaction
(Figure 6A). Similarly, PI5P, but not PI4P, reduced the recovery
of the TTD on the PBR peptide in pull-down experiments
(Figure 6B).
We then asked whether PI5P could modulate H3 tail binding
of UHRF1. In histone pull-down experiments, PI5P induced
H3K9me3-specific binding of recombinant UHRF1 (Figure 6C).
While PI3P also showed some activation, neither PA, PI, PI4P,
PI3,5P2, nor PI4,5P2 had an effect. All attempts with PI5P con-
taining different acyl chain lengths to induce H3K9me3-specific
binding of UHRF1 in the FP-based experiments in solution failed.
Also, the isolated inositolphosphate head groups of the PIPs had
no effect (not shown).
To further investigate whether PI5P is indeed the cellular
molecule regulating UHRF1, we made use of a specific kinase.
PIP4Ka transduces together with PIP4Kb to the cell nucleus and
phosphorylates PI5P on the 4-position, thereby yielding PI4,5P2
(Bultsma et al., 2010). Addition of PIP4Ka and ATP to an H3 tail
pull-down reaction of recombinant UHRF1 abolished the acti-
vating function of PI5P (Figure S6). ATP alone had no effect,
and the kinase did not alter the outcome with PI4P in this assay.
We then incubated HeLa NE or a buffer control with PIP4Ka and
either ATP or the nonhydrolysable ATPgS. UHRF1 was dialyzed
against the treated lysate or buffer and analyzed in H3 tail pull-
down experiments. Pretreatment of the HeLa NE with ATP and
PIP4Ka abolished the activating effect of the lysate (Figure 6D).
Incubation of the HeLa NE with ATP alone or PIP4Ka and
ATPgS also slightly induced some H3K9me3-specific binding
of UHRF1. In contrast, pretreatment with ATPgS had no
effect. We think ATP and PIP kinase(s) present in the NE might
account for these observations. No effect was observed with
the buffer control, and there was no differential binding of the
recombinant UHRF1 to H3K9me0 and H3K9me3. Altogether,
the results indicated that PI5P is a cellular coactivator of
UHRF1, allosterically regulating binding to different modification
states of the H3 tail.
PI5P Directs TTD-Dependent UHRF1 Localization to
Heterochromatin
Previous studies have found both strong and limited localization
of UHRF1 to H3K9me3-enriched heterochromatin (Karagianni
et al., 2008; Nady et al., 2011; Papait et al., 2007). We hypoth-
esized that these discrepancies might be due to different
cellular systems and conditions analyzed. We found that a
large fraction (58%) of NIH 3T3 cells transiently expressingM
mCherry-UHRF1 showed colocalization of the fusion protein
with DAPI-dense and H3K9me3-positive foci of pericen-
tromeric heterochromatin. Lower enrichment at these regions
(intermediate) was seen for 29% of cells, while 13% of cells
displayed diffuse nuclear distribution (Figure S7A). Mutation of
two residues in the aromatic cage implicated in methyl-lysine
binding in the TTD/H3K9me3 complex resulted in significantly
more cells (64%) showing intermediate and diffuse phenotypes,
while 36% of cells showed dotted UHRF1 Y188A,Y191A
distribution (Figure S7B). The results suggested that other
domains of the protein besides the TTD are also involved in
heterochromatin localization. Indeed and in agreement with
recent findings (Liu et al., 2013), after mutation of both the
TTD and SRA domains, no heterochromatin localization of
mCherry-UHRF1 was detected (Figure S7C). While the exact
regulation of UHRF1 subnuclear and chromatin association is
unclear, the protein might rely on different domains for target
binding, and there could be a cell-cycle dependency (Papait
et al., 2007).
To determine the regulatory role of the PBR, we coexpressed
GFP-tagged wild-type or mutant (K644A,K646A,K648A,R649A,
K650A,S651A) pre-RING domain together with mCherry-
UHRF1 in NIH 3T3 cells (Figures 7A and S7D). We thought this
region might exert dual effects by simultaneously interfering
with TTD/H3K9me3 binding as well as by titrating endogenous
PI5P. Quantification of the different phenotypes indicated that
an average of 12% of cells exhibited a shift in their mCherry-
UHRF1 distribution from dotted to intermediate or diffuse
appearance upon expression of wild-type GFP-pre-RING. This
effect was not seen for coexpression of mCherry-UHRF1 with
the mutant GFP-pre-RING (Figures 7B and S7E).
To further establish a regulatory role of PI5P for UHRF1,
we made use of the PIP4K kinases to manipulate nuclear levels
of thecofactor.Consistentwith thephenotypesof pre-RINGover-
expression, coexpression with MYC-PIP4Ka and PIP4Kb (PIP4K
WT) relative to coexpression of empty vector resulted in an
average of 9% fewer cells displaying the nuclear dotted pattern
of mCherry-UHRF1. In contrast, kinase mutant PIP4Ks (PIP4Ka
G131L,Y138F and PIP4Kb D278A) had no such effect (Figures
7C and S7F–S7H). Given that only a fraction of cells in the popu-
lation (on average 22%) relied on the TTD for localization to peri-
centric heterochromatin, we deduced from these experiments
thatPI5Pbinding to thePBRhas amarked impact (40%)onhet-
erochromatin association of this UHRF1 subpopulation.
DISCUSSION
Regulation of UHRF1 H3 Tail Binding by Conformational
Rearrangements Allosterically Induced by PI5P
By identifying a mode of regulation of UHRF1 by a cellular
cofactor, our findings clarify discrepancies in the literature
regarding the binding activities and domain usage of this impor-
tant epigenetic regulator. Various reports used different experi-
mental systems (i.e., protein expression in bacteria, which do
not have PIPs, versus expression in insect cells, reticulocyte
lysate, or mammalian cells, which all contain PIPs) and investi-
gated full-length, deletion mutants, or point mutants of UHRF1







Figure 5. The PBR of UHRF1 Interacts with PI5P
(A) The indicated fragments of UHRF1 were dialyzed against HeLa NE. Proteins and cellular factors inside the dialysis membrane were separated on a C8
reversed-phase column. Recombinant 63HIS-UHRF1 was incubated with the material eluting at 50% acetonitrile and probed in a histone peptide pull-down
experiment. Recovered material was analyzed by western blot. Input, 2%.
(B) TTD alone (mock) or incubated with the C terminus dialyzed against HeLa NE or buffer control (molar ratio TTD:C term. = 1:2) was analyzed in fluorescence
polarization binding experiments using FAM-H3(1–15)K9me3 peptide.
(C) TTD was dialyzed against buffer or HeLa NE. Protein alone (mock) or in the presence of the C terminus was analyzed in fluorescence polarization binding
experiments using FAM-H3(1–15)K9me3 peptide.
(legend continued on next page)
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Figure 6. PI5P Releases Blocking of the TTD by the C Terminus
(A) C terminus was incubated with TTD in the presence of increasing concentrations of the indicated PIPs (molar ratio TTD:C term.:PIP = 1:1:5, 1:1:10, 1:1:20) and
immunoprecipitated using antibodies against UHRF1. Recoveredmaterial was analyzed bywestern blot. Running positions of proteins recognized by the primary
and/or secondary antibodies are indicated. Input, 5%.
(B) TTD was incubated with increasing concentrations of the indicated PIPs (molar ratio TTD:PIP = 1:5, 1:10) and analyzed in pull-down experiments using an
immobilized PBR peptide. Recovered material was analyzed by western blot. Mock, pull-down with beads only; input, 2%.
(C) UHRF1 in the presence of the indicated lipids (2-fold molar excess) was incubated with the specified biotinylated H3(1–20) peptides immobilized on
streptavidin magnetic beads. Recovered material was analyzed by western blot. Input, 2%.
(D) Recombinant UHRF1was dialyzed against buffer or HeLa NE that was incubated with the indicated combinations of PIP4Ka, ATP, or ATPgS. After dialysis, the
protein was probed in histone peptide pull-down reactions. Recovered material was analyzed by western blot. Input, 2%. See also Figure S6.
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Allosteric Regulation of UHRF1unmodified and K9me3 H3, and different interaction specificities
were observed (Hu et al., 2011; Karagianni et al., 2008; Liu et al.,
2013; Rajakumara et al., 2011; Rottach et al., 2010; Wang et al.,
2011). We propose that most of the differences can be explained
on the basis of the following regulatory mechanism. In the
ground state of the recombinant protein or highly purified cellular
protein, the C-terminal region of UHRF1 is folded back onto the
middle region with the PBR sequence bound to the peptide-
binding groove of the TTD (Figure 7D, top). This prevents the
interaction of the TTD-PHD linker and also the H3 N-terminal
tail with the TTD (Figure 4) (Nady et al., 2011). In this state, the
PHD domain is able to bind to the extreme unmodified N termi-
nus of H3. In an intermediate state that is artificially stabilized by
mutagenesis of the PBR, the blockage of the TTD is released
(Figure 7D, middle). We think this conformation of UHRF1 re-
flects the cooperative mode that we and others have observed(D) Recombinant UHRF1was dialyzed against untreated HeLa NE or HeLa NE that
a histone peptide pull-down experiment. Recovered material was analyzed by w
(E) Scheme of liposome flotation assay. The sucrose gradient was loaded with l
analyzed for localization of UHRF1.
(F) The indicated proteins were incubated with liposomes containing the indica
analyzed by western blot. WT, wild-type; input, 5%.
(G)Summaryofmultiple liposomeflotationassaysusingdifferentproteins.MT,mut
minor protein signal at the top of the gradient; nd, not determined.
(H) Fluorescein-labeled wild-type (WT) or R649A,K650A,S651Amutant (MT) PBR p
well plates. Fluorescence signals after washing were recorded. Averaged ratio of
bars correspond to error propagation of SEM reflected in five independent expe
M
for the isolated TTD-PHD fragment (Arita et al., 2012; Cheng
et al., 2013; Rothbart et al., 2013; Xie et al., 2012). It is character-
ized by a slight preference for H3K9me3 over the unmodified
state, as seen for C-terminally labeled peptides (H3[1–15]-K
[FAM]). Here, the linker sequence occupies the peptide-binding
groove of the TTD. The N terminus of the H3 tail can bind to the
PHD, while the aromatic cage of the TTD can recognize K9me3.
In an activated state, the PBR is bound by PI5P, further stabiliz-
ing the domain orientation, giving TTD access to H3K9me3.
Large conformational rearrangements not only free the TTD for
H3K9me3 binding, but also block the PHD from binding the
extreme unmodified N terminus of H3 (Figure 7D, bottom).
Further biophysical and structural studies will be needed to
clarify the exact nature of the overall conformational rearrange-
ments of the protein in the different states as well as the exact
binding modes of the H3 tail and PI5P to UHRF1. Thewas incubated with phospholipase A2. After dialysis, the protein was probed in
estern blot. Input, 2%.
iposomes and UHRF1. After centrifugation, the gradient was fractionated and
ted PIPs. Fractions of the liposome flotation assay after centrifugation were
ationR649A,K650A,S651A.+,majorprotein signal at the topof thegradient;/+,
eptides were incubated with the indicated biotinylated PIPs immobilized in 96-
enrichment of WT versus MT of four independent experiments is plotted. Error
riments. See also Figure S5 and Tables S1 and S2.

































































Figure 7. Nuclear PI5P Regulates Heterochromatin Association of UHRF1
(A) NIH 3T3 cells were transfected with mCherry-UHRF1 together with GFP-pre-RING. Fluorescence signals were analyzed by confocal microscopy. Images of
representative cells of different phenotypes observed at the indicated frequencies (n > 500) are shown. DAPI was used to stain DNA. Scale bar, 10 mm.
(B) Histogram showing changes in frequencies of observed nuclear distribution of mCherry-UHRF1 when coexpressing GFP-pre-RING wild-type (WT) or GFP-
pre-RING K644A,K646A,K648A,R649A,K650A,S651A (MT) relative to coexpression of a GFP control in NIH 3T3 cells as classified in (A) (n > 500). Error bars
represent error propagation of SEM reflected in four independent experiments.
(C) Histograms showing changes in frequencies of observed nuclear distribution of mCherry-UHRF1 coexpressing MYC-PIP4Ka and untagged PIP4Kb (PIP4K
WT) orMYC-PIP4KaG131L,Y138F and untagged PIP4KbD278A (PIP4KMT) relative to coexpression of empty vector in NIH 3T3 cells as classified in (A) (n > 500).
Error bars represent error propagation of SEM reflected in four independent experiments.
(D) Different conformational states of UHRF1. Top: the PHD mediates binding to unmodified extreme N terminus of H3 in the absence of PI5P, and the TTD is
blocked from binding H3K9me3 by the PBR. Middle: when the PBR is mutated (red asterisk), it is dissociated from the TTD. The linker can mediate cooperative
bindingof theH3 tail by thePHDandTTDdomains. Bottom: PI5P (blue star) bindingby thePBR results in conformational rearrangement. The TTD is free to bind the
H3K9me3 tail. Unknownmechanisms (indicated by the question mark) block the PHD from binding the unmodified extreme N terminus of H3. See also Figure S7.
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unclear at this point. Our data question whether the cooperative
state seen for the TTD-PHD exists in the context of the full-
length protein. It might be an artificial state of an isolated frag-
ment. The increase seen in H3K9me3 binding of TTD-PHD
over TTD varies from 2-fold (this study; Arita et al., 2012) to
5-fold (Cheng et al., 2013; Rothbart et al., 2013), which might
be due to different experimental conditions. In all cases and
likely due to the flexible linkage of the TTD and PHD, it is not
sufficient to account for the large binding differences for the
unmodified and K9me3 H3 tail observed for cellular UHRF1.916 Molecular Cell 54, 905–919, June 19, 2014 ª2014 Elsevier Inc.Whether the slight preference for the K9me3 over the unmodi-
fied H3 peptide with C-terminal fluorescein (H3[1–15]-K[FAM];
Figure 1 and Table S1) reflects cooperativity of TTD and PHD
in the ground state remains to be seen.
How are the hydrophobic acyl chains of PI5P bound to UHRF1
outside of a lipid membrane or micellar structure? While muta-
genesis of the PBR is sufficient to abolish interaction in the lipid
flotation assay (Figure 5F), we think that other regions of the C
terminus and/or additional unknown components are involved
in PI5P binding. First, in the liposome flotation assay, only the
polar head groups of the PIPs are exposed; the hydrophobic
Molecular Cell
Allosteric Regulation of UHRF1acyl chains are embedded in the lipid layer. Nevertheless,
inositol 1,5-bisphosphate is not sufficient to induce allosteric
activation of UHRF1. Second, while addition of PI5P to UHRF1
activates the protein in pull-down assays, it does not have this
effect in solution FP assays (data not shown). We speculate
that the phospholipid might get artificially enriched on the sur-
face of the beads used in the pull-down assays. In the nuclear
extract, PI5P is bound by UHRF1 and likely other factors that
might work as ‘‘sinks’’ for the PIP. For sufficient transfer across
the dialysis membrane, PI5P might need other small molecules
(e.g., ions, peptides, RNA, etc.) that stabilize it in solution.
Cellular Regulation of UHRF1
While our findings identify a role for PI5P in modulating UHRF1
function, regulation of the protein in the cellular context is likely
more complicated. Recent work had reported partially overlap-
ping and redundant roles of the TTD and SRA domains in
UHRF localization, where the two regions appear to mediate
crosstalk between H3K9 methylation and DNA methylation at
the level of DNA methylation maintenance (Liu et al., 2013). In
contrast, another report suggested that cooperative interplay
of the TTD and PHD is required for this function (Rothbart
et al., 2013). The fact that the concentration of PI5P in the nuclei
of murine erythroleukemia cells increases 20-fold during G1
phase but drops after S phase (Clarke et al., 2001) could indicate
that switching between the unmodified H3-binding ground state
and the activated H3K9me3-binding state of UHRF1 is required
for differential localization of the protein during the cell cycle
(Papait et al., 2007). Further work will need to clarify the precise
crosstalk of the chromatin modification binding TTD, PHD, and
SRA domains of UHRF1 under defined cellular conditions. Regu-
lation of H3K9me3 and unmodified H3 tail interaction by PI5P
also likely has an impact on UHRF1 binding to and targeting of
its enzymatic partners such as G9a, DNMT1, and HDAC1.
Another level of regulation of UHRF1 is provided by post-
translational modifications. Several proteomics studies have
defined serine phosphorylation events within the linker and
C-terminal region. Also, acetylation of two lysine residues within
the SRA was found (Choudhary et al., 2009; Dephoure et al.,
2008; Olsen et al., 2010; Rigbolt et al., 2011). While the functions
of most modifications are unknown, phosphorylation by CDK1
at S639 is involved in degradation of the protein (Ma et al.,
2012). Phosphorylation of S298 within the linker by PKA inter-
feres with TTD-PHD cooperativity in vitro (Arita et al., 2012).
Based on our mutagenesis studies of the PBR, we speculate
that phosphorylation of S651 (S651ph) might have a regulatory
role in PI5P binding and in modulating H3 interaction of UHRF1
(Rigbolt et al., 2011).
We predict that PI5P, as well as other nuclear PIPs, might have
more general, so far unrecognized roles in directly regulating
the chromatin binding activity of different proteins. Consistent
with a role in signaling, the amounts of certain nuclear PIPs are
increased in mammalian cells by physiological ligands or pro-
cesses as well as by cellular stresses (Shah et al., 2013). This
might directly impact gene regulation. In general, nuclear phos-
pholipids undergo changes in abundance that match the tran-
scriptional activity during the cell cycle (Fraschini et al., 1999).
Defining further chromatin proteins that are directly regulatedM
by PIPs or other phospholipids might establish new paradigms
of signal transduction in the cell nucleus.
EXPERIMENTAL PROCEDURES
Reagents
Detailed listing of plasmids, peptides, antibodies, and proteins can be found
in the Supplemental Information.
Dialysis of UHRF1
Nuclear extracts were prepared as described (Dignam et al., 1983). Protein
concentration ranged from 10–15 mg/ml. Proteins (5 mg in 400 ml) were dia-
lyzed against 10 ml HeLa NE or comparable buffer (in 50 ml tubes) overnight
in dialysis cups (Pierce) with a 3,500 Da molecular weight cutoff at 4C.
Pull-Downs, Immunofluorescence and Fluorescence Polarization,
and Liposome Flotation Assay
Experiments were performed as previously described (Fischle et al., 2008;
Rusten and Stenmark, 2006), with minor modifications as can be found
in the Supplemental Experimental Procedures.
Binding of PBR Peptides to PIP Beads
A 10 ml slurry of PIP beads (Echelon Biosciences) was incubated with 20 ng
of fluorescein-labeled PBR peptide. After washing, samples were transferred
to black 96-well plates (Corning), and fluorescence intensity (excitation at
485 nm, emission at 535 nm) was measured in a HIDEX Chameleon II plate
reader. Results from three successive reads were averaged, and recovery of
the peptides was normalized relative to the input.
NMR Spectroscopy
Chemical shift changes of the residues of the TTD upon titration of unlabeled
linker peptide were mapped using prior available chemical shift assignments
deposited in the Biological Magnetic Resonance Bank (BMRB) (Nady et al.,
2011).
Molecular Docking
Docking of the PBR peptide to the TDD was performed using HADDOCK v2.1
software (de Vries et al., 2007; Dominguez et al., 2003).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.molcel.2014.04.004.
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